var title_f35_23_36208="Benign teratoma ultrasound";
var content_f35_23_36208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign ovarian teratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 252px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD8AT4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigApcfpSqMnGM05C/+rVSSSDgDk0ASWkMk9wkUSMztgYHU/Svqz4RaH4ZfQIzo9ncW2vQW6i8+0Pks/coD9K89+F/gm40eCy8Vag0RuVYSR2kyfeQ98+vNel6nZqZP7e04tZylTIwQ5OfXFAEt1p0C6qXkm+zz7SSwGNw/x7VueEbuWLV0mjug8UpCNnHQelUND26jYXIvJ0up5EzGThc59uxrM0xI9J1oAT+VOMbVYfePdSfWgD36x1eFJja3DP5gG5XI+Vh6A1rQTxzqWiOQDg8d64vwybbWY3ChxEvMgbt9DWlNrenaLMbcMyx5ChMd/WgDpsjOMjPXFFZay26yxXkUmYZBgY6A/wBO1X/Pj2hskA+1AEtFIrBhlSCPY0tAEck0cQy7quKeGBOARnGevaq9xG8p2MiMh7ntVPUnkER3ER/3QADigDTZ1U4ZlB9zVW61G3t0YlwxHUKa5spPLblZZGL5yHU/dFSWi6NEQJ7gO6j7pJ5/Dv2oAs3XiFpIJHsVUqvBduimuVvNeurq3umZyEAADAjHvVwWuVufsnCSOQiYJHtkfjWfq0Nrb6eY52E15J0VBwMe1AGJbx3F9dDpheMMcbvxrorS/ig22/lG0hjwC68/rXH/AGqe3ST58fLh/kztI9/WoF8QTwu1teOBA7DbsTLEfU0Adve6rYTO8AeSWVSMPt9TnrTJr65iuGeJWkdEBjwOAPYd65DU9Q0+C4tB9qFtG3DbuRk/5/Suk0zxXommWEhF2LyROCwXd19KAIIfFwF3HPqcLfbFyAg468ZNcl8V/DUvj+VLkpb20sUW2JyevJPzcVpeKPFttqVtIumqIJs7vMZBk+oFYNnd3uoaQr3odbLhSYxhiMc/yoA+WdW06Sw1CeGYeVLGxDAZ9eo9RWW5DHIAHsK9k8f6dba+4WCBk1OLO2foioP4Tjqa8gu4JLeXypkdHUchxj8vagCE4zx0pKKKACiiigAooooAlkiCRROJY2Lgkoucpg454/HjNRUUUAFFFFABRRRQAUvbNJRQA5OuT+QOK9P+HPhERKmsa1GxjGDDAGwW9GPt7VH8IvAkfiO+W6vmU2nzARK2GJx79q9L8RaRqOhalb5X/iWsQFkDjKDOOR6dKANzxZc6ZqPh63a2upD5CfvIW+9nHb9a5l7i5n0hreSWbaF3IUc8kdc+1Psbu3W6nW9QXKo+5fIGRtPr6U7xBqciTQJpdiTHMm1lzz+GO9AFO3uHhDaiLyZQIx5aY4YDt0rauLi38T3Vs/ly21x5e1mIwN2OKzI5JrmxQPC9rDHmNkI5GfUGtDTLe/1DTkhtvJhjiIy+PmKZ7igDdTU9TtY4bd5NpiYRrJA+C4HYiu80C9/tGCSHW8GTYfIAGCD71wFzF/YsmGdblJsN1wy9ORitfREudSvI7RZ4UnycLOcEjr1/CgDtFgFuNqyqCVJ279uD7VnaZ4g1JZXglxNtbDDnHHqfyrHa/lnu4oZBE7wMVO8HHHbP1rfutE+2WTm1EVrM+Msj8cd6AN/S/ECNujknMc68kBvuD0961P7fkilQJm4iI5LAAj/GvN28P31lgSTR3Makv5iHD/Q9zTRqjxxT/ZnlMaLgB85/CgD16z1eO4iLtGybDhgT9ar6rqDvaNLZJFIo6lupHcV5KviTUdOjeRgLi3dRls9vSn2fiO6urh1tf3zsBiFT8o/zxQB6QtyLeNbq6XZ5i5UA5wT0/nWOLZpZxGyozTnd5h42+lU4xA3kJq91NavgHYWyM+laGr2pEAnt5fNVBjPQqPb1oAvm6g0+1W3hmHmjguVyM/WsC7u7ZYZZxayShchnICnPc49KZZ6qmo3P2O4t1SVRku3ce+aq6nBBeW8w0y4ljVRsZg2AMc0AYOo3Ftb2X2gylVkfckGM9+/51meKXUW9hcQFVCjdgryfTFSRaZp0cvkzu0rJncQ39Kl8LanazaleQ38TStbk7CR8qemaAOMvLSe+Ju5oZooi67Gk6E+uPSi7McOovbOFmwuXeLgH8q6zxl4k/tCVdN022Nwin94yr93HTH5Vx+h+MNNtLyfS1i8mQZ+aSMklj+FAGp/Yl1OLeTcBuUhU6EA961mlisNMls7q+EhQ8rH1XjkcVxGq+MNStbiezsbKWaT/AJazHqc9h6DmtGC1S30xpmm8u4lId4gc7Rx69TyaAJ00eZYJ9RMzRadGvywkcynPTNcp468L6v4/mgmsbWGOe3j2ovC/L2BPb8a9I1DVdO1fTSJZ2tIoVCqN3fpnFallqliLJNMtDm3lj/fTkYPp1oA+NdU0+50vUJ7K/iaK5hYo6HsaqV7/APGnw/a6pFbjTiHvrVSqBQMygkcE9z6V4JcQy287wzxtHLGSrIwwVI7GgCOiiigAoqVottvHL5kZLsy7AfmXGOSPQ54+hqKgAooooAKKKKACiinKpY4UEn0AoAQAsQB1Ne4fBr4Qy+INKj8QXMsUmHJhsWUEvg9Wz0BqvpPwois/h3beIdfiv7e/ln3RwND+7MfuevNdx8IfiBZ6N4i2vAYrXZ5ZAwD9cUASXFvNd+IHbSNNazngG2aFF2Dd7YxzWRqniK7haTT9RC3EsYL+XJncqj19ute2atqGi6+X/sGWOC9bktjDZ7ivK/GtjeQrdzWtnvu1QAysMEDvz6UAcXF4s0aDULgwfuRPH8y+WTz7fyq3YzX2oWEF1aQOpgfzJCp5VR3AP1ril06+upVWGKBy6EjaRuGDzx2Nb3h3U20m2juLyW6aRG8qSNhkMnt+HrQB30mnz3iCWDU4jcSpuCuP4uuPrVvw/dajcrHIlgiTQ5imG7CyDP6dDWHY3GkJqaNZb8SIshhkf+X41pzs0t+08Fw0IfBKLkE+3ueKANiZIm1EtJapEy/LvaUuPypmoRGXaba7jkuY2BCRjDjpS2psNYtS8kM5voyPMQghlx39DWtouh2j6jHP9oRJA4fLccD+HHfNAFTXzdXemLefZxD5IwyLwx7ZIH51j/b5IlieS5l2FAcOcHP/ANaut1jVza6pdpc2kUQkwAu7gAdx+dclqmm2c0dzb208bbh5gcyfdHoP1oAZNrUlteQfaJZ1jcbl/eZB+o/Kq2q+KhJdxW0TMqLlVde5rmtRjhNuZ5mlNhbkljJIRkjsO+Pesf8AtfRWLXLSRR7BsSFCRIPcUAd7YX0V5ZTwTajCuDyjzfM+c8e2c1R0DV4bHVmgtb0q6/OSGzx6V5Bf3rfa57qy/d7JODOcMq+ue5rctNcmt7gS291Z3jCPDNGgGD/WgD2TUPGaXM9uuxpJ4zkgZJI/wrTh8bMlm622f3zLjzCQVb05rxXRPE0kl073m2PzV+WQthgP7vr610ZaX7StxfzRpZx4HkoT85z1NAHtltrkNnHJLq6I9yycZ4H51yH9v2ZvJIrJZri4kyQgB2n2rzbxL4jieWE292Zo2wFSJ8gD3NW7S6vtKihl/cMtxIMS5+cKe30oA73S5riTWczQrLEVJZUI+Q+h9K6Cx8KarrAylkbC0kbfIRwXB9azNE1mwMdywuIbeaMYkGfvn1Bq5qHiXxHcaEXsLpIbb+AL98jpmgCebUNL0D7RpbrbJPEhUSHjH4/jXjV4uj3mtzyRztHKkheSZVxuPPTt+VQ+Jb2zjRl1G4N7qMjYb5juHORn07VlI0V1DLHdTxxqDvAUD92PQ0Ad3ea1pek6EfswNw83WfblsevrWR4bgvb2GMxkTeYCWkk4VAO+O9YF1r2haMkf9jXct45G1lclucdBnpXH3Piq6d2jtvtFtEjElRJhQSecD9aAPcpLTRdO0Z0mkaa6HLOB97uTn0rzi48W3dtp10YS7pG525BxjsufWsFfFNxqejtBO81zctlYk3jCDuWqCzurW2aMa7JPc2kJ+W3Q7VJz0P5UAa2l6hNYQnV9c1Efapl3QQMxkJPv1I9K5jV0uRfRahbmRryYszSyKNpJHQZ44FaLfZrW5Oq3emwslwT9lgkk/wBUM5GQOvX9KsW+sjVNatbnV7a3uLO1lDG3JwrgY4A7A4oA8+orq/ibq2ka14tub3w/p0Wm2LKqi3iGFDAYJH1rlKACiiigAooooAKKKKAFAJOB1r3T4BfDBNW1FNR8UW8sNm4H2YMMZbcOWHpWb8LvhFfazbQatqMyWkTYe2Rl3Fjn+Mdh7V71oK6zot8LfWYFmgPCyRL8h9Cvp249qAPVpdPjOhvpWoxxzWzR7VfHykdgfQ18W/EfSr3wp4meW1hniWNgEdR79R6ivrW38V29sVtryQiDPyyngD2OelY3xJ0jS9V0zZeQbxjMc8fLDPuKAPli2+IGpCWC5jlCyxA/vETBzjvXfaP8TLXxBZJa6o7ySAZeSM4IGPb8K8l8X6U/h6/nhibzbJwQVB569D6VT8KW88kxeyDIi/MGBz25H17UAereINO0y6ubaTQ3Rp9u5gDtIHsfxrN0eS40i4vIdUtZVtJclLlgWVfx/rVVtYhijhu7GMOWQxy22Mvkd1qK28bNDpTC4srkaexMLl2DKPQHP8qAItchhhlS+0y/jEmP3wjk+9z1FdfoTF47JbmZhGPnSQn/AFhPavNtPubeXTbqc2ENzEucmKULIB2OKXTtZvYRbKJz9mLB0jx9zB6D/wCtQB9AaPDbwaiJoLoTRsvzQ5x+JPtWyXhsZVYw2xVmKmRX5z/SvCDfyB01aK8ljZn2tbrzux3xXpfg/wAbaPdXIt4rW0uflDS7SCWHfg96APQtdGiWkCS3Fybify9/mKwbnsteOaybG+M1xb6s1ncb+YNgG8eg+uK7vUI9L1W8doUNjtO1cj5W/E8fhXF+PfDqhXa0vLVr0gGNXYBiT120AU9UtLXVdOC2syR3KjYwwDyO5A+nSvMNfsbnTrlnYx3JLnaVjwc8dK07jWl0qGa2lWcTMMSup2tG3171R1zbLYfavMu7qJ0ysko27T3HvQBgX0z3N55eq/ugvKqwC5OO/wDKsOCdreffGx4PbjNdPDptprCBH1KGN41CrK4wuTzgmuz0L4e6JcWUM800k6hcyN5mzcf9nHagDz2eK41K3MkSMxXDFwf5/wBKupqr2EO5Z7q8uGVRJ5inbH7A1d8UadBo+p/8SmUw20mF8syZ/GsT7RJYmZLWWORnziJE3jnqc0AaGnyKtq96RBDEG3ASvlmPoBV4+KlljW3v4DDEvXqC/b5fT61hz6XdWltDqF7a4jUcqTyeeOKzLhnu980siqwwFQntigDpLPxZ/ZWoO1lbbkZhw7knGe/Xmte8+ImtahcpDYxPBHyrKgPzDtmuM8Of2eNSRtWZhaAHcFOCeO1a19rGnx3LrpLzw2uMAbfmPTqevrQB0ulaWJN114kvorG2GWVScuzH37VjLbvdW19Po00rIh2IGb55fcAVNpIufEdhLp9hEblk+dnl/gye7Gn6VfLpMjW96/mTrlA0CZ2A88Ht2oA5va+mX8U2oqHdRyjKM5I4zUeqX8N5brKIokmLYIA5P1puoRwT6tOzXEohyC8ko3Pk9elWtVGhysn9jJcosYG9pv4j9MnAoAxIpWjlDREpnGQGxmuhsvs15ETdSLCjcu7HhgPQeorFu0u5IUubkOUbhWZcAj27VNqGo/boY1eNYREgCqg+8emT+tAGtdzWHlCe2kZmjDIsszZLdcEL271m6New2/nreBwkqna6rkhvWs9ZvnUuisoIJXpu+tPvryS8kDOFVVGFRRgKKALM8llF89vbswb7vmHgY71Q+aR2KryecKOlWdPgt5zI15c+RHGhIAG5mPOAB9aZZyxwzAyh2i5yqnG72PtQBWopzHLEgYBPT0ptABRRRQAV7r+z98NdL1+2uNa8SeYI42H2KMHCsw6s3qM44rE+DXwofxkH1LVZDDpUZwsanDznvj0Ueteuabph8ITGyjZf7MYYXDHaMdj6GgC7qPip9E8TG0urZ/ssp8syRjI3Y4Pt/wDWrp/BXj+01C7utJ1FFe3j+eJ8j5K4W+vLLUZZY41kSRwVYSKWVwO6n171gx6Q+nX/APalu/Lj5iOjKODkdjQB69450eK8WF0ut9rMfvRHO706cVV8L2GoiGSKAma2OVWJudn51qeAbMvpFvc2nlSwEfvIAcgZPOPQ10LwQ6Dd/wBo6bPm2PElu/JHHagD5f8AjPZs0s6T2gijSQeYQcPgd8e9cBpnh+6TRNQvNH1WEhBuMRfY+B39PbFfXHxQ8KaT8QPDdxLb74dR2gqwHDjrg+x5rwDUfg7cabp0zsJESRDgb8gf49KAPKtMnurC9jv7MySCOQnnufT+ddjrMcF7oM2oBVe7OZJLfoM/7o4P86dYaXa2ljNbauGiaQFY7lWxtA6ZHrRoNpb21zBpdzeoNPlJVJuhzigDzyzgunZp7UrGQeVDYwfoa3dQm1O1itYtbUGAqZYSgGQcZ6iu08e+EbWziWGSeKKWQAx3Sj5JAB0OO9cKbJ7CCJ9QuBcW8Z+WON8lR6/TrQBr6Ej6oEZLuCLby0ch5cfWrPiG50qzkWLR4jBds4ZpomII/H+lY81rp+ptb3Lyi0gVQCUTkn39K9B+G2gaTq0jwf2tb3CuhxHKozuHpnmgBk3xA1aXw7b6EBFPbxsJmlAAkYjqM+lWtSv7fUdMid5Ypb2Nd6So37xPUAev1qzq3hPw54S0jWv7UNzJqD7XsPIclcE8gntXI3S2N7Yx/wBi2mxwAZCp+Yk+9AHK6vPHBftGss5guB+9Mycg5Gev+eayrvUJTbm0WVzCjfIo4ArvJNOsJ4hfXP8AaDtEMSeeFKDHrjnFcpfDSNT1WeVJDaxu3AQfKDxzg9qAMfT5YReRvdhnjDBigHDH3rdfXNTguGFkZUtOCEkXCisbULWG0kY29350e792yjBOO5FOF3e6nNb2/wA0824CPuSf60AdPqXiG41CSFIYrS6umAQr5W1h+dZ0dxJp7yC9K293EpAjKYyCcce9RXHh3X7S9SR9NvLckgB0jJx+IrUbwxq9zMZNVjeSALxO7YIHuaAMO4l+2Wqzy3MjTgcc54z0xWVcBE2qikEckk8mrU//ABLr11tG3/LsJYBsE+lUW3FiWByTzn1oAc8TpGjsMK/Iqxp8tpGWF3AZAeAwJGKinjnGBMrDaP4qhPX1oA1YNTulRrXTS9ukhxtRuXHYE1saHqD2Sz2eoSR23ycHytzsT/Dnt2NctFIUU+XkSHuOwpHlkeTzHdmf1Y5NAGzq2qxyRm2itIREP4z99j6msaNwhztUn3poBdsDJY1bwlpGGDq1yeQF5CfX3oArySSvCiySsyLwqFidv0HaiJo0YmRDIMcAHAz71GTk5PWgcmgBKKcylWIPUU2gCzYWNxqE/k2kTSSYzgdh6moZY2ilaN8blODg5qSO6miUrE5jBGDs4z9aZAyrMjSAMinJBHX2oA63wX4HufECG8uZltNLTJeZupx2Uf1qLxHoGnWWlvfW18qSNKFhtD8zNH/fJzx9MVPqXjHWNa019MsrYQ2QCjZApyMdMn/9VYWqwyKyRyApLhcRty7sfpQBk0V3Xhv4Y6/4jtJZdMiiMkSl3SV9oHGQoP8AePpXEzxPBNJFMpSSNirKeoIOCKAPtfR9CbR9EhvPDwDac0YdFQghBj7v5Vwfi/xsbMym8sPtCSZR41GMnP8AOq/gLxV4g0G3iksokvtHlXLxknIHoB2OKj8Zaxp3iF57vTIVd2XLRfxI/bA/Pn2oA1tGe1vtHiaNJYCn72AtwVPoaj0K1vdRv72GJfNidc7Tnarfj0rjbTUrmxQIXYWswLESZzEwGSPxr0v4favp2mIknnEecAJN59egoA3PAEl1pjG0um+zuPukN39DXcyX8d1KYrjy47wDqoOH9/euC8Tvp1yFu7O6Uy7txKdPxHU1nad4jhXUIv7WDRqR8k8Tbl78n60Ad7ea5LBbqsKJDdQkr5b/ACrIM9sfWs3VdRabSprbVZDE7r+4cg8k449MVkal4lgkmNncx+bs+aORVyf/ANVcte3ttcGIm8eWxk+WRQeY2+n40AeZfFCws4C9zA0znJWRVk3K34evHavOL6+tpLWGKJ5Q8Q25cZAH09a9y1fSNIS6hs1uGuDKSU4OV9q4vxB4AufCczXM1k95ZXALKZI8DnoB+dAGDofiNoYIbTVpYrmwKFFLKTs9CfSudu7N49ReKwnW6jB3qARkj8a67w94dt9de7hu1azSP54QiBsD0zSaN4WsEvZ1uhKLSJj/AKWrkEH+6QKAOQV7wSrvtGkRBllKHj16VVa+mW6We1VbVlAQeV8uK6y9uVs7q7trC9ZYoWPlsRnI9f1qrp+nrq8k8LXcEjyfOJpwUP5/WgBLIeI/F00llDDdX4tYvOl+zjLJGMZJyaxoBsJfT5ZX24Plk4zyetddpZ8SeD4tQlsJJbNHh8t5oDu3L0I3DtiuAWKQ5fBJUjIz81AGjfarJPAYJYsH+Lqpz/WstWKhsY5GKV2LtyzEZ43HpUk8KwTmNpFYf3l5FACwtJAVuQEb5sfMc89elbun+ML/AE52axjtoSy4LCIFicdc1zyRh42YMoK8kH0phxngED3oA7B/iF4gl097W5vVmic9CNrL9CK5+TWtSlikikvrho5OGUucGs/HGe1JQBcthcQW0lwkIaBvkLMMgH2qGKOS5lKoC8h7etNM0hTYXbZ/dzxSLI6vvRireq8fyoAtX9jJYiMTspkdfuA8pz3qmOvpVm8kglSN4/MM55kLnOTW3pGmeHptNkn1LWJYZxnbEkeSfw5oA51QCBtDGTPTHFNOcnPBqefyorgm0ldlU/KxXBruI/AFxf8AwrvfHT6hGPKuRD9lEfLDIUtuzwec4xQBwB9qSnbTs3Y+XOM+9NoAXHGe1JRRQAUopKKACpAUWLjmQnHI6D/Go6fHIY23LjOMZIzigDr9H1+70nR/sNvDAs8j/KqrmQ8dSa6z4ceDm1CWfUtTkPmRsP374IHTp6muN8EaZJcztd3CiOyQ5ebGWJH8K+5rsdU+IrWcaQWEES26KoCq+QBnknHfFAHrh8SW+i6aLHRoEMCkNPLL8o9Tz/nFfPnxX1jSPEPiyfUdFt4bSJ1CyqgIDyc5YDH696ueMvFtzq+mG2Z4raBlyURiXmOeMjsM1wKOqLwoZj/eHAoA9T8L+MZ9GsJImKywkBZozw/cZX/A10M7aRdR21/pzRpuYeYFO1hnvj+leZXd1Hq8ti9zbG2mlwDMg+Vj03EDrXf6ZpElpdW8V7bMsnWG4WPMcnsaAOkuNIg8pLu5lkuI2IbKjO7pzz1+ldQNO07XbEWuliMXEag7Bwam8HadJfRz6eyW7LjgDkH6HtVHVdM/sHUCSssE8bD7vysB6+/1oAl8MaJcWWsS2zwMJ2GSspyp+maW4k0qzEun6whtLmNiVZwQrD0FdPrmjy32i2V/pmqxTng4Y4ZTjqD68jiuWuIJddna11W7i84ALuK/MQPrQBd8NxaZqF2RG6tNGNyMWz+H/wBasDxreafb6iJxGtpPHnzivQ57kVBp9xc+GNS23mmS+UMj7TEPlkHbIPIqeXV9Lubm8a4svNjzuMhHzKO4OaAOUW+SPUY7mHUIp7SQYyn3o+OMH0r0dPitaadoUena/DDqFmyeWk4wxJx06dea8B8fXGl22tQz6ATCkmTJCvCg8dqw7jVr2XSmtHeJrLdnqTj6UAdnrOv6fBrc1/4fMkUJJWaAdAexH4VPY6fd3NvJPcRg6dcDzAYiQST1JHcda88gtJL6NG0sNJMgAeEEnPbgVvaTLr2mlIbhLu1U4MbShvL69PT8KAF1+wcK/wDY9rM9szbfOSNmJI9utY9lpmrSRJE3mWsROVMoKj8zXp2jXPiQQO1pfWU8I64QYUg8gVQ1nQdQuoW1K71xDbEfNA/GD1wO1AGJ4W1a68J+IrW88QWkmpaOgIntxMNrkg4PpkHBxXL+ItXtdW1y7vIrIW0LyM8ccbYwCcgE1HDpmoalq8Gn2+XlupRHErScMx4FdDrvgafw7cXWma35VtqcOCGMuUYH0NAHH3FtPH+8eJlWTkHGR+db+jeGodXhUJf29jcYwY7uQLuOe1ZFtdS2UkkPmnauQCj8Ke5HrVa8meWYM8zSkcBieRQB0T+FjZC4abWNPSSMfKisWL+3t0rmlt5WQukbMmdu5RkZrX8J/YH1ZRqjHYehJ+X3Bq8dSGmanKumy5VWHlKQNrYPHH9KAGad4J8TajEn2bSrhomPBbCj9TXST/BjxUtn9otoIp8LuZN4Vh7c10WjeM/EM8Y23NlYJu2s8i5GcdMdjVXS/E/i6614WVs1xqck5PlW8L8se5x6d6APNJ/DmtwBlm0u7QIeSYTj86yXVkYq6lWHBBGCK77xbq/iXU7ue2upLm0SFvLeDIQKw7HHQ5pvinwn4dsdK0m40nxTBfX1xCZLyJsfun7gY59evpQBwYYhsrwfalZdo5I3eldL4cvfDmn6T4ht9d0yXUNQuLby9NuIpdq28vPzMO/b16Ed6yvDt1LYa/pt7FbR3UkFwkywzDKSlWB2nPY4xQB6R4H+BfiTxj4ettYsr3TIradS0ayzHdtBxzxx9K2PsHiux+Ed34Sez0tLE62ti90br955hcc46bM4Gc/hXI+LtT8Sy69d6ncTS+HodQfzFtLWdkjU4AwFU4zxXXX/AIR0iP8AZyTxAWlfWHvw7XZlb5iWK4Izj2z1oAj8Yfs+eIvDvhy51W41XTZobVNxiRiGP0zXiLDBIyDjuK1tR8Q61ewNa3urXtxAcAxvOzIfqM81kUAFFFFABSkYOD1pSAAMHJptABVmwtzdXSRgcHlj6D1qtUiO0aMUfaWGwgdx/nFAHorz6bYaabNLzeCo3QQHDP8A4CuIvrK4j2J5G3cRsTB3nPTA6n61Z0Kyuyst7aW8kxt18xysbMIk/wCejEDCr2yaht9WvzqBuVbzL58BJDyV+nYUAVb6wnsdi3SiOVxuEZ+8B7+lanhVdLR5p9YRZY8bEjL7eeuf0/Wuh8P6NpaTS3/iu+851IYx7t271ye9c7r17batemLSbSKzsYsmNOhbnqx9aAOm1LQLjSZIBbl2skfdG2MlCT39ua9c0/UwNMtbPX7NkKhRHcR4YH8q8qkh8S6Tdm3nhNxA6YlTqHTgZU+uOeK0LLxNfWsU1pNC9xbYzHFLkMgHbPoKAPaPsD27W9zo97GXGCJ1OSvswHUVL47kvbhLU6vaeazDZ9riOCOmePSvPfB3iyWcQiz8tpU4uLWXhmHt+VejTeJra6sNlymyOIbijjBHWgCDQNJksrNor/N1A3Ty32un09amvfC1nfWxjs7seaPmWTOGHfBFVV1DSZoY5pp0eHgrKjkbGPY4p7iSe6RYCZX6qwO1iMevSgDmdRvNW0/TZYbyM3kiZBToSM9s1yz679lhMd/bvZlxmOd1O0545/GvT7nUVtd0epWizQDr5nyuKW3utDuoWg2RXNo/yy2dwBuGe4PpQB84eIdDuTHJcwtHdZ5LRtuH0xXHsssf7p0ZS2CAwwfrX1p8Q/B+l2nwftx4d0xGuPPZwbc/vVBPc9x04rwGLw9b6qzWzXzW96AQEvEIJPsR2470AV/CepyaBbzF4QzttYBPvjPTI7itmx8f6ndXQUwWlxDGMtFKNv8AOuXWy1XRvEFpaui3Fy0ipEiN5iyEnAA9c103i67NrdPYeI/BhsdUjAHmRuUYZHBx0IoAvJ4sthqjx3+lrbJOM7rVsA5xjP58/SuqsvhfpWt+Fi8OrXEV2xMn+uyhX3Hf61yv/CvtSXwZZa1Ncaa9pdSlFt3lKzgDofTt0HtWn8LZNK0fULqLXYp7uFoGEUS3B2q3HOPWgDlNS8EXmkzpKNRRREwdH34OR0II6GsrxDcS29z5l3dXN3NLzJ9qBLMc9QT1GK6PVr06L4jTUI4oJNPV1coWLnPcEdvWvQviR4w8PePdBtbiMwRz2KECNF8sjOMg+1AHhy+Hb66sF1e3065j0cy+W1w4+QH6j/OeK2fB3w+vfEuuy2VndWEYijaYmeTaCo7fX+VQP4q8QXeiP4cjnjGktKSsYAAXnsRzUmnxtoM63Wq2kV3E42rPFMDxjnI/EdaAMnUNJVNQjWF7aVN+1oonweDzyfX1rpvHo8K3Ett/wjWh3lkiQqkivIGLvjluprE8WXulakwmtSsbA/cRAMis7Q/7NeR4b6e+hV+FMJXH/AqAOp0jX7qLwLqHhyLRrOS0uJRNLesf3oHt7jFYdjqX/COajbanoOp3NpqdvnY6DJXjHHboaiuLOSDzf7KlV7TbtZ3IXnqeKzbrT5ERZlljnVjgtHkgH64oAbqeqXeo3k9xdXEskk7b5GY/fPqccZqjWvpGhz6pMUt5IcL94l+fwFWdS8N3ts7AwKmPu/vQS3IFAGTDcQoY/MtUcKcn5iM/WprzVbi5mikXbEIhiMIANoqnNDJC22WNkOSORUdAG1qviG81O0hgujv8o5DE5JPr9ajPiLVz4dGgnUJzo4l88Wm75A/risoAnoCfpQQVOCCD6GgBKKKKACiiigAooooAKKKKAJ4Lq4txKIJ5YhKnlyBHK70/unHUcDj2p1ndPasWgIWU8CQjJUe1VqKALDMrSKFMjoAN+T1weackMt7KwtYSQo+6P4R9aq1eiuzbIBA5A77Tgt7n/CgD0Lw74n1abS4FmMd3BGojAY/OoHYHtXc6NqWm6rEyXdt5kidCB+8jPHX1ryl5j4a1oyxwGSxuVy8TDPynrg10bLGtumraHPIYRhgCvzD/AGT+dAHWT6dYWFwbuwiMdzuJOwZDfUdvwot9dg1xzbXImtbxRhCBwe35+1WtBtYfGelxyw3JgvYCGdV4IPpn0q3qNjp6utvqdrJFcwfOlxGcZPqaAMKbSjpcSyASFCcsIV65/wBnpiux0PxLLFEsHko5yMRuME1iRX0V8X+yX3nmFsMGABU46mpGvVSVLW4hErD5i0fBI9R3oA7qTxDo/iG1a3mRo71eqSd/x9K1LJvBWkaUkl5oc8lwOZGU55PfORgVz0PgK21my/tTw/qDvIV2lJOoI9a4eLVtQ+2z6drkrWL28hQOBlXA780Aev3l/odlp2nao9ldQ2cchLMCQJF9Ov0rI8Q+JPDOo2F3J4N0qKTVbmB4i9xFlSpH14NXvEFxa6h8MLOws3i1JY1yzHgDjjpXgkUWoaXb3Nzp6ohtpCvlmbDKo9D3oA52Lw/4q0i/S++ymP7LIJUYjOxl5BHtkZzVzWvFWo+J3f8Atlbo3DKMTIm9Tj19BXe6V4u1HxDarHbRvKoUJL5kYbBPoR1qlrHhh9Kt5L2zvLnTVfLyAx5jbv07CgDzDSL3V4HeNbQXtqGGUcEoPU4zxWkfFkuk3G62sEtdwBaGdCwxz90muo/4SjRZ7BoLtGlulX5ZofkJb14/rXO3slzJZBdZR5IduRJIMkjt9aAOf1i91S/n+1usIaRQ+yIc4/z1ra/4QKD/AIQOHxLca9ZpNPOY2sV++n/1++Klt7GB1je3SUyBSA3lEBx04q0/w+1680+XUYLGOZIBy8c3K9eTnpQB59eQfYnCwTmQv3Xpj/GobbYjfv4ZJF7Acc16v4U8ELJpxl1m4gikHzbWHCHHqOp5rC8WeGxZ3cey/tzblm2tCv8AOgDjbh3urQNFZKkcZA8xck/SqCNtOQBkdPavon9m7RVfxxLFfQpPbrauQHTjn+vNeL+PLeKDxfrUVrAyxR3L46naM0AYsl7cSQiJpD5Y/hAAFFuZ5WS3gZsMeFBxSW8cLIzTOy4PbB/Skk8kFhGzn6dDQB0Gn6w2hRIsKwmfbywAb1rJ1XWL3U7rz7qdi3YKcAfQCs6igB7yO+N7M31OaZU/nRhcJAm71Yk1CeTQAlFTJ5KxEvueU8BegHvnv9KIbea4ZvIid9oydoJ2j3oAi4x70lSCKQswVGYr12jOKjoAKKKKACiiigAooooAKKtLZsLYTysscZ+7k8t9BVYDJwOtAABk4HWldSjYJBPfHakZSrFWBBHUGuo0rGlWKz3IjikmxtRvvFfU8euaAPStLtL240uKK/0+2v8AT512qQcSIMcD0/8A1VyVrC1jql3YQSPbTgnZE42r7Kw6HtXoWlxvpiu9gXu9KkOXjc5aH/d9RT/EFhH4q0bztNEc97BlonGFlU+hz1+lAHN6d4lGmX6m/tl069UjM8KfI/puH4161pGr6f4nskXVFt5lbGJ4Dwe3515S88M9kun6xEkGrQgqsj8rL/n+dN8Fx3Nje3CJ5STjDCJWOJPXg8d+tAHqGvfCq2nkivdFnnDJyQhCtjuQcc/jXHz6NHZ63Db3F9IJVX77R4ZD0+b1HPWu88M6zNqFli3JsruM4MMhwM/5zTtT1SdpP+J/psazK3+u25Vh/vUAcPLda74A1pL6UtLpUrZa5gO4D/eAP0rf8W3+k+LLGK5jlgllfAOByw9DmqviO0u5bUzeG9QRYSMS2EwGD7jNcKVu9GuBPc6X5cMg2s6HgfhQBo65piWdl9q02W80yeNdrCJi0bAf3lryT7TqEt/cSCVpmlJ3KzEZ6dq9gkv9fMO6x0trq1I3K4Xdu/D+deceJrAXczXcVvJZzctKFBARu/HYZFAHP2mo6v4c1Avazy2c+7cQjcEg9xXd2HxX1nUIms9TiS7jYYAB2kD27GvNJJpPMYXOZckk7iefcGrGn26XUoCLLEwIwyZOPWgDsPGsHkW8d5aWy2sJYYkKYk3dwexqTw94kuYtLktJdl5FIB/rYt2GPYf4Vm3rw+UbA38oIAKbgcN/wE/jzXrHwo8J2MumpJ9n+0zrksx47dvTFAGL4a8O6mYFlnvoUi3Ei3DbCvoPSvoD4eReH5NIuNNvJmRZSBNE5wHIGfxqhpXgjwpqRdLnUZLecjDW74BH+eK07XwVoOjrL5WqGVeXDFgW+lAHLfEX4faJcq40DVTBIykeWZMpz61494f0mfwH40tNXv2hv0tpSxjKl1weDkV9P6PZeFWiU3YdJcffkzz+lZfiPwbpWs3GLC9PklTuGzPX8KANDwdpug69qcPi/wALsgS6gZZ4FAUBsdMdjmuF8SWej/Crw1ql9c266p4l1VXTyGXftVgcAccL60aZ4a1T4Z3d1f8Ah/VC8coIktLlf3Rx3wOhyetePeMYvEmt6rdavqGrO0j8gRAkLweAPagDy27hns5/OnsrVV+8Im6flnNZMj73LbVXPZRgCtjVrMZaSW8MkvrJkVReOySAlppZbgt/AMKB+NAFKinNjcducds02gArX0fQb7VXT7HbtOCeQh569Pb8ayQcHkA/WtmLxPq1varb2dz9lhAxiBQmfckc5oA7S18JXOmWz3Wqw6ZZxgcNNhj09D3rk/EGvX8xazj1MS2Q4CwJ5aH8B1/WsW7vLm8YNd3E07DoZHLY/OowuxQ0iEg/dycZoAcLmYQ+SsjLH3VeM/X1qGlPX0pKACiirEFs0nLssUYG4u/Ax7ev4UAQGkpTjJwcj1pKACtOXRL6KyS7liVIXOFJcZJ+mazKsItxcRquXaKPgFm+VM/XgUAJdQtC2Hljd84IVt2Px6U6zu5LMu0IUOwxuI5A9qr45wSPrSUAP+f/AFpz1zuPc06Rpp33yGSRiPvMSSQKFilkTeFYqOM/0qaZZ7dIpHkKO6/KqnBC/h057UAfQemQ3emzyw3H+lWErbkJGGjHPGO4rLvrC50e4mv7FpntnBLIh27W9eK1dHnuInSz1JUlliyBv+V9o7g966HTE0PVxPbW96tteoMNFOwwSe2PegDhpZ4tXiiXUbOTy3+5fKvKEjv7VF4h8M6lZwxXFhG03TZPbtjHfd/9atXxZH4g8OX1vHaaaJ7WRsfK25H6cZrSsPFO23MFxGdJuwAywT/6qT2U/rQBk2U01xbhBcCHUVAyhz857EV2HhrWb20iWPUoRKkZw8b/ADqw/HkU7wxf6N4ob7DqenrbX8YLZTHzZz8yn074rr49J05AlvM4lYfKsqnDjtyO9AGj4dtPBPiMK8UaW9yhwUU/dPervjTwDHcaWp0/yZkTBdWUZYegrEh8HQxlp7C6WC7U/IcfI464asLVdY1KNHgN3cWFwq4WSN8xkj2NAFO8sltYwtk0lvtBG6E4KH3WvP8AxXbateI5guYbiRwV3GDGfZsVsXl5rF5qEe6SH7ScBpBJsLD144NXxaz2+JpJWs7luXWTlHA/Q9aAPAmsZdPucXdpHJNE+BE+fmNa9tpdxCHuhFLaXQO8xMvDcg4HNewarpNu8S3ojiJTBcKA+e+cfhXMa7e2b2im0vbR5B963n4A9evIoA5TUdQs9VsPLu0kivk48zavbtk81J4FfWorkra62bOQcBJSyrJ+Xekk0qfVp03aa02nS4Ja3cNk+qmu28NeHNMsruCKHR9UCSAAvIDhR9T/AJ5oA34/D2satbmeS9mW7A4lil3An3q94e0XV/t6Wc8UjyE7VcSYHAPqa7Cz+G88ypc6VdSwIWBKBjnHpkGu6i8E6e7RTTySrLGv3PMK8/XP1oA83GotHLJa+Y0U0JwxY5UEHnJ6V6Z4T1s/Y4obiKKSZeDJCOPqaz9b8O6K0JtktGUsCpw27Prz61peEdDg0+1MMbvDEvQBxmgDS8Q38B06VFj3uQflaPPOOmDXyl4y8U6jo+r3AGik+Ydqqy9fYY9cV9U61osdxZSfZrlllxje75wK8d8R+ABLMbg+Jg1yvUOmQPp+tAHy3qviC5e8nkv9Kt0aXhgUwQR/WuaumDTuyxeUpOQmOgr0/wAaabZW2rz24YvPnP2lCHzx2FcTqs1vb6ln7U94q4BGzYD7GgDZ8DeB08SWjTyXk0WH2iOODdnjP3icD8qx/GOjvomo/ZAtwLccoZgoLdj0+lbGgaxruoyi30mdrSML3l2Rqc/r9K028FSqj6lrmuWc8i5LLI7P19TQB5pRXTXMUWo3jw28Fodhxi1jKj064rCu7SW2u2t3GZAcYHOfyoAr44z2oJLHJJJ9TW/ovhi91dPMBMat91nB5r0jw58PdH0W3a/8QyLqBCZWIZWMH+v48e1AHl+kLpyBTcQzXl03CQJkLnt05JqXVtNvIzmTRZbJSOFZWHXpy1dta+JtEtPECy21ta6Zbj5f9GhDu34jpXS698QtAiiaK1spbm6dAN8uGb8vy4oA8NhxDcL9ojbaOqkc013MrF5G57VqalZ6lezy3r2lyUds7nTGMnj6CspxtJXGCOvOaAGUUUuTjHY80AJUrqyEReapXOcBsqD6+lRUUAaEtvZ28fz3Hny8HbF9386htI7cq0t1IQi8CND8zHH6D3qrSk/pQBakvpGmR0VI1QYWNBhR/ifeq8jtIxaRizHuaZSkEYyCM80AfY2p+HNG8V6PHcWqyWN+I/kZcg7se9eZap4G1TTr+OW4iAdz807ZBPpyK9v8O6nHEr293BHeWjYw0Y+dfciu3htbTULAR4jvLMjG1j86D0oA+Ypda17RbY2Wr7r/AE4riOUfw+2aynvrzWdLe31C3Wa3wTAcAOOex717pqnw5tJbi6bS7xjHJy1vI33e2MVxFzox8NXwjv7OWazbgqRgD3U0Acf4Ma60yZPM8+BlIKNINwx9e1e1Wt4dWtIWvLRZGXpNAw3DjuK5lPDlrf2yXvhq56DJtnJzx7HoaXTZZbQiWO3uIJ48LJGRjJ9VzxQB2UerG3hNvIPtC4xkDa6/hXlPjfVYbmT/AEidvJLYDAbZI+TwR3FdpqOsqLVbvaHwfmDrgj3z3qldXWkeILEPcadHLOqjIGNy/T/69AHI+HZ9Jg2Q317FcWz/AHDnBjGK6jWPDqanozppOrJNBLGT5Eh6Ejse1ct4l8M6JLb5m8yPavVeCn1A/GrPhDw1pTwm1sdcLlui+Zyvt/OgDzxLu/0XU5dOu3u49g2Ju+YP6Hnt71j30FrK7PfRySsz/O6jrx3PWux+Iml3+hXEX2toL21ZwIZH5K+vT+dbXhzwddajYw3NjqlqXHzmIYGc9if0oA4zwFqH9i6gjWl5FLZMQvkSP9z35719FaRqcGqaajWEgWbGcMQQRXg3xBsPsUJtk8Pym9DA+ZBHlc9ySPpVTw3e60uw+bPbqozieEoCP96gD6u8LajfxMI5HjSMEjDtyOev0r0AJ58QFwiHIzwc18xaJ8SLezdUmbzp04MTnJx617BpPjiC7tFewIY7QTGxGe1AHT61apbqLi0gDzoCQgPX0rBlbULpozd2awjuVOcfWrN54qazs4Z5Y2aWVc7I2DbfwrzvxR8QdR3NHa21yJSSAxi+UHseKAPQJNL05IzNPLLv25IEg5/CvO/HOreHsNaO90jMNokVgAP1rl9T8Q6/fwBrqGNRyQY+M/X/ABrl9V1q3dCutw2ioowct83r/jQBX1W68PaXJJc2O67mAKl2xJwevt/Wsafw14d1aV7zUdRtbW3YA4UkNkdh+dczrOq6BLfOluWgtgc7gvJP0FQXs2l3ipFYXFw6/wAaRRdv6UAdvL4f+Gi2qBL27kZVB3pIxGe2R+Fc14li042E0Nlc3k6E5W3jt2BIzxzXbeAdQu40jt9L0GIJgDzbqIZLfXvW74s0/VdTgkFxNZwFV6KwXigD58+wanY2r3FuVggIb5twDEeh9+elVfDd5FZ6xDNcLuXPU1ueIYbKz1Ef2kzXIyQ0cU2eR3HpXNajcW0zKLO2+zoowfnLFvrQB63J9rv4Y7ixkJCZeOEOCc4xisjWB4v1iza3+ytbWyHI3uEJHvn+VZHw2064uZZbyO6aCK2PzDOMg+h/Cu41bUD9gmjF1bvGy5XLFn59u9AHksmm3dsHMgiHHMrNkAe3vV3w35trcPJDZPczHGx2UjB9q6bwz4b1O9v4ry8hSZHbKKVwFx3x0ro9S0LU1iZjdRQjIb94/wB0c+g4NAHMXlxqOoRuPEGuR2MD8m3iUluvA46GuTv9KR5imlJPKigHdJjLZ9MVb13SLq1w8t1CWJ+6j5ye5NUbDV59PwtvIN+D+95JX6UAZk8MkD7Jo2jfGdrDBpmOM9qkkaS5nZiXllckk9SadcQvEFEjJnH3QwJH1HagCClGMjdnHfFJRQApxnjpSUU4KSCQOB1NACxSNFIsiY3LyMjPNEjtI5eRizHkk0ynFiQATwOlAH3jfeGYpQL7Q3TzMZ27sHnnFQ/2re6bGTqlu8DIeJ4DnnnqKbaxz2Nit3ZTSXEA5WSM5wP9od619F8WWesB7S+ULOPkJVfvHp0NAHM6jrdzdMLiK5Usv3ZFGCfY1bubt9d0loNRiWQIM8cHNL4k8MLI5k01l2vnCgdPqK5KK31jQLwP5LSxfxw5yMeo9KAL2k6CRM4sZyj543tg59/Wu7sLSQW4j1RlWVBhZAfyzWFoo0PxBtls7uaxvSBmOYkc+gzWrNaarpqlb4Rz2h4EgGePegDnvFcNzZyBWhgmtuCSp4Iz3FZNv4e0y6BliSa2mIzkNgZ+tWPEtpA/y/vYlOMbXO0d+K5m5i1PStkmlXcpi4yW+dfxFAEPie3fTY23XMdwoyQk4xxn1H5V59JbwXV5FLps32e4ZjhSCVDDoc9q9IvdVurqwLatZwSQnjzEG4fU1yn9kaVPLHewW5jBYFHtJ8Akeq0Ac74uj8R/2ME1N4rqHoZE+Yx/h1IriE1K/wBKhjeOWQEjKyxtjH1FfQWk6RruprIiWa3lpwPmHlyLzz7EVyXjX4aeIYmE+j6ZOQ/EkcoDLz3/APrUAcHo/jnUWumea/EUh43S5KsPf0rXn8fXipiS/tXjABCbfMxXKapoE2mziHX7aTT5t20Ps+Rjj1FT6fFbaWyyG0tb5COHDbs59PQ+9AFiDUrG6v8A7Zc+cZGPVQVyfX6dq0bfxLdRXqyWYkyh24ZiFOc8eoro7D4gWmnxCFNGiZFGGTap/DHatW38a+GNWj3yaJLBKDhgihlHHJP+e9AGdB8RxBhbuykjmGBvFxwfwrtdM+JGm3VnIjsY88ZJBB/GuE8S+ONKHhK70WLTYWDy70m8kBwB2zXnlvcaLMwaTzlfBO0A8ewx1oA9E8ZeMrTzd8F5NgggiMjng/54ryO9vnmu/M81nGd3zDv9K09Yhhe2iexiWJFP324JHaoItQ1CG0eGE25VgMlUUsQfSgCrqN8LtY9zltv8OwL9RxVrT7uXTts2k3JSSRcOsgBIH5VkTJIpDSqwLd2GM0+1RXZszrCQOCc8+3FAHWt471u2Q27Xq3KYHBj2ge3GKyr/AMWarexrG8qRoBjEa4/U5NYtwoWTAlEvHLCowMnkgfWgCxEySO7zyS+c33SuOT7mmR7Vl3TqWUEgqDyTSQQSztthieRumFUmtuHTreI8qZP9+gCXw7PZhgrllKknDj5Rn6ck10EVt/aV/AYt7puAIhjwVxz9PxrFwiriKKOIZydi4z9a1tK1660yEx2yxFWOTuByfbg0DsdXrMytoxsNOjkgdSeS+WA6n1ri/wDiatckyC4uoolXIbkKT+hrQtPEtzazGSK1s8nqNjYP1w1Jq3ibUNThWGQxQRAglYF27sevJzQFjJsPDGpapdCZiMZ4C/w/06VT1/QY9OSNYmVnwS538Y+lbk/iDUZY1jM2yIfwINorDu7ZbqbzJnc9yAcA0BY5+FpFBEbFA3BOcD86SNFLAyMRHnG4DNdDLawOqhIljC8/IOp/HNQSabC7AkuOMcY/woCxiSbA58skp2J60ytv+yoP78v5j/Cj+yoP78v5j/CgLGJRW3/ZUH9+X8x/hR/ZUH9+X8x/hQFjEorb/sqD+/L+Y/wo/sqD+/L+Y/woCx9R6LdanpMsYkfEROFdDlWHoRn0rv7SbTdUjRp7RIboDHyALkn0NeZo8Woxg2Ej28+NwgOdjn2rp9D1aORfsWqBrS4QAKXGFY+oNAjotViuLePfaymRVGdr/eAHpXM3+ttJEwcNkD5ldeVx3zVq+1nUtPLpeWgvLJvuyxn51HqR3rntX1hHjMliqyA/wuNrduuaALEd9JeWZSK1S+YDJ2MElBH86XSPH15pMv2a+eZ7UfeiuQQ659/zrmYNWtLS4S5u4Hs93JdBwKv69dWepWLeddI6cMlxjqO2TQA3xjruk3qG4tbt4+MNGTkHn0/OuYcm3gS403VbhosZZN2Qc9evX6CufexFh5sOrQxahbyHclxCfnHPetHwfaB9TNrYYmgb78MxyV+hoAla7v3lCWt1HPauBkBDvHrkVganoNrDHNP9teN1bftwUYEc5Fd9rnhSbQAdQ0+K4jbbuMaZIbPtSeEfHmn3F/HZ+INNQhjsMssQbdzjBoAk+GWrap5MDWGu28oUAiOQ4br05616pdePZrO18rV7i2tyF4d14/Pv0/SsseENGvoheeHDZxyEbvLKAA57Y7Vw3jXw/cOBbTWflkHBOdwPGOmeKAM/x74hsdVhnjS/0/UN4/1DLg59j+NeM6RqNlpd7cQ6hprCNiR/rSNueeO1dHrGi3OjqssNvFdIpJWRkKstcdfqLhmur6WWKYjK5XcoHagC5e2Vrqd60tkklrEWGC0gOM0ybSm061RVukZm5cAkHGeoHcVn2sWoXLF7dB5bfLlQFz7j3p9/FKIke5nlLgFVjzkgA0AdNodn4GvvD+sza1q99banBDus4kQnz37joe/riuJY25n3WsdxsXBycZWrZtpNYu4LXS7C6lu2G1I403NIe/A5qWOx123klia0uFeP5XSRMMuOxB5oAy7meWQFGmdkB4VqsWTW0i+VcRmSTohDbR9T+FV7yW4eVhc7g+ckEYNQpG8n3EZvoM0AWtUGLj5QFT+Fd2T9aigs7idGeGJmUdSK0NFh0yS5SPVEu1AOGWEc9uea9ET4cS67aqvhjS7xYXO7zbiYDOPY0AeUxRMZ0QRmVj0RDkn8q73w34V1f7XHO/hVZbbAJ+0ONvTqcnP4V1+gfB3xFpN2s7Na286fxtKrY+lb154B8TXRJGrSSx8ZRW28DtnigDG1LxbqGnQw2bW+mWUK9UtVDOMcduBXmdenReFIYL+MPbTPIuVO/wCbcT1Pepv+FYRECR5rqCEcszEOSPYBaBo8ror1EeAdHUNmXVJWHQKFT9StYt14DnnvNmnzrbRf3bk+Y3f+6AKB3OIor01fhUUiQ3OuwRtyXJgIAHtlqzNV8D2sSONL1b7ZMMYRIc5P1zxQFzhaK6E+Erq1iL6tqVhaZI2rgsTn6GsjU7FLCOV5NTtDtxsRUJZv1+tAXKtFUbK8E7Hzrm3tkzwWRmP5A1Wk1OXzCsQjkHY7CM/hmgLmvRWKdVnBwUjz9D/jSf2rP/ci/I/40Bc26KxP7Vn/ALkX5H/Gj+1Z/wC5F+R/xoC5t0Vif2rP/ci/I/40f2rP/ci/I/40Bc+ldKddOnB0q7We3JBa2m4ZPp7V6JANF8Q2fkStHDOMDDcYb1/SvKbi20vzoVlVra4YkFlbhj9fT610el6PcJIm6WVAPuzLzuNBJY8QaL4i0HdJZzyXNjkjaCXAX1/XFcl9pa7+SSJ7W5wOV5Wu9k1HUdKQRtctPABgMcE59x6VzGqi5vCJrKOFyTuYRdevf0oAwrjT9TuYttzAGiY9dvB/DNXtO8NvJCgETpCc5JBZWFbNlqjWo+zyN9nc4+S5H7s+wNb2j+JIYruOK5tjEzcYBDIfofzoAwYvhnNdxbtLuYGjDcwO2Fz7elaln8ODbtvU+ROnU4yPrXS6h4elvGN7o9xLGQMtFHwT/kfyrm28QalpNzHBd307Y5PnJh157Z60AWL5de0yFYl1BZIOhEg3bc4/GuP1PSLvUGJP2AzBid4TYck9vXmuyufEFhq9t5Ujwm4AA3btrfl0NYUcib2s42jTByGZx1oAyfD1z4p8NT+R5CXSPwjyPjH+NSeIvFNzdXSxaho9xa3XDLNFLlP/ANddHc6JfLarLIlrdw7cgiUowHpmvN9W1WK5nktLSWSKdcjybh8qPoetAHQ2eoW18GSXVHgvT1jlgyo9KwNQs7e4kEN1p9nMhH+ujOD7HBFZFwbnTVgzExEmF/dS78Z/Pj8a3tD8MeKNQmSSKQTo4+7OgHHTHHegDLn8K39tFI0MFteQzAn93F80XoevbFczd+CtTlhMkGoQXDqM7GiZXHsM17Tb+BtetMSILuH5cfu1LKf84qC6tb9Jj9vheUg7cxrtbj6igDyWKz8VeC7jTvEP9l3lkFJMN6FyhyOcg5qhb3F3q+sSarcSHUb+8nLNG4PzOT6LjrX0loXjDw1JpMvhzxA80tu6GMR3SBtgxjAI60aBpHhHwxdfb7vT1iuAnnWSMmC455HagD5x8Zx3lpfx6bqWn2+kXKgEq0RYsCM9/wBK1vClhfXsEUdjpsV47Dc7OpRY2GQM9OSMHiu68V6M3jPxXPq2q2F3cPNjy/JfhVHQcVt6D8PxYYnsNRudPBxuSTLfmKAMvR9JvtGmWK68Paazycb413Y+pI616JpXhTVZ3jna7jsLfIbyIV5J780tvDpWluHv9WkmdRgEp1/zmt/T/E+kTR586eQLwQTt6UAVLnw3Gj+ZcPkKPvE859hmq7QaMrCMvK8nTBJxj61oXHijT7h1t7C0nLMdu5YySppJLAXMYhHmruGQZExuzQBiy6rpGlFktrVDNjjGCT9e9ZepXOo6u4ZtQisrZSflCZJGPeu1t9BXTrd5m/s5dvO9xk/U5rg/FWszzPLDamKXGVDIhC0Aczr0bOSkOtzSBQFYImM9qxFh1K1heLSE86VzzLMeVHr74qlquka3ey/aEuFC9SqAqM+5pdO0rX58Q/bTCI2yXDAcex796AKdzplyT5+v6jcZA+YISqnHtmm3+v6XYweVaSJJMwDLGjD5jzxkCneJPCbyQM11rV1e3AJPlK2APbPaufh8L6nZs0kFzZ6fbkEFkxK+fqaAMPWLTVb24E8zC3MgyinJLZyRjNY//CM6xIglmt2UN0MjjJ/DrXTJpAS682W/eRl4aaWbafqF9K2p/FmmaLYfZbfynuD/AMtIzvbPqWPSgDzCfTpYJjFJkHsSpAP51rIYIbIh5o1cL88cKbvzPb8M9a2NQurJ0SS7MU8kp3rEPnOSe+O/TiuY1AyyybUMcSYx5aHoPcDpQBbk0DXru1+0xaPfm0P7wSfZ25H97OOeO9YLrscqSCR6V7Fpnx58W6fpEFkJLEC3hEUbG2UsQBgZHY4FeQ3U73V1NcSnMkrmRj6knJoAhoopR19KAEop77eAgPuT3plAH07JYwTL5cqyq2ceW3JQ+x9K6Tw1B4h0mRRZXMV7p8h/1UowVHbmsLW0bTteeK2mlCbujHPf1/CtXw54k1CC88kGJk3bfmXqOaAOyvdMa/ti93p8tvu4aSP5lzXCa/4T1Kz33WiSl1A5MDcj6j6V7NYXs8dnG6txIvzKeR0Bp2oabaz2b3oj8mfGSYuAeM8igDxS31G+fTVj1iyh1ABSG/d7JBVe20Iak5bw7cP1GIZ34Q+x6iu6v5iUDFELHAJI61z6WkVy5vIwbW4VgN9udv6cigDT0G88XeHnZLq0m8kHAZk3qR0zkVqa5rNvrem7NY0qKYEf6yH76c8cGsKy8c65Ybo1uEnQEjEy7uP0robtI9Y09J7mJI5WjyWhG3JoA8pn0p4LiWXR5opIwMmKQ/OD0xVNLzzNq6jYSpIDhuDjPP3TXU2vh2yvtYXzmn3AkblkwetOukbTNVa3hkaSJW2gShW4zj0oAu6BrdpDagCWZoSuNkq7gO+KcYvDk1000WnQmaQnzCVDEn6flW7o1yHiEb29syHbkeWO9c14s0y1hvhdwRmKXfj5CQO/+FAGlLYaRcJ9nGjWysRnKNtPTrWBFomp2GqL/ZNxNCv8G6bgDrj6VTk1W4cFZNj4L4Zgc8D1zXXeD7kXkSfaLeBmHRsHI4B9aAPQvCsHie2t4zdGG4Q90PNO8TO6IZL6ynCBeSiZI/H8Kp6drd7ZXcUEEg8ljnYwyK9DtJTcxHzVUggZGOOaAPNtO8N+FBZJr1zZEMoJVZmyZCfbNGjW+mXks1vqdsGtphshkdtzRDPAHpXQeJtJspYyGhAAYkBTjHP/ANeuJuraO0YLBuUZPIY5NAFi4tNP8L6i0CWcs7Y3iSI5BHUVs2GqadeqX/sq5AGfmf8AirlxJOCCLiXIwc5Hb8K0Jnnjj3rdTblOeo5/SgC/rGlWNyhddNn3deeefWq3hvTo7eYtq7q0fREIxge9c/eare5lPnvxnjPX61Q0F5L4h7iaUlm5AcjvQB61t022hVbNI0A5znGPzrO1G+0C3x9t1YNNjhI2ANZNoqKjKV3bVJBYknI/Gq174b07U2SW7jcnhtqttX6YFADy1lqj5twUt1OcO3UVFqtp9ltH+wQ2vyoeGOTn3FXNQgttPtWhtLWGNQCmQvOOlctoDv8Aarh2kZi0m35jwB7UAeWeLbnxbOxBtmt4DJt/dJkEevSuWvru5s7RzqEt1vPA8sEZr1/4j+I76xs2+ziEZ9UzgY6V5dczNqWjpc3YDSNGWOOAcAHpQBwepazJK7fYRcqVOG3y85xVrRtIvLpQb29cRnBI8zBAPt7+tZ1u+LuTYqJgEDCj1962NEskaU3Jkl82M4XkY9fSgDtdG8JC5VHtdOJjPy+bI2CffJ/GuT8ceHdN0zKzXtvHNgtsifeWOfStFIrjVbkR3Oo34Qvs2xy7BgfQU7UfDWl6bbSXMdt506oSGnYtz9On6UAeUlipOzKqTkf0pQxjAKNgkc47f5xWpb2kd3JJJMWzuPC8DqazLkbJ5I1+6jED86AIycnJ60lb2l6Vbz2pml3sduducDvWdeSiG5ljhjjjUfLwuePxzQBTIwcHrSUpJYknqeaSgAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of a benign teratoma which has the appearance of a complex mass (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge Londono, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36208=[""].join("\n");
var outline_f35_23_36208=null;
var title_f35_23_36209="Villous lymphocytes";
var content_f35_23_36209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Splenic B-cell lymphoma with circulating villous lymphocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced peripheral smear shows small lymphoid cells with dark round nuclei, lightly basophilic cytoplasm, and bipolar surface villous processes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36209=[""].join("\n");
var outline_f35_23_36209=null;
var title_f35_23_36210="Hydroxyamphetamine and tropicamide: Drug information";
var content_f35_23_36210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxyamphetamine and tropicamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Paremyd&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenergic Agonist Agent, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mydriasis/cycloplegia: Ophthalmic: Instill 1-2 drops into conjunctival sac(s)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Paremyd&reg;: Hydroxyamphetamine hydrobromide 1% and tropicamide 0.25% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term pupil dilation for diagnostic procedures and exams",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined (as reported with Paremyd&reg; or similar medications):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, MI, pallor, tachycardia, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Behavioral disturbances, headache, psychotic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry mouth, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, intraocular pressure increased, photophobia, transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, cardiorespiratory collapse, vasomotor collapse",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyamphetamine, tropicamide, or any component of the formulation; angle-closure glaucoma or those with narrow angles where dilation of the pupil may precipitate angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; increased ocular pressure may occur following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; monitor closely for increased intraocular pressure following use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Patients with hypertension, hyperthyroidism, diabetes, or cardiac disease should be monitored after instillation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F180795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F180805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Paremyd Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-0.25% (15 mL): $19.20",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydroxyamphetamine hydrobromide is an indirect acting sympathomimetic agent which causes the release of norepinephrine from adrenergic nerve terminals, resulting in mydriasis. Tropicamide is a parasympatholytic agent which produces mydriasis and paralysis by blocking the sphincter muscle in the iris and the ciliary muscle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F180793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3 hours; complete recovery usually occurs in 6-8 hours, but may take up to 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 60 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8768 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36210=[""].join("\n");
var outline_f35_23_36210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180802\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180812\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180803\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180804\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897573\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897574\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180790\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180777\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180791\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180810\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180794\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180781\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299490\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180786\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180788\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180795\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180805\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323187\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180780\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180793\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_23_36211="Choosing shape of conization";
var content_f35_23_36211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Choosing the shape of cervical (uterine cervix) conization based upon configuration of the lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36211=[""].join("\n");
var outline_f35_23_36211=null;
var title_f35_23_36212="Alopecia areata severe";
var content_f35_23_36212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDpUGeQOenNJIAwyfz9aWPDAgjvSucj5cEdfWugyMy7GCc9+OaybkHnjPNbFwOCc54/KsmfjO3lsc1ky0UzgfhU8HBzg7faon65BOc1PFyTuJB6n3qRl2EEAnpz29a1LcfKOtZtuOoyOPStS35wO30q47iZeh5A/wAasp055AqtH7/WrcXA57du1akk6jnI9PrVlB0HFV48Y/pVpCC2cj6GriJko4Xc+eOT7UvkLIP36hz/AHWGQPw6UjfcweclQfzFWO/PerEMWBEx5SiMj+58vH06VGzENsk5z91hwD7exq1UM6K6EPyCaYGfc9Tnkdeazbg4c5zwK0Zt20iT7wyM4xu96zZ8knhfzrGRSK5ODkgYznrT9+47RjOM5IqLAwCcsc55FB3GcKOPlyfUfTtUDLCIXb5sgDt71OzeTEWbZtPtyT7e9UTM0eUDOxyNpODnPTA71ct4zGrTXLGSQ++Qv09KALcKXLISxEUfXOfm/PtVq2JKhVDOcYJcA5/HHIqKCTe6rJguo4HUe3SpRcJJdSR+bGQgXzARjOegrRCJGuZIgdwULgnK5I49P8/SnQpJD5r7zJIAMKq/fx1xz0zwPpTGcMkrKBlwYkBGRgDk/T/61NExsrITQbZY1Xewz83vj29qYjRBLx+azKqkZDZyaHMrBWKqycY9fqa5KHxVbTRttlVViYqFIzuGTjH6VuaL4gtNStEMUqPLjDKp5yOtNTT0uFjZj+XGQDn0qbcvQjn6VmrdETBBsBHLDeM+3FWhI7Dd5i5PHyncBVpiLQVSegyaQqQOCfxquLko4EqHB5DAVOkvmLuiO5c457UxkErdyMMKpT8gggVduIy6/wCsYHsVwMVmzsyfeIPOM0pCsUpMcj39KRO/0/CnSYPT9KYnP41h1GTDvj8vWl7cgZPrSg8fXpSoMk8VVhD4wBgZyRVqIYFV0OOB0HFWYx696pATJjJHr6VMKjjHpUg6HmrQg7ZyaXHr+lC9MClHt1pjPPosFe5AJHNK4zz0Hr/OiInoOuKcwOOMjmucozrkEg4x755rKuBuXqCf5Gti46c1k3C/NyOB7d6ykUii/U54Pcg1PAAADxnr+FRsMP04x61ZtwM84x39qkZcgJ9s9TitKAcgdaoQD5lB+taEPDZ9fariSy9DjB7kds1aj+6M+n51WiPIxx7kdaspxt7Z/nWgiygwARj6VZQDjPPbjtVdBk4PTvmrUY9O/StIiY6QbkwuM9fyOf6VZU5AxxUcY9RxTrcYjAPVTt/KrSES4wMDpUcoyMk8VKB71HIABziiwGbdsREzdEyCf8f1rLlVmc4zkjitO9ZS2wh3yPuKOv58dKyrmVobcF15AwdrqSSODnnpWUlqUiF0ZOQoxjgZ/PnsKgeeNS6ROFfq74JC56n68cCqU10hWR2DtJgfIqY2joOvv3rDutYnhuZIbOCaW7QfvicvHEvYvjoM4wucn9axlJItRb2OmuLgWiRsxdJJTsQffkI9FA6k9cfTJGKUQ3kgM004gUYCwKVwp9XbHzMPyHT3rlI1uhI9w2HnkDB53lyWyR8oUEhfXA+Y1aWTyXR7yVYkAwonZI1B7dST19QKj2sTT2TOstGYT+UG86IYIDEfMT79+x/Gq8eqta3bTwOF8ySRGE7fKyDbtG78OvOC5rn2uZ7u3nbTY7m4DdTbyI65IXGdvKjueM4FV4JEsdKErwSpFPG+6eNlcsqnAwp9zwe5I9KPbxD2TOsnvxJ/ZtvFP5cgYEhD98BQSATxj3PYcUkKG7V7iVpJDtzLETyI+cMvfgH8RnvXByNeTz3N2rRpLbWoYeT8rD5gRkjjB2tzjbyOa6CHUTBa28tu7qVAWMkbWU5xtcfdKe49OQKI1ovdidKSPMviDNfaBfK8d26oGz5fJ3DuCfTkfWuRg8XX1hLHf6fdzJMXZnjBITbngfrXonjJX1SxLXtsWjQLCVUYZwPuEN+QJ9BXkGr6feW6QzyoqQ3Ak8tY24G1trDHbnHXrWTd3dMtaLU9V034q3l1D5/2NJpY8KYIwAW9y2CfwFdlB49s2srO61C/eCV/la2tV2eW44YYbJbqDXy+0joNmSFByRnvT4GlYSeXvOF3NtHQd60U5Ii0WfV9n400iWHzIYdQvozxFNMgjLY4zwwBz64Fb2h+LbG7uUh23NnOw3ATA7ZB7Hofwr5k0e58ONZ27XiXZl+7KiS7fxXFdDDZy3DrD4c8SRRgjfDaXU27B7DceATVxqyE4I+po7pZU3qTnp14qG6IlTpya8K8HePdQ0W/l0jxCrxagn3o5CGSQf7LA9fcV7FZajHdWySx5aKRQwIOSOK3jUU0ZuLQrfKckj1P1p6AZzjmoQ4OQT0PBx1FTwnIwxwRUiJUyeByB/KnjJHTB6f/AF6auec5x2p47DoR61aEyRBkAjgYqzGowKrxHJ+tWo/z/CqQiVB3NS49qavFOHvVgFH50pHGRzRjtQB59EfXHqRUrDI9j6UxBwCScVKehJwD0rnRRn3SjAJ/Ssq4HUcY/Kte6B59+lZNxktjPeokNFFxk5zxn8qngxnJPB6+lQuSGyw4x+lTwDhcgZz2Pesyi/b4z246Z7Zq/A3I7D2NUYAcGtCEEgEjGTxVxJZdiByCetW0HPPUmoIR8o6nn61bQZOfStUhE0XtxVpBwPQ96gj4Gc4HHJqGXVLaEnD7yoydtaXUVeTBJyehp5IIGMn+X1py4Rm3sVXAbP3R/niuZOsXc4/0eNYw3OT1p6W1xPLvuZGkBXJLH5c56VzyxkF8OptHDye+hvveWsfDT/N6ZqldaxaplIpGaQg4+TOPc1QuI4oVJIIJ/iIx/n61TnAijMkypDbqh++cY5A57lj0/TBrJ4yb2RqsMurHXutSbdtvBEwBIJkfpj1/GuSlfVIrifzb4XAceYfOjVBGRliRubIXgdhnrxW6LR7yRVKzkEZSGEhHJ/vMx4QdgByOe/FZlzDbnZMXjSIMxVgm7zmBA4B6qDxuOcnpWMq1SW7NI0oroY15cXtyyqHkaVmCq4+WViRklVHA4zyx796l021uR+5i8oKn73a/zBV7ttz9SWJGSevU1fd7fS7WTU9Ud7XesggtmO4uxIAfbjr15IHQnNcfq/irTms5rWR7iS281cISALl+MlyM7xnKhQwUKuBuJJEWb3NNFojXmv7yW8iTTJYkxGWFzdEKNp/iVFUsc88DjHryakks9QRRPHqWwyEEKumpES3BJ3SHLEDnJzg4rm28ZFb0NaK8UjZY7pNsaLtIUlctuwOgAJ44xTI/FGpXEzstzLcISqhDJN5TkjkDa/GSecke4HSnYDptTS4ZYZhcx3m9gEaZY4rjhWJKlCQ+AMHpyTTLLWbiCa3a9W5njicSSQlRGzHcozEcsGIB+6wPJ9RXCWt+0EsUcgQXJzuQGOGTLEhgTk8cLgc4BJrUudQ+1oEHkXB8srJLC0QLtndk8FucMcgcZIxjIqGhHUaPcxobo2yiaxvGMLwRfLLbyhwuAp4G4MwZOpwOAGromgjjuFWNvMsbxpo42CYCSq/AI/hyCeONpyK8y0PV3SWe+G65SaRftcR5doV3YGQcswBVlJyQccgcV6ZeTy3/ANmu4niYXbLHLMi7VlnJzFMR1VmIUN7k5qeW6B7jdXtbaKJYZ0/0cqsAOcbJBKuA2exVjg9j7EVyvj/wrFd6FHBbyeVNFcnbGFAG6ZgOT1xmMfl713+o2I1G1ijY5eckABdpZAoOD6kY/lUN3p8k9lesIXbUGIYHAO3aMKfbgHpzk1pFNNkSSZ8tavoN1a6jcwrGXWKUx7gOCdxHH4g/lUFlpNzcXk0MKqCkUrsXO1cKpY8n6cV9A3GiRq0zWqbU89GRSvzZI53HuN2786yPF/h4W0MrOqqs2GlZgdsiAruRR6/SrTa3IcEfPwJUipBKUPyZGOQa6zxb4RvtO1KRBZvEhYjZkYQ7dxGc9gRXJyW8kbFXXBHvmtNzFpo04tala1+z3mZowQyOT88RHdTXpHw0+IT2t9FYX1wRA52pI4xz2Bx6148Rg4pyZzxn8KNtUHNfRn2zaX0dy5ZAPLcZIznB9QfSr6ZUBwcgdQfSvn/4SeN2k8nSr+X9+rr5TM2C6j+HJ74r6AtHVpMIwZWzjPBx7+4rpg+YzkrFpTuT5emakA7jj+tRqhUMOhHT3qVCGBIP4elarzIHqO2etWk/Kq0fWrMfHX9KaEWEFSVGnzHrmpB16VYAaDkf40etLjjv+dAHn8eRkg4PvUgHAAx61DHjbgnt61Lng8DPoawKRVuQSCO545rInTt3PHtWvccjpWTc4wxORziokNFMgHJ6jn8qfGuABuyPXOKYzHcBzntjpUsQ4z37nNZlGjAvI2k/hV+EBRgcY6CqVuAByOAKu+asMTyzYHZVHf8A+vWkdFdk7l2Fsg5BVR15wKguNRiRytvEXkHQ9qz2e4umGVKxkcJ61agtygCkEMegArmq4u2kDpp4e+siGV7q4AM7nHoOKljj/hER29SenHrV2CFd2FAPXk8lj7e1W7GP7TdO6OAgAIdxkEcjI6frXLeVR3kzqUVFaEdpGw+YQsFHO4jk/h/n6VbnWVJCdknEagKoyxyThfatdITAF2OZXb7qmLOfpgiue1LWle9nTy4yYvlUK27ceBnHplsde59Ca19nZWJ5rsbcTR2ZEs0TTzRjkhxhCfcd+g4Bx255rGmvZLu7Qv8ANcR8RRRAkJknLHtkdMdvrmsnUfEebjZEQSrHfIziLLHrtHLD03dccKBnIfa39vLLIZ54YIlRdlsu5MqM/MXA4UfXt+ND7Iq1tTQngm8maWfCW6q29G4VwBzubGWHTpxzgbic1hS6ldQ3Mtz5ltG6EosjsEjtwv3iARkhCwHHViFAJyKr6zrA1MqgWSNZji2hEhIKq2BI5Y52rk7VPBJGemBzd1r4sNQWQWyXbq3k2atJmGAA8ucD5gCSe33STjJFCQNmd4w1WMMZZ5bu5kic72vAsiySlsrhDwcLjJIIGdoUdTiaatzqjkx26yT7C4DzMgRMffZ+ig9TjHX06Z1rf2c+tCbVc3kbSTXEu/CKWMZOfXBITjsMDOc0yOazt7QNqf2qWFCv7kKo8xsDJkYHhc9FAJPrVNEcx0dno8U8Nw8/2O4QEK13OGaGHbkHbtUFzjnOcD1NcjrN5p0UpFtdCRkxsa1j2rJ1yxBJCk57dOfUVRUvq94QYJZoo1/1ERO5j/dXAPJ5PQnAPJrGkBwWZSCeQcYXHsKaRm59jR/tNjOS0CSRZLCKQkDOD1ZcMT6HNOk1CIqk1sssF4GG7BBQjHYn5h075/WsjJLZPPFKBxnj2p2RHOzqdA8QT2V1E4Z2iWMRyRqxXdFnkHsRySB6+3FeteD9VsrcraXEkiaRewvGlzCokNsCRsMuBwUfHOOjDPrXg1oG84BGCvnADHAbPaux0HWls7Eo8swRlIiRIg7FtuCpHHUAHPoOOazkuxrGXc+ptEnTU7G2kmIN1boBKiqNvmH+IEceuD71Zhj8+7V/MXLMEO08NlAysPTOPfrXi3w48ePatBbXk8RTO1Y5PusflL7XB+8flxn1IPXNes2uqWUl7JtbyoEuXkTgcHDDaRgY+YsB9e1CltcuyH6oGtLeRpfs2zcNuQRuLHgZ9c+oxWVqOmC/V3uYpAB9xJHAIzge4weeODW3b3X229R5mi8mZJDEFYNxtO1c+43H6gYq8LcT2qclmUAFmHJyo+968Gj4g5baHneo+GLe+t44nhxJGcFHAI7j8q891v4Ym5QQaQIYJkAYtnC7vmJTPU9sc9q9nlSQSb4lYxZRgpOWAJCkD16Zxn6elFxYwXUJKp8jgSKvTkH19RzTjK25EqXY+PNW0+4tLphfxNHKFG5QBnOP4vQ1Xsobe5YRvLHBKzBVMmdn1Zv4e3PPvjrX1Vq3g2wuYpxOg/egHAOC2Pf8a8M8a+HL7wvdF1trdokOYpFjUsnf5uMN36g1al3MnCxxEkE1pcH5JIJo8PtbqAeQwPcHI/A19E/B7xoPEGnrp9+wXU7YHZJnll9/WvC01H+244rPUPssU0aCO1uUiSEDn7spUDKn1PQ47ZqjpGp3mk6jFdWcrw3EDZHPp2NWpcruiLJqx9u2028Lv++DgmrAXacjp05rzr4eeObXxJpiu7BLhMCVR1HvXosbeYgYEFSOo6V2wakrowkrEqDkc/lU8Y9+DUMXfNWI+cc1SJJVGDx0qYDOM0xegGKfjnnpVAGB+NHSlo70Aeex/dAA/wAKeMY6HjmoIjxzyT0NWO3GMDj3rnLRVnOBkDkVlXKjAA6fpWtPnHoSeef51mzL3UfhmpkBnSDk8jkVYtzggngfzNQlQX+nHNSROAN+RtHIxUJDNBZI4k3Sg7c4wD94+lJBFJe3PmXBwP4U9BUNpC984c5WLooPU10VnaLgbYwB0JPeuatV5vdjsddGly+8x8Nr5MQyMErwP6n0q5aWm/oRhu3XP/1qnsrECITEiMnn1/Q/1p9wxmxFHIqwld0rsSMJ/Un06etRGFja5HGYJC8YljS2U4kcZJc/3B6n/wDV60mo6qbNoxbQjzW+UCQbmIPdUB5wcckgCmO00iiDTYRAqjasrgbgMdVUcIo68n14rK1G8trG0nbTyiO4JlvpQWllIHGwdh34/wAcVtsBX8TareSQfZXkYzTja0MEpGc8bSygFuTg7cAdNxrClyFis9OjlMibllkSXZDCdpykeOrAFgWHTnB6mo5XWaee4EwhijIEk2/ARQD1Yc7m44XkD3IxY021gutPeeWS/bTxGzG3gi8r7QwxkE4zjJwFyBhRycYqldkvQoWcUlorSJpsOxUwi+YsS8gcFiCTjnpn1zis/VbqWd1tYYYkt/lEvMro4JOGyeTk8AY5+Y8KM1oeItciN3HDZW9pZRodsZBLohAOXfA+cgducE4+vHazqeyAA7zDcLliqfNIoJ5BPzHceM5GeT0xlWG5WMzUL2cKbjyWE0kis0jBdhVATjqAqnHC59T1NcRNrU0txcSzOXeaOSLGfLCITnouBjnG3pyfama1fzarezNPJtaRmKqSxyBwqLnOB9fQ5NLd29rBBYokK7pbHMsxfOJPMYlwO/ygKBTM3LoP8PNBbQXs98zhZIJYVbYDgshw3Xqew4656Csq+mMqCSJkAkZlKIRlcYx8o6Dnv1OaXUJnMSW4zFEvzeUpO0HaOT6sR1P4dABT5opo7WKRmjRYEXywMEszkuOncAgnPTgd8UyG+hoWV7Z6ZpKR26q1/MpE85TPkKeqR/8ATRhxn+EcDkkjC3PPIsQfcOi7+359KQkbQig/LyQSad5apEPNSXe4yOQBii4krFcj5vl5X3oXtgj3yPWrMvltMAcbegEa46dDUM77pMKoVB0UdqExNWHyTEKIFPyAknjqeOf0FbHh+BZYLq6u5GCQqqLlQ4wxxgjOQOchgD8wA4zWLFG3mSEruKjGD6npV6O8TEVtOEMAk3ySIoDt7knjjnA9/pgfYEz0nw7BceU0MscENsF8+COWJTcBGQr5m3HzEo27aOGAI61pQajcQ3umwxxyJNFCGBhc4eNJdw6nn7yA5zjnng1x2m6lby/YofOlihty8oiQrG7qcFUUngYKbskn7357Oi3Kvr8aXUzzm7ESzTXKZaOJf3soXGcdYxkZzg84yahpGikeq+GtdM2no5jjGoGOSaKdXz5yk7iQp5Pysfl/2QeM16dp9/DdwW1xE6PA6YXYdw3ISMc89m4PTFeF6OrahiTT4EKRRLNcGU7URedqDBHmYxlmXk7iAcYz1tpfTJqEM9zOftCksVMfRmcAqm0glzyG3cZJHABNEbxRd77nTXM72kVrJdjZDuIkkJDbNpY8jHIyB/8AqqxdnyJ3lg2spxuXHBfoCPQkd/p9a821zxUy3+oaeZHaJ4uJy+77M4aTCjvtfBHPOceleqafKtzomn3dsp2yQKyq+cBWHzD2xnp7UQjctyKrxrIN3mq6ABuh6n2rlPFOl2Wp6fPFMoeVjuGTtUA9MnrzjgCulm1KPThK0pJVgDtHLM/sDjcT/npWJDci3toL6e1eaSTIhKyqS6/3lHQ555z0x1odh2uj5e8X6RNol61vtZYJG80BhzjoAfasm7nm1AiaRlaWKNUYnALKoCr9SBgevA969s+KUS6hpbSQW5Rgd4kPA2jnqwH5AV4bI48sq8Ue7dnzBkH6en6VUJXRzTjymn4W1670DVor2ykKMp+dOzD0Ir6z8C+IrfX9Jiu7RlXd9+P+63cV8cJJJGjBcFGHJKhuPr2rq/h14wu/CmrrNGS9lIQs0XbHqPQ1tTnyPyMmuZWPsyNgTwOe9WUUE4JzmsTw7qttremW97ZuGSRQw/wrbi5xXatdTC1iwtPFRr16e9SDoe9UAvbFA9qTqvf8KUfQH8aBHnEBJPPb06AVNyR/LNV4BhvbHB71bXG3jPp9a50WV5gMHPQ8VQuE5znHfpWlJjBLH8azrnAB5yN3NDQGWx38lvk5wD3pYojPcASNiJOSq/1qK9nAcJGPmPArY0aBURGb7xO0bu7etclafKuVHRRp31Zs6XbqQqoMkjuK34YI4IJJJ2AUL1/z/Kq1gqxQgQgNKwOM98dz+dWowWZV3Fm7SHue5A7AdM+tZQjY6GyKSaabbGq+TGABjjcgxkknoDj8s+tVY3DMZ58i33gQx9XuGzgOw6kZ+6vQDk89Jp5Y/wDj1RwsPy+ZtGWAOCE93Y8kemPekKSgyStILZMkZjceYF5yS/RQB6c9eeTVpNsTaSK19O5jcXyusMSktAjANIeuCx45PXoOp6Vxeqak0t2GELG6kQFD5ZKiPnovU5OFUcBicnPQWtZvi7OLeNYLSJxHEEQNLK7AbVy2SzHA/DnoKpQWvkxTiWIXFx5Zlm2ScZbIAeTkKMbiW5OMgYJFA15jtNtGneGS/EVwYGiIjVvlMrnCoSBz/GxCAknknpVrxd4iuZLcWVtJHbBx5n2eJQgRM5LlfTAG3zGG487TwKLRWtNPbVr+aKFEDbEiTG9cbc/NnbkBFA9DyCc159dvNqUzRPtto5djbScJHgfvJnJ6ED5QT03e9GvQNL6lWKV78zSSZhilzJ9smffLDEvUjPAZ23HIGS23oBXM+INW3RTzWkbxWZbyItx3FQuAEDfxFVAJY9wMYrZ1J2iu5ltYvLa4aKQqWKhUIzDBubGF2lGYnOfUDOeO8QyrK62oeNorRXUSKu0SuTlmx97nI69uwo20Jbu7ma4kaJr3yhCocGMdVC4wq5PsD161oQKJk05J4Xd0XaCTjahctx+BPX1NT3f2iMi3t4oRCkcdxLHGPvEKGO48njLfrT7+MHQ5bhJJpZ3m8uViu1d20MMc/N/GD6ceuAr3FYwNn2u6Es6/u5pHY7TtH174A4pdUvDcOg8mNETmIRnpySSR3J+Xk9gKbc5tgEXcPMiCn/dI3Y/HipLO2clSc/vSFBHoWA6np170XFylaSIRxpEpMlw7ZYryPYZ7nnnFE0QgYqiyLKMYDHkf/XzmrkcZe83WpkQISxbuBycA/wCfWraR2kFtNsdFYIkYkkjywJ5kk/DhR/vUrjsZ1vp0suny38sgWNDtBJBLHPJxnJ5PXFZZGOO9dJrF5HdultZRzJYWudnmqqnHfgcZ575PNYlvC88xjiXLsQAAPxJ/DGapMmSFljaG2RjgNJ8w9fQfyP51VQ4YckDocelWtRO+52x5MSBVTjqMcH8eTVPt701sZy3NfSpbSBHkdQ0jApsddygNwT14OMkHscVueH0kaxwsiqt7clXWRgxeOMAgEdQu4rz3P0rlLZ3SeMgkMGB/HtXsPwn0ZhqehvIN89xGjtEEBJiaRcKBznIEjEnHXmhouJ6Bp1t/Y+j2ulRxJbSXH76aUMS5G9Qi7jxnKk46AA4xUHjK+i0G21uaGKMizijtbVH5WR45igZ+mRkMSe+Tya2vEJe40vUriJysouZ5oB1LJEnkr9R8z9P73HSuA+ODiOBLW1ZhGzx2SlWCgsrFn3DudxU5+p70SVtjVbHOaZ9u8SQ3EykzxBPJM+4KHfcyg7TyRtL+/PtXu/ge5t38OQRXSiSKM+ZGQGeRo2XeigeoLMM/SvA/hpKIdfCQ+ckNq3mkAcqEuFPIyOditmvafhcWtLbUbNJGDWcz27tk58sMwUAnnAww/ClB2kDWhf1HR4r2KQiKO1ZSdivCpwxGF6cDAzgZ3E5PU1ycFodAv47eZ2QSDCSmVxMCeiqoGME84APU56V6Tq5mMU3lx5txnzZmx+7Xbkldwx2HJz7V5rquoreW80ECR26qTJ5l9MxmkXackggMfXcxVTnHNTOFioybDU7dJo5UuWub4tlwstsSdw6nnBIIz1C8qcV4v4t0CG11FrZ1aC8nIkjjdcAKenTPXsK7bUtRiltpps3V7OqbmeCdE2tgDeccn8DzmvNvEN9JdzlriSXc5LuZF5PuMfqOnGamITRz7wvCWIyAG2kjpn0pW3LuDDbuUNhehHqK07dEutizTiOEyKkhfOE/uscdB/LNXLrSBJ4WfUI54BNZXhtp7cuu8BhlXXn5kOCOOhGf4q2Wpztcp3XwI8cNo+pjRtRkJsbkgQsT/q39Pxr6hibDDnhuhr4S0mFp79YbZiLg/ND7uOQPYnpX1v8ACDxN/wAJL4Sgadj9rhHlSg9cjiujDz+yzKpHqj0FelPyOmKhjY98YxU2c9K6zEBS9uKb+v40h6ccUCPN7cnPTk1cQ/JwR75qnDjAz6dKtpn5cg4/L8KwRYMMDOPesvU2MaAEcscLzWtNhQWBwvqTXOPIdQvw671ii4UkdT61FaahG5cI8zJbHSy1wHk2jcNw+n0rqbCyjG6ZwdkanBbv6mqliojkQKpYuMZxgZ9a6C3gPlnOCBwAOPavPj77uzt+FWJ7RmSMy42lyFRT2HJ/Mdf/ANVVL6f7BaiC2ObucrDHsG5lGDls9OFDH6CpZzAJMeeBGgLPhuvrnH+e1QW0YbUNPjRRPNOJpVWQ4G0bBlsdFyefyFbak6AywaLpVvcTSeTcOyiM43MWOMqi4yzHoW6k47VzWq6lO+nxSXER34JVQwKQliNiY6MQvBPdm6HkUzUtQN7PNqtzJ9qW0GI05G4sSFCgdM8tgcldvvVbRtJOrTub2RFgWMNdTKwA7SGKMjgd9zdskDoDVLayFbqxNI04SzfaZncRFmh88kszA8uFOflLYJZv4UUZJJOLF+0dvAsC/Kjo99PxsBQfKikcEKMcZ5xzwW46XU7i1RXuLmFotItlEcFhEBumVTnAXsrMFAXvgZPavN/FM8k3npfTKr3c+JkDK/mKnzPHkdQo8pcfdyT3zhSVhp8z1KGtatLd3mLcMuxWMAB3MCqnc4xxvweOyDPQ5Nc6XMYu5Q8cNqB5czuT88YIIiQdCSEOT0+YDvWrdXsq/bILUrDPIvk+aMBWj+9IxAHCYC9NvCnrzWTE32OzMiSTMkCDYs4DFckIFCfdLhdwxnAJ45XiSntYguEubq8hmvw/m+U13KDgMo2lmPXIyxjHPTPoK4y3s1u9ThRoJVW5ZZJFzkImN7ZJGfu9CR713HiNJ9Mh1DT7YZKxtBcMZTuEQkZ5csPly7jYDzlQPeuTtIWc3ty8khcB4oghY9Y2LD3xGgA5/iXtRLR2IjrqHkf2hdahJHbj5EkiAjiJ8x2DEKO+Rx07AmqtuDNqP9nRwNO0lzGDjJ34Lrggd2Lge3HFdhoGlxQ60wuxBNDCycRu6pwNzfN2KlxnHo/PSuXuIUfWZvKZIWjLtv2kCABV3P0ycHcB7mpKetzG1WzkXU5Yn4m8z7Om3BU7PkbBHuDW/qGmrb2cJeQKkEW0biB5py2ePXG3kcYyaSxWee4tNVkJfydzRxbQBAsOxlUZ64yR05OepNXG3ywXe43M8kUQDux3CEtjeM9ud3T6cVLZUYnOG4iitWUITdTGPcRyVUglifrkLjsM+tUGyNPaV8+ZPKAAe6gbj17ZK/lVq5JjSU/NDMihmI/iY4KgDtw2aZqdqkcYRZAxht0bYvzhWchmywPGNwH1GKSYpIyYZHL7vvfNwr8jJ/r71YjIitpZcEu5KBsdFxg8+p/pSQCNYoS0ZeRmbCvkIQRgEEehyfwFSajbvbRKucpJCkwx0wVAH8yKq93YixTk+Y7S5JyMgdCcY/QVCV5O0bhkgVfitwIL1ywDxBSpJGSSwHH/ANaqazMu/ZhQy4PuPSqTM2rElnC8ky+VneT8uBjBxXvXwchktmvL1do+y2sQRM7cbVZuVB55Ycnnp0rxzRoA1niWdVRJPMKbfmG5ljyc49ema9l+FLr/AGBqRmhJ8yxmkRNvyNxhckDGSWIBJwOgBJqov3iktDstTla20HVoIpR/osZRWJBzIAJCme7Fsg46AN6ivPvjGcXmnSGNXiDwysCxKkugkbI9hjueMV6f4dsoG8FS3UyiRZriZp7kE/vXl3ZweSQAQv445OTXj3jmT7Xp+ijcJNzRW8iEqCClvtfn3I4P4UqmyNImP4Ckjs/EhVid98jZ/hyGkIAB99wr0ay1BdB8UXiq8ywR3RQySIXVEMkiZzkHbuA54wfUHNcPpenzebHt8qeBoZIhGsp4kREkBAxg7xGQBk5KnocV6U1lJcJ9phMslpeRymJiN6As5kRCW5U71dfUEcjnNQk3sO6O21e+/tWGGCS58mZhlJERnjRsdhkgtwcdenGCa8n8TaTDB5jbGTc5cnUHZFlGeMQx5bJ/2yK76yht9V0q3kliaGcRqzMAcSLuwdyY4xkZ9x83BVqwda0q/t5jG8FrC867d+yI52jJIZhuIxzgEYzkVtN8yvYiKadjzuDT7zU0kQX88SrGs8kNtvCNnjZnfxjj2PauU8T6JdWDxxX+lmzBLbZydh3k8b8/w9ecDg9TXd634V1czoIGuUR4yoeKIOw2c4IBB6HP4HFcXrllP/YkkGoS+bNBMyIwXGwBdwJJ5KkGQY6/u+9ZxVi56nImGW2A3RnEiHIJ6rn+hH6V2nwxhUay4nT/AECaE290rKrGS2kGHVSRkMMblI6FMZrnX8+4st3lkXVmVDMuBgAhc9e42nOOoJ7muj8NME1aN4IPNedQ6Quu/erKdyAHAyRvGTnkj0q1uYtHL+JdJu9B8R3WlXG37XaSBFliPEg6o4PuCCD716X+z1rptPEstq8m1bpclT08wdfzFcz8RUkv9P0jUTHl7SBdNkmUY8xUH7lmHZghVT/uisy1mi0nxFpeqaP58NjNslQSsGZWXAkUke4P4EU78r5kK11ys+2oyCCPXkU9STwcZHBrM0O+W+020uVIIkQE4NaRyGz2r0b31OTYcOhPFJn3/MUev+FB9DQI82iPAHHt2q9HnjP5E1Ri+YjOR2z6VcjIGMjk1jEsp6pMRFINrEDgD1Peq+loZAA3yhm3P7+1Mv2823BJPqzA4xzU9iWE6hSFQcknt71xYmV5JHVQjpc6FYo4lhYlt5OOmTk1uxQmZMynESkED1wD/Ws3SkN0guZEKBxiJT1VfX6mtS9uEtUdAcCCISvjt1IH47enelGPUuT6FOQJ5kqfcRpFQjIG2JOSc9snI/Ks/Xr5LXT5ruc+XLPA8SMRg4cZIA/hVVHX2qvb/Jay+biTygiMBnDSnaCnudx/H8DWb4mnVLnThqOy4vJHmkVGGUYLHxGMdt2MkenXBqou7G0ZWl2ouL/zGaZI4FaWWPdh1jKjYuP4XxsBY9CQoGVNdUnlafYx2k+DJBhpYo+jykgRx5PCqAAcdhyc98y3uYbHSDKVuJZrpmubjIG+WQndtC9ycsR2FUEI+wzz6xuWPynvGQNnzXydwyDnBJVQBnjnNO/YLX3Idb1Ce7ha52SOAogtPOJZI+v709yxUOc9eQB1NYiie5SS0hluF+zRtI08oASFU3ZxkYDuytj9c5Aq1PqHnF5pFijkjQHbsOVUNhImHbPyrxn77HooxW0yIWvhudZ5douLeKdjvIBbOFjU9BycbRznk9RlLVg9DnJvljWSQtb2QMVnaxiQZ2sWLFR1YsySMSeTtXnFN04C+uW1W4Co0KtPDAzLsyCohUDHzDJJIA5L4z1psFmNRu59RVZZLSyiCLEnynzmRUUKcckKcse2Rwc1vaRpoXTh5qW9sszJIiMzKvDEIuDn5VJzjIO09yKUdXcc9FY4/wAUKTDfQyuJQluQCx+bdCoj2/7QDu7dOuaz9KsXMMMlvFKs80qvANhLh1Xe7c/7BUADrkA9Kv3tusnh21leCSWW9b7SsnVhGGG8MfZTnGP+WnPbN+0JsZJri6ZnkF4sSICXYKDuQqCOQ2MY44cdcYqHuUl7pYsLR4PEc+mqjZZJLU+TJv4yTjIwGPJ5xkgH1rlZQlzqesyQh4VuLnymSRMBVkmUhSATjC5PPTn2ruNAfyNcJvUka7tYrm58wMfnmCRFQ3GeNgbuCWrAs9Lil03VImimVTeiDDDqqsqjgckjeDnGDn6CptdaDbs9TL8OWPnmWO0gd3nsQFB6FmlI349FwCMY+5k1XureXyJgIiHviCoJ3n5S3U46Fjk8YJHpXbW2j/aWjhtpwjy2RtttyRmSfLxfKincM7w4HAwMnNY1xBEy3lzFayeUsQjhAkGRGUAGR0zxwR3cYFU4WJU7nD31s7ancW00StPMIUdtv+qb5CwXBx3A5qjqCs7XrJuwp3MAR83zbc+/UcV0+oWfkeInhVfMRJnmwi8ttC4Oc85K/QZrE1O3f7TclnWQo6hsL8mWCgAD6Dt3FYXs7GrWhTe3LaRbyhZiPPlt1LHhfkRiAvX+JifqKsanbvcWbNId00CRxIoABC4DEY74B5/OuifSnlsrdreR/Le5cRlF2hQ0aHdu7EqH7du1YmoJP9hknU7gsg3yDPytg5OcehA+oNJt3QcqszBYAI5TIVI0wCe/yk5/EmqiMEk3ovy5+UMM8V1N1pb2IZ1XdEXMIdlIRuuGbHTscVQtdNWWK7kmLGK2ki82SMjAXDbsA85JAA+v0rWMrbmMo7C6OsUhlWaOSQm2lkZY8g5BDD9ATx2Ne2+AdVnk8Lam1r5kbjTzKzJ8qqiqxWOLrgZOTjktnpivIbeJ40tbgAIbj92pZtiDO1WGDyRgj2A55r0DwheXFn4DeC3Ct5haEOzZBxtJVfoSSTnAwueBirhK2oOJ6lq9/Fb+E7PQNLkWMRw28CNwFVnSNDIcfV2HToT6CvD9bkF9e3xIdUjuWW3jQqVVP3xxx3GEyfrXpWteTZ6KLWNgklxcwWeBncyofMnkGenSJBnGMnvXketQT262UatKbgs5fCkBS8hYYPTkOMn6CicrhFGz4blkifT44ZFCbOo6eWWdTnsTtkAx1Ga9QsLS9srPT2hnItp5BNbgozqXkDB4354wxfA6/M2DkFT5x4OiDeKbMzmO4iDuGVQWQlpCpBHU4Gzp3Fe1aGkj2uo6dMf9Ika4eBgANjrJ5igL2wc8+x+tXSV0wnpsP0CW1vNLkZgxVJA8m195ywIGP7rfKecbWwOu41tSWxuZY4Lg2stveoyOHyEmfI2lT/Axz2yDWJpfnSo+p6arzxSQvHPb4+/sf5goP++DjsVYjrg78MEM+hr9lYsjKrxBxuDpjcv44IGfYelWnpYl7nNXNpNZ63DbXZWadJWWCWQld6NEcqxxgMNoPr1IHXMHiOws5tw1C0d4Z1Xe0nlBMo+cblHXDSLggZLe9afiVfMGmXFwSpeeJTIcschvusAfvKeVPdTircsqPpcDuv79ijJgHBbcBsIPqeOeOmacWndA1sz501vwbd6F4hksZFjmtpo3it53GVaMnauSvdTj8CKl0C3WPWJbG0uUg2XKNBIMsIjjzU468SBkycgbznpXrXjCy+36Bc2k0cm63YvaToDuUxngMB2KqAccg1w09pAl7JPCcJcjZGpVixnZEmiGQeCWDfNwDz0yalKz0B6o5/xpE81petCDDYMsdwoJ2q0UpAyF5KuGb5lPrkcV51pgnlMunhWdwzSxLnG2RRyfxAx+VerPcm/0eOC4Scz3Ok3dhkBtjywOrISSOW2bc4H8IFcN4mgii1CLW7F2R5p0mCPg7VdQysCOvIcH0xRIlH0Z8E9W/tTwZANw8yIYPtXpQwVz1Br5/wDgVrBg8QT2BAW2uf3sQUcLuGcf+hD8K9+hPBXqRXXQleCOaqrSY8dPf3oxQDnqP1oNbGR5pCfu9N3f3qxIzeWwU/Mw2jmqtud2MD/9dThsyKSBtFYLYtFLVYzb28MZOXm7DrtHHPpS2oMkZjUEFvkxUeuLs1KBy37sxE+4x60mlylRb7idwLPt7tXDX1md1FWidxYXIjtw0iPiNQvqCfrVHUrlpNE1C5QMVmbl+m44CgDPYAH86gWfzbiNTJmOOMTTovKr6K3vwSfYe9ReLpWh0hYmWNR5AkVd2GXe+ACegyOv+9Va2GlqS3Lmxt7GIMPNt1Eyb/uiRxgO3qR87c+g96wZEN1q8ESM0UOBZxKQd4hYqWd8jbuOUbA65UVf8xr+/eOcYVQrNhQCWONo56kqCAO3mCs3wuHudZsVOZ0ivcNIsgKksTkZGRjPTHJ2/jVLQTNvXoVgeGHfJH9puo900gyyxhG56cnl2+uOOlUtXtx5dr58UcaPE13cCTHliNRlIiTjuIlPIzvb0q5fSiTV57q5dhiXf0K42xyYweflBjOPXJNYeuXVzc3TiQB3iso5miaMA7ss+3njA2Ac8fOM1TsSrmE8TX880M7SeYm9p4t2Su1FeQ7sY5wBnoN6gc03X7gywX9xdKXkjmVuCFRnUyIqnGSQAGPb7kfXJNWLiOWCzkSR5JZmjmLorBVkBfqT1+d0PAI3bcfXElkhkAKxF44yGEbKFhmcYXdwctuHlgYB788ms29Gi1uiPRLaQ2dqkSG5nlfeQshhJZuQNwPy5kMa5HPyEHGOLshudYsbyOJmjtbOFI7JYPlLO7rFudgMYwDjPP77gHdxYvIxbXsOlwJczLbAJMVU73IIIULjgu5j4HAAY571q+GbdWe0ndxHaWkZmkLEjzJUkJRQfUyENyM4XAz3cF9kmTu7nNa3pTrrsOlxxLcC1EFvE/3VIDKrsQcHDSbjnJ+6oqBiUk1S2vPP+zXyrDHKuAU8jLRyhepIA7k8SA8kV1N9ZeXZxoFukuby6UglPnEcYUqPqz7ec8YfismSyhmvZWgMVx9lUoiImQHEjCRQOclg3B6YA65IGclrdGsXdWNC5sZTrlokccii/itgZC4DbXUKWO47WwV289eexGMnS/LthrU8Ey5a9gv4kkXbvCBmmjCqTgblRST3UetbGn3Qn0yylWV5jp96S20K8hxKqk7gecMwxjH3frWH4vuJbW2M9qkxjczZK5YBcS4Yn+7kJt5zkfStLWVzJu7sXiVS68PSyebLkz3Hlk4EiyQ/IQOu/KDnvkVb1HTpLZYtPgZnSEw7Qq4y6qm3GSMgEDHtnqTiq1hcwabcwR28txIlnYuVnKDeUgZAnBOVJkDMwPUE9jVl72QM+o3crloVhu/3mWYSrGzyZAxgqSuAQfm5xitNLEHH39okV/O9iYxcKs6xs0apmHEQQ8kKuNrcA8Z9a5+6tY0eFFjgjAjSIyFvNIfawYAAEt1/Dn617Pf+HBFqtolxELtZFiQBhjaN0YdseudvIx3/AB599AP2LR7aBG8ppY7h3VSpVwXViobocc4474zmspUGmaKqtjJstAE0dlaXxeGykuRGf7qAqgYkckt8x/4CKytV8ItbaEjLJI7XF1Ivk+UwMyq+1CByCctjHT5Wr1GTSY4LeVkuJIzhEiMucx7SuRjqATjv/OugudGFtJvRJZWhe2cbmC+W4YEnJBwQAxJ6Yz3xWscNdehm6zTPErfSZprKdpInmvnc3YxGz7RviVcnHDENuwOg/EVVsvDwlFxYASS/aLxZ7mR+o2tIQpGcLlRub65HAr29NIRtKt0tJcGWCEyOrkgpkElQMZJPGfQk1yOpaGthFewRRlLm4kKLLGdsnMeDGyj7qghiTnowFKeH5dQjUu7HC+I9GF/LZ/ZLaOW0LwRRTRMPliZkBK5PGTkcjpt966DwzAtn4Lvb1olWOy80xuAAXkkLo6juAV2nt8oAHJzWzp/h+J4WVoozcOyDa7kBQfLYLtHYGPIBxwT61Frdj/Z2hxWVpPM0bF5nUocysV+Ytnt93ntnPHQZyi0nI1g7uxTt7GXVrq6aWSHyY2BmWb5f3RGML/tGaQhuMDjk4OMXxJY/amnkX5IVgaSBkyVVotqGPI/2Bvzx09K661hmi1C+tmGXcx2qMcLxCC7sM4AVpnDAHAISksHFprRju4o2ie+jmc5B3LLFGhQAH5VxISGx0HfHMwitExzb1ZzPgTTBZ65ZKwIcX08ccgO3zVPksFCdVwGJ3HnJHpXqRkjs5mjErYjkX/SB1HyqZNzdeBnHIyWNZ9tpsj3OnSpHtkEsE7TKXbf+42vlWGANu3rzkCp7ecnxRrREzPHFcIhUryikhT17gr9Pmrbl5FYzvzamz4XuD9veJHRJUm3KQSckx+55PyAZ6nNT+F5THus+TbmUywEKCBuUu0WfoMgexHpWPDPPb3KXsZHnFGyGU7g3z7QQOjEsAfcjtWxpSqn2u0hY/wCh3qpbucHIBDxHPsGA+nB6VNymkQ6vbrP4fa1iLNPFNFJE24jkswxx2yrD8qzEunj0md40LtCUnVSvRT8xQn0yHI9q07u4Bkh8k4DXbqg9dr78fT7xrLuHU3zxW+G+12iQbdwwXSYgZ+ilv8ipvZ3KtpY0rmEuLqF2AR53Eci5BUMSQcexyPTivMfEWnznU4oTOfJjMSBIFysrLGpPH8OAJueRxxjmvSdSm8u2tkdmMKvLA5AJxtfvnJzsLEe/5VxPjARxXNpqMjubhRvYb8BpImVsdhjl+nYmrckyEmecot8ZbD7NGVt1uZJQSPm877OokUd8EbTzWjpml6HPaa/br50glswWUbWWF8biozgqyy9xwQ1U9WjltYZvs8jSRu0VxgOd0RBwQM98befQVl3MlxZWWtCBoopHlw7BT8ybQcrj1OKhTsypQujW+GDtZa3abIZY9oGwycN1z+PSvpy1mE6iRDwwzmvm3TJFfU7C5WPcZUIYFsbX3jn9a+gtAnD2du+SRImc+h7iunD6KxyVtXc1h1brinj16VGvU/lT/wCddSMDy+3xuxgnA5qxb5cqOeVJxVaM4+8OBweelSwMY1fp8uRzXPEtGD4guQdQk+bGxQOvbHNSabM0I+0v80jqFiT0rNumWa/ZjjDNzj0zWpJtF3PGg+W3hVVPozE/0rgm7ybPRp6RRurJ9msI4Aw3SnMpGQXY/M3Pbj+lUvEOozPCywRpPcTh5cSMAHOcRADpgvg/SM9BUUsyvfeS77YLYAtJjK5bjnue/wCVU9UuEe2m1DDG3haO2gQAEs3PzdPu9BjGQGNUrg0bOkOrFxBMzyGR5pZlODkhckemBgZ7YYD1rM8ITJZIjOXjECbyHXneHKscD0D/AK1p+EysGh30bfvZEiLM5B4WQs3H8TM2QMf7P0rA8NeYLNhJECIWMTx7+TvBy4IPzdOoPY09dAS0kbetXUkZcohM9xPJaQRtkgMVwoI6ZAl5PXgAVmaz5M+ozbkS4iBaOMB9xlbcGO3j5m3uDjpwR0p5neW4tQWjRku3usocBnZXJbOSBwoIyeTyemKq65c200umJZeZ5cQkM53bQEYAoTnuMe4zjOKTlfUSVtDPjRYtSO+IujT+SrRkqs0mRGmTnhR87g85JH1ppQ3mvW8NqjQWlixlAQMAyRnPDckEZ9ec8dBU7RmW5uJGgZIIpUVSvO1iVMhIAOSq7cEkd6taZGz/ANoPbsyOiC5D7stbmYDar85ISNBjGfmOT1p2voJy6mXB5lze6lcKky3F0RH8uSNzEYRecg5L7iD3I6Zrs47Ro7q208wun2kRSlWfYoMSBGAC/wDAed3O446VV03R421PRYXuGLzxmeUyM399j856Eqo78jNaGpTsbhrqJY50gRhEVACmTaY1LlR1LA4A9sHFaRVk2yG+Z2RV1G+cajc30IV5Ycx26owGbqQExhRyRjcDjsZD1NZhtY9Lgt1TDW6RSQMwwPli4LZ6k5LkEdOPQ1u6EIru9s1t3ZrAyedmRQHkJD7ScYAOUc/Qr6Vj3ofUND1OTLFY44o4UVd23IZuBjgfxE/7Sg1jLVm0VZGVopltJL1bgAG6jvZJN0RY+bHbQyjLA4A3oxA79qyLW0kkSVtXIaVbAT/NI3yq3mO44XA+6TgcDcDxiuh02+d4LK+mEaKushZZQCdkcqsqjcTjGXCt3HasjxraW9p4ZiW3uftct5ZtEzqWLSSBJX5wwAwN3J7g8Vsl7tzB/FYpXtzYPoA+0M8k16sc11NEoYgxmAncc5I2lxnP8R9eJ9Auri61OGWdImS/hE0lvjgRrLg5J+bcVjYY5JDDtXI+Ioxp+laWlsxmaU3C3bZAV5NwbaMcdduV7ZFbPhu/ivfGVi8D7rWKZoCpQ79i2/loDkkElncdzuBqeb3kiuXS57Bot1JrunrPI7pMJFVmywCRlo8AZGemcnrnJHUVneJTYRSKXl/f73MJV+QsgIKjr97a3JH86xfDmqwQeNSrX0xihDrcPcKQd6OqEHaQMhFjyQCB+eea1TxDLLc6rMIJftHmmKNjhfLaPBYlew2j0HX1NdUqi5fMxUW3oeoS3EB0a1sYY03rPl9kRKI5dmwf9jcFzngDFSaN4iin8QafbQLgySMquVOxlKbgfRcSYBJ5x7V5u2tpqnhWS+uZAyw3piDKwQbYwjOAvTcXbgnGdxHOOeVsNalW4h1MtFPAlz5awxSCORRGWIIXqQVXkjPYml7e1hch7x4avYpLl9PhjATz5oHO/Jx5pA3ZPQ7QAeuQwxVWeGC88P3s8lzCEkIeGNeSZS7bgMnDDJUAc/dNef6x42ih8aXTxmcW7zrcq0iZOQUcruGMIE5J55bmtzw5qSzpqGm3VypktdTCiOM7mhTcw3Nng9e2MEetU6qasEYu9zce0k02xUWETwyTI25EUAyeVEzAFs8BihXdg/KT7GrevaUk1rCYy322a3kbEbbDgBsxrkDAxwT64PpS3uqmbUzyDJiQQRFQNyEHBySexY4B5zSw6y097OmfLKxh4nVtwwfkwQeQv7rPHHJFT7rjY01uVIoLW40We9uCFH2tknYrzjYISNvruxndxheoBrONp9tkYyEBLtEDFOGDwyqgRNvJJUgY9xngU/UFMPiDUdHZ8BHS5A8zhkIQyDpgku2TnjHfmniJTcBFdGuAgg2KCCkzJu3luqggOMk4O0Vity2tCR7yNNKEtqwuRaxTbZIgI2ysaL5bKPlUZ7ejelR2SyR6nqayDzEl8h9kigHA3b8/UMp/HHaud1iWOXUbnSCoRVmuXcqVIyC20kY7rtwOnY8gZ6fULm1X7Feu8Km/00AFePnxE+MjpyScc8ClUdwpqxetZ3gBe43l4UiJkkYFnIlKnOTnBwmRz1pPDsixeIVilmY+dd7wQpwfJVgcn3WIHPfPvQqeZY3C2zFHnu5BFgcNvkVY+e3BBqqN1t4ha4g3LEkd0V4BUE7o0JPuAePespOzNYpNGhFk6npiMSGE6ySbV6EqQT9PX6VmXjSvr1pLA6farVn3lOhVGVAx+pYGtQW+dStUQkB7uZzz0WJNpJ78s361h6bE96819DEyXU9sJo8ZGfNuXb/0FCT+FRdlW1Nmd2mFzEh3F5/tagZB+UDIyD1/xrl/E0AuY0ikxkXCzq+RjDo6PxznBH5Vt6XMr6xcOdvkThvJC8EAh9uB1wdmR9cdqw9fma2WKQqGaBROwVtm4ISWAx6qTQpA4nANcfbhMhjX944GS7bclVICDpuPzdegrnNavDDaxKiALdWvlSFxu+YMNxHbv2rf1KJbQ6gY/NSWPUElUA4/dkAqdvXOHGD9fWuZ8XW32O7ggjSTy40yPxyePy6+1KTaQJJmj4X1Ga9MsWCGtsyq2doYb8AH8MV9I+FnU6aiDJ8t8dex5r5b8ITqmt3pQjyWQIA59ZEHHqc5r6b8JMn2aSOKTfhRzjAyBgj8xXXhWzixG51UZyzA8mnk49qjQ5jU557U8kZ5z+VdpynlkWAB2PSm6xIYNKkuE+9sbjGO1CnJzgDvmo9SKyaZcLIW2mFwMH7vHauZ7GsdzC8MiS40aCd1zIxJ5AOCTwCK2pxuYuSFilHl4A6kcj8eKTwdahPB9m3O5SGLfjyat6zm3sQgVSom3x5PAJ4P6Z/OvM5rPU9GCOeW5TYWmkKRXFwUdlGTtGR09vSpNXWSS2tLdEMQe6G1c8KCCQR9cDk1Qumdp7wKxVYnaTcx5925+tSWZlu7gJI8mI4hsYgnyhnkn6bcfiBWyehfLqbwvZnuoktQS8sKbI07KnHXvtw2OwCjtzXPeHblLTR40jBcAq0iquWOAq9+hBdsn1NR2OqSFmnWMSTPAsDY6rGEBYADozjIPYU3TY4otavIWuEMi3JeAKn+vVl8wDoeNwkHPcAcZpOV3cOWyszZu4XS4FpHsma0YbmTO0IkQG0DpkKZCOozgEc1Q1OCOO4nt9g+zymGPzFdcyyIitvI5xuMn3TgDA963LV47aMeeyFZp/OaRU/1ZDgEhRkDABHB6A46isO7tJIb2zlui0clzkOi/OzHzoy248Z+QsAQTx+NTK/QSLMttb3Vi7kIGa5MhbaF4JykW0jJzhu+PkPXIrT0SOOaMTmRRJPP5jpgb9kbMACedwZsD228DFc9PfGDS3tmuTJJC6m3dh/q83ON+X+7kD8N3HU1tS6nDHoaXMJFzhiV8tAfnBY5wc/dGCT6k8dDXRGxhJPY3/D9xaN/aGpPFtZYGES9NmFEcsY5G7LMx7n5SM96j8ReXBp1tGU3TrEsoWNvLCkDCAIfRs8npg4rO8PwTJaRxSowLYdWGHGUbc7nAALF8EHuFYY6VNr17FqFzO1y5AieSSVkG4C3hHl7Qo/jd5JgOeuMe1VJe6FONpCy5tNDuLYZElyqPEy8ty4j2L65TAB9GYirmusj+assW63Z5N0kbbd7ZVsZHVcsPlPXBGRVq0tmuriO9lKI0cStHFGCVRxv2gH0yeo/uVjaxtOl3u4M0BhYxezDbuRcdcAuR/8AWrnTsjotc5C61Qaa2mSvGJbWKe01CRYImPl/OUYsQNoI4z+hz0rePLue71Kx06S5lgVZ/satHKrGW3kYFOv8ODIMknoM4zWVf+I5YvD0tuzQvbSPLaSwlchN8ayoSSeAkykjPUMfocHW9XbVXlu7aEoqINRBMYDL+82kDGRtGBgDjr0rRztGy8jn5ffKGoanNFIZwywymW5kVIz8pLOAEYdMY3c9+PSr3guafQbRtSyWjbKJGku1zLyoI7jDMx4B+6KoXNxFC1xY3uZYpVtbgnHzCUbd6Z7ZDP8AkKZr1v8AZ5JbZJPs5hEcoXdhF/dpuIOTzmQ9PTpWbbTLWx0dxroTxlY6gsgkguzFdxrI+Y9rrtk3DsCyAt/k1kXOpeZDrDR3LTXJudgd2+R45MDkdOxGc9Kzg8eoWOkq3kwy212kTP38qXBXOOwKt/31isuG5IDW6ICHIgYKv+s/e7sn34ArRtmcUdHo2tTQaSyyvCunm8kmMboG371jDhQemF5H0rE1jzrW8+z7o8WjND5qqMNnd8xI9ck/SkurZIrWQxMZbaC6MPOec8oPTkDp/smqWp3DXFwJ5VBbYIicbSSq4yR69PxqPIrzOkj1mzl8VaczyMdNIigmZxtbY8SpJnjnGCenauu8AX09zrOoed897PA07ONo3y78llHX7rnj/ZryS1jWRnSQtuVG2hRk7tpI/DI/Wu8+H91NDe3U0Bjl8mUAvyCwlDp+W4r+FNydx00rnqHiW4itDpF1aRmb7TcQRREAhCQjYGOuN0hwvsaZotwLHxBKt0slxHuv0jeViFdhIjg4PYKJPxrA8fXT23huwNrJcLcR3cVzHt4wJIzIGxnGfmx26Y604uE1xmhhEskd3IoQHhlnt33Jj3cnGD3FHPqacmh1/iG3uH12zvJtspvw0DsQf3jNgOw6Htn6A4qDw7raTnWpID5ckscF8pcfMFDxKoyT0ByM+jenFP1K8Q6JY3LTozaZPDIzqpYyxuEldxxxwGwD/crN0FYdP1JdPmj8uSW1/s8HaWUHbIRzg54gBz6ntT5rSDlvEwdQ1Ar8TUtoyUR3KCIkbsMjErkdRlVPfkg13EtwJfh/4OiTzkWNbLfMgyQChib8lOc+oFeWROY/iFpDTrIGDmFXChfMdGK8jv6575Fd/wCEWln+G9xIZQzW1j5sZ25UtgSAk+21+Paknf5icUn6HolpbGHxRbgqVtVmdECkhAyCNgeOCQWUcj+E1Qnnh2QXbgurXayn5MjyY1kGOf7xAH41LDli8loEjkkF5sywyr/u4yc9ztPJ9Qaqa6qpE0C4B+1W8EfO4bfMLcfQsR9GFOWwQV3YW9MsMEzQMWvWgXTYAW6yTSF3Ptjn8FFS6FvkZjagNFLH5NufRBhQBg9eXP41n6jM8yoFidZJHkeLyyeWkAjTac8kRqfxauk0G1P2dHVAIrdVSBB90quM/X5twz071kk3IqTsjH8RrFZ6zutGwI0aABRwqxsrg+ndv++a5bxbdM8Vm2PKDQEPjBw5LYGfYDr712ni62BW1iRkWRJyjE8LtKspz6dRz71wGu4bwnbibdOzxKARkHL7kDKR1wSv1xTaaegRasc61stw7RGYhpoYB8qkvuAiVgwPqQx9hXM+NI5WvL25Enmxx4XeSBtyMAH68/nXqVxYQAwPbqbi2Vt0RChNrFYW55znHJz+HWuK8T2oFpqElwvzyGLMYwGZCxYHjoRgVpUhoZxmcZ4bBW21Eo5EkMBkJx/dkQ19J+A4zFNcKJPMWUb0OO3f9a8B8I2ZuBr6F8GHTZWfLdAJI92B+Ne2/Dm9kub9ZCQ0RtVQcAYKkjIHpxWuG7nPX7HpsfAIqQfjUMRyePxqYe9d6OQ8nU98Hk9Pb1qrrLhNKu8ZBMTAA9uKtBUzwxGR1NZ+omOWKaGYMQwwMDpXM9jSO4/4TXhutBS0kOSqkFD9a6jUbRpbcKzYdW+9jPQgZ/HNcB4EWTTNZLK2EkkYbf7ue1ep3kSzhFVc716E9815M00ektDzPWrRWNuwLCO5iMThRyTnP8xVCzuYyzF2VFitdrEDB3b2yPchSBj3rrPEcP8AoV4EIimVRNEf7pXlj/IV5tCHe4mtzFI0t4pZBFhhuEhPHsQDzn09KqE7GqVzW0WZL3ThLGxNzG7xTIilVUhwyg+uR8pPoAKNftFgtNOlSVRHcxhmCAeYpV/kIJ4H8eQSO9VvAcg8yAcrHOrJMyHaN6u2Hz65P6Cres2dzfGWGfzIrWyhDRkLnDtkKPfG8EjuCfaobui7WZ1FlLFOiSkiFN5Bds7cglCnccFXbr3rF8QaiLiTRWYJLH5/niPoTFgK/I6BgrN2I496fo+oO1hcSxyOF2FbmNgQgZVI27R1KnIPPPUcZp0cU1zDcXeP31paQbSBne+1mJ9ssuD/ACrSUndWM+XuUL+4s2v4YZ3R3Ma27eaRsjVXI4GQMBAuDnnP40yLU7a90FoY1yTqIiRw3mNgkAnkdNmccjccE5xWPfKs1zZvARCvmSKd7bSQwYxtyMAkKFI7GI/3qq2MyQTQRQZCywwT+W2drTeSQ5IPy4LtIcZ7/hWrm0rmagm7Hew6sq6nfusUkSJauUXKbWQMzEqfqzAk/wB3txT/AAsi3dzZQTsskfnQvMw4DLlWCA/7WCPq2ehriNI1FtmoNh987T22wHKFQ0QYjgkDZwPfPrivQvDEKyajcSTERQK0ty+D9yD5lU/TCfkp+lZznzNWNIxsmdZIS9uIw4WG4iDKMcsrk9PTCb8H/aziuf1xB9itY5XjjMVpMJNy/KkjBI2+Xr2kI9l/Cuqli2XmkBldUFwE2bcsqFwiKff5SMZ4GPeuN8cLLdPri27Bfs1ml4rrkgFYnVx7/M5A9waqUrahE+e9dlklvLhLWdmgm/fEKcAsuRkg9gAfpms2C5Md4TE7qFtmjO7nGUIZfpknj/8AXV7xCEig066gxEzqSIVziMHOBn9fx9qy9M3SapbrHGC8sqxBD90luMH2OaI6q5lPSRsWiNqN1bFZ7eJJ5XfyGZnMPlIG5zkkEAY555pvjNoFmso4HYkWqmQMRkSk5OMexWotNjlfxDHFbkAO0mxAchSFZVGTjt37Aio/EFybnV9saxoJFjRUzkJlfU+5Jz6Ec8VS3E9IlbSyilDI21w2xQeME/NGx9twwfY1Pp0ci+XesjFEvF8xXHB+bP1P3WzWfPG9vPfW86kOmUKsSCGRgPxPBFPvLgyW8Lh/vj50yT8y/wARz3Oc8VRknZl6xu4Ql/AC0cfl+ZHhsZmRwQ598bgB71DrCKsFk6vuLQI0nPKuck59yAD+PvS6JJGslyLogRyQyOjhfuybSFORyOpHpmp/EMRQ28CgbVt45DjOT8mOfpjFK+pSWhiQNsnXPTPIzjIrtvCE5trXURGV3XGn7sOQCHinV1AI652Djqc1w/AUfL34b+lb3hS6EWvafvI2mVVYHgfeB+b245ontdDpb2Z6j46lin0GwIQvFs8hJAcq5Dq8ZGeeI5Tn6YrDlvJ1vNHcRRJcW1zbiZifmLxgKST3UrsOeO/euxs9Okvfhxb+X8zWkpQ4PR08yJcnqNx6j0Kjvz50sZuNtsGcukUkTZJAV0Qlfx4b61jNtO52RtJHsqgWU9xbrGTaTPDeRIqja9rIiExr0B2kSj6P71wltcXWi6rHY3kjS3ulX8BYAHMsKBiWHoAsjcnqGPpXqV/A6aZok8MQmmto4gpbjesjDA5I4DNIhPYEccV5Z8QyLa90zVfJMywqttcoPl80gME5HcKVHvtxWk9DOGph/EgSaT4vtWifzIYZ0uISB8xBC49+VVfxr0/4ZSRy+DRYy9JUFi4dcFQWdFJ9flYAH1PNea/F1YnisNStfLJuQm1w3zAKqleOcfeI+q123w6vI5dPtpBkLdS3ClSdpQKI3B/N368/lQnZ3E1zaHaeHLvztL0+KICOVmePy35bdMUJY4HXnPp8tT+IZIZ5fFAhjJ8qKMKS33jGASw78fJ+BrE8ISkanpzX6sxt5pmuC64AEMuN3tw+K0NVZxZ20P3JriCeGZQDw2ELAHPPC5+gNUneImrSDwhItxrVxfSPuEMKpEGxgMQ43YyeoAXnBwF9a7TwvEsV2sB4jS2XcM8b9q/0z+lcb4WlaG3iEjxMJ587lxgKswRDkdsds12mgFhA88oA3CRjhugZlx+mBRDTQmps2Y2vSEQtMQTuG1h6gLhs/mteY3d1KPDFlZkgyO8Cqyn7mJFYHJ6YAA5r0TxNdgWeoKobcryFepB3bcZ/74I47VwWp2iJdRoWMIgkVsqwLAqd3Az33qPpQ97IF8Opo37zQ3OlvcSxPbLPNHcRHO4Kg+V2B4OURTjtnNYetodQljWYFQ8UVureWQCwVQR6nmX86ztT1UQ6+klzFLD5d1ITEznCxlOGHOchSwPUcYFdNYWrard2PmSYSO0hV1k4ByoYSKx45CDP0xXT8ehzP3dThdHLaJqGuhZ9sD6XeQBiBmY5TIOB1P8ASu5+Gmo3D6/aQyqoWKDYHC43AsSB71yXiCaK18N6gI5IjcX07kkxjIG4AgHtjA6etdd4NkSLWLJVjbzPK6t0IBABH60QXK7IzqO6ue0RfeGBU45PrVa3IOD14qwOmc12o5jyRj7e/BrMvZChO9Ay9xnr7VosRt4HTjis3UIhMvJK4zjaelcrNImbo16rarPF9x+Dg+v0r1fSJ1uxHKvD7cEE8D1rxCWEWWqxXklz8oyrAnqK9V8KXyNbK2c5U4YGuOrC7udtOV42L+rWjPbSyxqBKhDKpHJBGDkfQn2rxnV7KW1vNStkTBglEkXHJjbJIH1yRX0BcL52kyIwDkoGA9MYrzH4g6dJFrWn30S7g58srtzuIyRke4zXJNW1OmlLoYngW3RjdQhmQctGknJx/GuQPc8f4VftLVnn1O5DRl52CFU3BNwdEXcPTp7DIrL8L3Q068vY5Nw/dgrjnaCSCQfUqSB3OPrXV6Ogmhcw7AWt/MxngKCQQfbhc+/NJSvY0ktzB1y1XSG1Ex7ljubS4/dDKt5uAFOOmTlQTxxz2q74VuhHYzwSKrPNJHbwsSCpyo4OCOfmJz6A0eI7VpdEWYsYLiBp5S+wsQEbbkbfm6MO3OM5FUtFXNsjxQFIom3o20FiwjBJOD8uMngfL0IrROzQmroyPGtotjPKHtYGtba7kKzyx4coZSDxnnmXI7jdj0rj1vsLcbIYgbBZFyDkuseAC3PJwR+tekfEWQO895CxhngnabiMcuwiJjXI6hVJx2z615QJlkvvEs9uY44JY5pUjkKsMPkbR2JG7gj0rWTurGS0dzb8DMz36wXBzELhEYbOmZIS3P0XB9iT0r1LwyzOkoPyPqHk25UfdaHDyEcZx+7dev8AtGvM9AbyUSJN0Et3qUsSuBkxgxR/LtHdv0r0XwPMG1B7qZPLhYS3Ei/88yVwxA7bOmOvPFZR0sbPqekahdufD9lfxgrdy3MUsGByDuXHB6YUA+249zXGa+r2VtqcaZMtzELcszYASMRzHA7/ACFh+dd1Zaf/AGlYXU08YjSbdDapnmOErgn2OCWz7fSuC8QTNc3ZmkVow93IMMTwyoYpSo9jtHvirn3M49kfP/jKHytO0rcsa77dJl2cgq4LAZ/2d23HbFc1YzNDdwyRhi6uCNpwc+oPY+ldz4zti/hvTyICrwoCXb+IMqtjHruEpx6Z9K4lFgiggcS77iRzlBlREoIwd3vz9AB61dN3iY1laSNfQyTfpJbQ5uIeEfr5jDcSDk4GULdP7oGOag14h729LhCEMaRkY+4FO3GOxXH6UaHcC21i0jklAtXlTzSSdq5BBbA6lQxINW9WSL7RrcspiWZp22BFJQIzcFT06Y98fjinoFtzHvpvtlwlyzu003Exd9xL5xnPXkY69809bMpYM9yrRlHAIJ+bBUEFV74yCeejCorkeWoggO5mClwOQzAdvxJqaXUWHmrApFs06zCGT5xkKRjPXGCQR3GPSnuZPQiiVRbskmBnOJOcHvj6cGunOnzXtvqt2jKYrGGGMyFuBnarKBnOPmP0rI0jLRRMVVbUNKrfvANziNmXIOceg456V6BY28Uul+OGspFNpIpRM/MDEirI5477hEB67j1qWrtmsHseTFP3KE984qe1cJhjkEODuHOB3pbKKF7kxXLeUucB92Ah/wBrAJI6jjvSw+W9220NHCZPuryVTJ9ucVTehENGfR/g7yrnT/EXh2eENJcMk3ByrJMmA4PqHSM+x/MeOhwmoxRNjfdBGlbp8w3glfQcryP7tel+ELu1OmeGNQGbie3jn0u9BBU+WG3qp7ElZAR7oelcT8S7aGzura7gLpcAOmUQop2SMp4PT/7E1lNXSOuDs2e26HLFqHguyN1JvhEEMPnA8hZgoOSfSRVbOPWuG8UWTzC7gvInaCefbNtG3y5QgWQ8D5ctkng8P7V1Xw9WO78DLHhmhlsIRJ8oJXO8KcAerKPy96pazAdZ8My36xssty8kgO7lJmLgL6cvC0Z+q+lVNNxRMWlJnhXiW5uH0eytpyyzWjNDJEf4X3Enjt82T+Nd/wDDmV5vCUauYjLDLNLHu53j7Ocggde4z2rgfHgMWvXhR2eCdVuI2YENggDnOOQRtPutbXwwu2tbaaQk4V2MaA4yRG+W+gBIP1qbe7cd/ft5Hqtk4TxdrtuLhWDM8VuZOeJ5kwPoSGyO+K1tQvgmozHam6O2+2RsTkozJH8wB6YKsMDrmuba4GnePbmR8qyyRIyt/F5RZycfjn/gPvV3X5Ujv5I2kKM1nYKu0fOhcbuv1XBP1pRdkDs2a2hqtv4fsoVA2RQwnPYorncR/wACQn8a7i1uF+x30I+UIipluCGA7/kK426jFv4fsUkRvMFnDtGOmN2/6N+8Qn6Zq1HqZOmfxF7iUwnnOXLNGB+e0/Sqi9bEzV1cpavKZzJvUsJwpLKcbS0qY59MN/OuV8bGX+0HRgEV5QZAV4ORjqRn+EHj0Fa2sXYWa3WMgK14m4hvlMYZio5zx2/4DXN+OLuLExWUvLsdC0pOUyCqZ/DmtbaGXNqef6retNOjDEa3AAUkZKq5cFhnoMkkAHHevVo9fXRYrO4nuGaygt/IVkXG5gpGzPQZAOM9xXg7TNJPbJI+PuqNxPyDcCPoOTXR6rqNw9pbafE7rbTRm58on5FkLMN4JOeV/nVU5uOpnOPMbXjGN57bTtu0tIXlIP3k3Mh5PQ5yTXoGlXEUeqaK8eWWKIqwXp95Tz+decaxeQT3Igs7YW0cNxHbpGxLMuxeTnrycH8a7fCvqunxRsv+rJGFAJPynn2q4v3mYzWiR7lYEmPJ6ZyKvdfesrR332yZH8AP6VqL93Fd0Xocp5HIMduapXJJyDjH1q1KeRjP41n3JODk857d65mWjkvGL+XaERoWnfhQDjvUnwv1u+tm/szUUKKMmB+2P7tdHp+jnVLsM3KgVoR+H1F28axgFRkHHvXLKV58p20opR5jvtKuC9sFbLcAH3qn4n0xtQ0CchcyQgmNh1DK2f6Cl0JXEaxsCD0yeD+VdOluq2RRgSrfe5zXPKPNdGilZ3R856myQaurIg8tjvUg5BfPU+oIOPbNdV4amCqruP3RQAhj0U5+Un0JH4dar6zoMh1K9gKhLdWIjwv3SeB/+qrOlqI7/Tba5jTdJxOueM8gY/AfzrjV07nfo4nSapZpNod4YQqbSMOWIYq7EnkdDk/+OVheAAz3RM5SUM2+aJwCNrLsOO/3ifyH0rqfEn+i6GFhPzzsEdMZyqgsT7jAI/GqOh2v2W+keLaI5jJGm4fw7Fwfb+I4rqS95GP2Wcv4k0eaLw3cTWPm7rSUM2WwS4Z9rH1YqUPqcd68q1ux060OoMSYoZXmWFG+9HkB41YDIxlSOP7496+idXsZV07UzZ72W5SPYr87mHIz685weorw34h2xfUJbfTlRyfkiBALMm4yKfYgsyn/AHh+Fr3ZWM5aow/Cty39qR2oLMBOz9cZ3RhPzxkYr17SI2abWrHbJGkZeSPAPEjoC8RPZTlgD0yfpXlPh6z83xZblSrNdKJFcsCh3YK89iTwc9DXuvhsgXbRzW/mG4WE3JK4yqZ8w5H3iwbcB6Lms1q7G70VzvNG1QpHbTyHzHuHQQNuwPmTKPgfw8SZHboa4nW4FtxdnlBHqUF6NwIHlSrub6gvC+frWlPb3EEO2GYjBaKKTO0ls7g4B4AyvA9d3XIp3jBUk0u2vlAe2vLYRFQo/dkFJIlI6YGGXHB+Y+prdu6aZjyWenU8B8U2psdEks8hvJuntmJB48t2KOPU4Z16H0rza9EeVeNdpACyKOxAHT68+1er+KkX7DeqwLs8cYRgpGJV6g+5w3I7V59rtpbaZ4lu7e3uI7izjlyjEb1eJgCAcEEnH6jqKmnoxYiOhVvYGVkWQHzYwpYqAfkC4BA74AGT9a1440fQrq0vQ0ctu5G5htMY3rwV6lSZB6kcnpwaFzBCtvbXenGZJY8B4pTkqc/KyHGGXO7jrxzVq/uNn9uQ3tuUvLpIsHOBGwKsT9CAent2q7LqZX7FDUhcwzRQXG4zw3DEMrAtyFIIxzzjIPTmsolWQbflcKd5J4Y57Cul1afytWcAusIKXVnMECMqN83THTBPHr7Vzd0qx3EqJnarEDJzxnFXEynuXrS4hYGF1ZVlkjcMeiuMg59vmJr2L4KQ282j+KzPuEF1HPbspGdo8ktwOmQAx9flrxSAKY0aQnaG25UcqMgk/lmvXvghcJEmsRyyKILwGEHdkI7RyKNw4yG3YGfQ470RspFq9jyjUbcwXwifKzBMOpH3XGcD37c+9JthCTPE0oliYNlSMYJIJ9uq/ka2dfKv4gtJAn71BGtxG68Bw5X8RjbzWNbQbr/7IXIEjGNmPADZOCanoDV3Y9P+FUj30Uttw0d3JFBtd+EkdHiViOwJG3P+4O4qDxrbyXehaRfSM8ontpWmBJ+e5R23n6sjoxOPvfjXPeCbxoLC/hjDpcRfM4TO5kZ4xxjujqjj3HvXWzTi91m0sZyqRSm6kGzBAZlf5lA45ZVOBjoKidrWRtTbevQ7/wCB+pwzeGNJikVvs4sri2uGKg7tkoJYe22UY91NRWryWsl3p0kCCGV8bgAPLlbL5I9N+4+nzV558IdUaLTzp5ldE+1fvMf8s43Xaz/7oyMj3r0fVphc6g1yIijNEHdEIyGjjMZOP+/RGO4q27ijdHl3xnskjv7PUrcKLe5SSBwOf3ke3PPuHU/nXPeB50cywSoxjWFixHOMnHT1+YCvQPjTBs8M2LxyRPGLt5RgYIWTfsx65TaPbYK8z8DMg1ZFd3XzMx/Iu44Ksc/gQKUoqwKT50eleLb0y+MI7gGUvPBG6yD72HjViRkYPyg1taxdpeT+dKSovLWGJc4IGLZCOD3+d/8Avmud1lw/ivSWEibIbSCAui4BAjkQgZ7jOPwp9vfuNRso2AcC3tzsboWVwo46ZxvFZdXc16JnqetvFLprIr5EK+THg/xGN3H5KqVyMer7Cywt5aLdxXCk/LhnB6HPYsT+taMlwDo1nA7opYRFyg5JwMnP0z+oNeZavfqDOjLuU5c4ODjcwXjt94EZ9at6NMhaqxteJNTaC6skeXBggiZl2gqpVlAPT0c1H41LXcuralHITbNdqisV28KjF1x0xkgj1BrkdU1F5bqa48xfsiolu2QOXCF8EdxvTGe+K0LWVdU0eG0FyMuJpzG3VpWAQe3ITPbrW8eqOaRxFvKrSvJM+3yUZ14zltuFHtzitCWC7i1a3trmYPIsac+aGVU2hwM9Bx29awhlk29SxGKssHllkIAOBkjGO4HSoYJ3O7tM32pRXUvMtwWusB92NxAx+AFegyzY1+zhXhk6kj2FcB4Hty9zcEDdHHGuT1wyngj8yPxr0GEGbxEkmc5YrnrjGKqm7q5jU3sewaMcwRf7uOa116f/AFqxtKAVIBgYxxWwh4r0IbHKeQSNkEknHTFZ122AR17HNX5u/YDmsu8OVJ71z9C0dT4NizbhwBk10UVti5R8dRjiuf8AhzdxPE8LsNyHbXX+Ur3DMDjHANciTU2ztb/dpEVpGVvCQOAeldBHJhFBGcjiqIjxszxu7+lWFHdWOaVrDWpiXWnLNqbykKSudqn3rMufDaxXNteQ582FwSM9Vz/9euq2kTK56gYNPZNxIPQjJrF00dMZtGDNZyTvfqoBlXaIm7cgZ/z7VFdWBhubNEBPl7zg9DwBz7V0ltCU8x3I3MOT6VFPb5hd5FLuBwB3yapLsHMUdkc0LxrJm1Zdp55HBGR9K8G+M2ltDYWOoR8SxubeReoIQEDPrkY6+uK+jBZhQicBRjAXjpXnPxk0JLzRpioUMHjlycnGAQxHv938qKl0rhTabseQeA7SGfxALrSZV8poJNsEoO6GT5SpGcgndyD7Z9QPoDS9CEloky/NeLswG+dlkXO85PTqw6dMV4H8IbAK95fQsxnsyjrGPmMkY4lXGRztcke4r16y8W6/pGo3Ty+F5ru1t38tp7a6UycgZO0ryThc8jO2olG7NEpNabnpKeGLeSzQ2DPFGVACsS6smcgEE9sDkEYIrlPE9hNbadLpV87pa3jyCOTqY5CpaNt3cBs56YBHXFdH8OfGmka691Z2s7JLD+/+y3CmOeJWPzKyH0Y8EEjDCux1PR4dRt2E8avG42+WQCAP8fX6VolpoYOo4StI+U/EsDXOiW1xNvSe2tiLyFDtdDGdpYccsrFj/wABxxmvGfEUOy8EsQjWPAVtjEqCBkYOTkYxj8jzX0v8Q9NufD2qS5TdbTF3iuGJIYhQZImUYHKjPfd8w7mvDvHWhNYj9zhtOkkVoyCfkJU4XJ4x2BPXA7g4cXZmtSPPDQ56Xzn077PMpdo4vkjLEsh3jJOe3Uj/AHjjvUmi3cq39vFMy72aNFeUBigBIIIbOMZx7Vo2rzQxXNxCVlmYoscsB3gqY2yMDlWB2NzyGFYtpfGe8si8Blnjbazx8tKuQRx/fHTPfj8bcbnNF2szovGlqklh4ZvLeMKlzZRxMpPCSp8jD2B27vT5j71yWsiMahLIg+SV3kAUYXBY425HT/Cu+1mF7jwtdQEyh7LU4TbxupWRoZUldTj2LH164ya8+1BQ8m9VILKGI9+9NPUU43Q61WWW1njtyzFVLlR/dGN2fwA/I123w41Y2yyMjxRywjODGf3gEyOqggHkMc9vriuGhlXzMojLEI/KYE5PIwT+eTWn4Vu2sb2GdCHlhuEcRMMq2DnkdwSACPQ0paCp6tGt4zeJNRkgTezC2yWyQwfcGYN3OMAj0zj6c5dTefqPnINjyTH7p4GcYPtzk1r675Fz4ikdJHnSZ97MFAYliSxI6Z6H6msO4ZhapExB8sk5AB5zg89cYxx9fWlHsVJPf+tDo7ydLHVIdQg2FZk2zw9NrhFBJ+hJYf7vetfVZBb6PoN/AxlnsvMimCNjYVkwMAdjkn6MPWsdlTUfDd8MA3kXlToduDKi5U/iAwPvn2qla3P2q3Fr5iiO4RQ+77qsCAWP4KpP0qPM1WjaOy+FcHleINStRg+dZNEqsuWMjN5aqOf75TPsK7wQGGexROXltYNpdslQ0xBB75PljPsD615/8LZxb/EfQ1nizFdS/Z2c/MC6nG7jsDt/LNeiatZhtMS5BZbq2t4XULz9xxu5/wB5yOnYdKfS7C+tkcn8UI/9Bms0DeTbX626OzDC5GQPyAH4V5v4Ok8jXbORiVTeAxHYYau48U3D32j2V40agXV/LqDoj9MxoxGfQAkfWvPNIBbU1KY35yn5/wCFNPRhL4kdlc6hLPqmj+ZKokdmD/Nwv7xufycVu3F5ax6lFdxK+bZIbmUyclibh2Ube3DAY964e8mZtRgl+848tlUfNyRGenrk9K6oBLKHV2ugrNbyWMLlTnlSXYDtwBWaRbZ1jXLCxht5BmQW4Qj/AG2kGfpgDH515zrd4YrGOaeJme4uXlDNxuTqg47ZwQP9mtrW9W8pmt1y4tYPs6Ek/Nklh+pFcJqd202I5BlAAF56YGMj9Tj3q1K7M5KyB5mk0qWQ7R5l0v8ACAchG/8AivSp4NXuLCyVbdyiu4kHAzlQVzn0wSMVliZ3tktlP7tZGk6c5IUfyUVDMwViE4AGOta9dDne2o6xu5rG8gubZgs0LB0YqGwR0ODxT7curPMMnaMsT6k1XVWbkKeBnI9KsRMHi8o7sdV245ORjPtRLYInp3w/jeHSZmJI8zaP1ya7LSmL6vHCvT77eucg1zvh1Vg06KHptQD8cD/Gut8M2b3Gr3MqnCR7WDdj7fpSo3aMaj1bPVLA4WAZz15rXQ9umO9YunZIQjHHetccjr+ma9GDOY8huMEEenOKyL1sDIBOfyFa1woI4rHvuh/l0rnbNEZVrq0+k6kk8RbacKyg+9e2abcK8UUmfmYA8968DugGvYQ3eRRx35Fe46OFMESAEbFByayetzaL2R1MeGYdsjH0qaJco2PrVRGIKbT2ySauQYJwDzikbLuQtwTmhG+Zh6in3Cdc8ioVG04PSs2jaOxZC7wwZuBgD2qRY1bhmx2/ColccH+dTpgjB52mpY7ig8kA7vWsbxbZDULE25QFnKquP4SWAz/Ot5MBlKYzTMCWQq64YEHOOmOlO11ZiTs7nz14I0WfQLq9LLIMzuCgUncNn+P8/Y17jLpYuPD++3L+dEgZnjGSG6nI6kbufoakk0a3S6kOwFZZFY+xKlSfxqWxS78PytLao9xZE5ePq0Y9v7w/UVFP3dxyqNu6OX8WaTZ+INFtfEOnOtrq1qnn297bMA6sByCf4hwQQfSvT/A2s/274ZsL5womkjAlUfwyDhx7cg/hiuE8UNZnTXl0pFit7zf5kSjaBIRksO3PP41N8O5F0jUHgZiINShWVP7vnoMN+LIVPvsNXdXIqLnh6HVeMNBh1fSZI5VDsW8xCRna2cgj6V4B4j8PXN7pVlZXEQMkiiCOXbkDaH3xSY4wSFweDwCDkE19OysGi2e2PpXnOvaTDc3mpWUhVBcIs8LAEFWDfN+uG475p21KoTsrM+KZvtFlNcQNGtvcpLwrKd2R8pT6dDz3HrS3+nrNi5crbXF2vnpB5exD1yAegBwSoHpivYvi54LuHWbVJo2M8E4V5VAHmRtxvOMcqxGfbPrXletW13JarNuZ49xcofmCsuSw9sFmOB1zmo57OzN5UbpuJc0/XA1vJeXEAVpo4bWeSPGUeJlZJQD/ALoDDvk9KyUsWsdXNlc2+4xsEZSQNyPxkE/UEHp0NT3JgFsY4jG0E0SKyoCGinHQP68FgG7jGea1b23ieOzuUuZUMnm2oSaQu0TqcqrMOmVbjHHyk/RtmSicJbgRXah8bVbnIBH5HqK0NL22+txK7r5MjKrO3ACkjJPp/wDWpNbWJ9clkRPs8E0pfY2f3YJ6epA5H4U67Xy/J+Xf5LcyKciRSSRg4+o/Kqbv8zKMeW/kb1vblPFN1buG84747cZwWfeoQHsM/wCfSoPEVhFFEs1oriMo6knaWc5GGx6HjI7YNdtrNkb3xVJd27xXLNZQvvjODJmTaJP94qitn1+tZ/jzT1u45DAxkkFtDcAFdudwxI3sdwBwccFuvFZ2szZ6o4G0kf7I4lBMSjbkD7wGMrn6HNS6FAXa6jJUGBfOB6nCn5gATzn068VBZzD+0LWR2wkior+hIwOfxAzWzpJ8qK7tXytzI7sm2MBtwVs4brkMoIHTg03pcla2ZrWiNYeKrO9mjEZzJcbA3XCjcUPvksPbivdde091iuII9my8W7iPyjc8jh5VA+uwDA/DrXhBYStprsjKWAj4HQvmOXP/AAIZH4V7vA80vhOUuRHdPLFOikcxMGkgK89Nsm0ce/XiqhrdDlo7ngtzfH7LYRwuZPIt7mT5xjBLliCPTCgfj7VyujM/2kuMFthGT78VvXWRNqk8e6JoLdmXPRS3DKc9Sc/qaytDgWSHAOyWWWKBD9W5P5VC+EcviRZsw0FzC+MBZIWAXOc+ZjGe33K0Z7hbyTVGjciJ5mn+Y/NgkYznqQD+tRyD7Pr8sJlkZVlQ7AOJAgY5Pv8A4mqM7/Z7HylcZd5A2DngYx/I1D7FLuR6tfSXVxcTuTulO/B7ZHFR6Xp41G8leaQQWFrH5s8w/gQdhn+JjhQPU+xqvcyAn1+UAHvx/wDqqxeajDHpcVjaLOYy/nXBkKhZJMYU4HJ2gnGT3PAya1prqzGq9NDJyHmIRSAThVHJ9uaSRl2PlcuWGCTyAKdZyeRewylQ4R1cqe+DnFR3DBp5GA2qWOB6DPFa2OdvQapIY/TvVuw+aZIxj53UZ/Gqa9T9K0dHj3XdqSDjzV5/WpnsOB7BpKAFx12IGx79BXWeEpZXv77a2I1OSO3cVy+kjdHIf7zfyrpfBymIXcrj5piuQKKDskYS1uem6YuI48g9M1ro3GePrWTYNuC4bOBj6Vpp93gEV6EXoYM8iueUJ4x6Vj3ozxz/AErZnUZOe/bFZV4v1/KudmiOZuz5dzG3911J/MV7jpWxrWB25JjB+teH6mDtcDOR3969j8HXqXWg2UxGcoAfWoW7NY9DqFlDIqrVuBiByc9h9ayomCPgHOKv2z84xxUPc6ImgwBUep9Kg4JIPaposYGefTFQSA7iAaGWgRuWDflU0b4GR9MioDzzjJpeQOOV71BRdt5gep6mpoyS5PX6VQhYtkn7x61ct9xbCnBHrUu4FqRFC7mABH5mtXTRH9md5BhQMnNZl9n7Kzfd45PXFWUu4V0Y4I27ck+tJK0jNq+hxWo6RqGvXGpSabFax2TfIYX3K8pH8YYfcYHGDj61B4fjutW0Q2VxGbXWLGYCQHrFNHyrD2bg8dQxFegeH4/sulGSQAM3OAK5S4/4l3jaz1EsRb6mDZTjsJBlom+p+ZfxFVKKVmaKV7pLY6nS777bp8FwAULL8yf3T3H4HI/CsXXgI9UsZcfe3wZPuuQffkfrV/TR9m1K+tRjYz/aIxnoG+9/49k/jWb4uOyxEyg5hlSTj2YU5PQIr3tBt1aW97bSpdRrLbXK7SrDIyUwQfY/zrxy78Gw6FrskUmWsJnO4SHcoTAwcdwMOD14/Mew2twXtJYzhgWYjB9eah1Cyj1G2Md5gOuNkq/e+oPYmpsprzNoScT508XeCbnSNStbiBLu50y4TyA8JG5Y1HK5HVsEFWP3toFctr2nSadYi31EM8DmN4ruOIhJ41ztlU5wcq0gI4I2DOOcfTv9mj7HCBGha2bzCirgseh4HcgnkV5r8QfCcMFrcT2rOIA/2rgLt8tjn5ccbSCchh1BIPzGh2SJvdnhGtWcb6JZ3Uf7x4GeOd1/iXedje3BxSaRMI8iSCKZwcBXG5XIK/KR05AOD3yR6V0dzok0dhdiZfNsrZSZPIVWaJWb5S4XoAScPjByPQCubjwsUKRhYnh/czZc5YFtwY+mMge2M1Leg0le56J4Rv4hqlkkqSRy2unyRGZOsm1vNhIHQnClef8AGt/X/D5Xw9pUrbiUtPIkI7qZ3iA9Ogz+A9K5R4JC/ntHKgtpI5MPGFwrdCO23L9xgggivUtU1OOa3urdrVkaKKNpFDLxGoLkqM56yqcdQQacXdNSCSs00fMksOIHidgHhlcFWGDkj5gPpgHtWu9z5kMF5EDC0bNIzLkncw459DtI9txqvqcMkmqMz5H2x3kZ26btzA/r+NLotvLNDdQbHKLG0hVQAflIc9e21GI9waG77EqNro9D03Tf7ZS1uYozGrGOMKowBIIg0jcfw7x244b0rvbnV/Nsr2bYA8fnMABgHfOk6HHY4JOe52/WsDw2Y4fAU9xbYS5sLCaJccESq/mCQgdQY3wfXB9K09IiWWx1q/kj+SPThP5Z5IOQijHb/ln+VCfbqNq+/Q8P8VPMkl4GJ2zSY65ywYk/zq1HAlhe6cS2wQlpdxHG5Qv+HJ96g1mZdS1exggRvJhTcQ5HzFVG4jHQHbx9a1vGVyLHVlayy3kDajsuQjsSxwD1xuUZPpUPoh9W/wCu5kKxuLgOWxITu3MQMfezn/voCs+QM6hyOxJAHqSa0IlmFvPHGeGXym3dgATj65H6VNLbKtrayoufMjGQxx2K/wAyKjmsXY5+dsCMbRgjIPfrUbBGhyr/AL3fjZj+HHWrF3CwWTOMQjkj1zjFUmHU9sYrpjsctQltUBZ3k5AU7R71WODgk1dhjAiLegJHuaq5Kq8YwQxBzinF3ZlJWRGo4Nb+iooFmFz5rXAIx6CsSBgjqWUN2wa6bQYg2sWIAOxMk7qiq+g4aJs9N0tRFbSF1YgIRkHoT3rpfCWf7PHHRstz26VzMTgaedpwZJAuD1P+c12fhy38qxK4G3GcHvWlFaI5ZHd6ZnywT168mtWNht5ArJ00gog9u9aiNx7V3QMWeVTYPzZ5IPOKybvBU9K1Zz8uWHPTmsu8HynjjFYs0RzuqDliSPWu0+Fl7v0ua3brE+PeuL1LjOOasfDy/wDs2uzW27aJlGOay2kaLY9tiI9OTjPNXoH5AOax7FtigOcselakeGTr0pOJ0pmnE5DZJFPlTjIAz6VSgJxnNWlbgD86zehduwi5Vj70btq4wMd6Ujd0H50hjZmOemehrO76FCo2RxV+0bO0CqKAsCMfKP1q1aEnBxwKpCZpT5ktHUDqpFQadoySxo2+QrgEoTwKmRwVI9RzTtOvTatJF2wSKHa6ZHM47GhfSrHCkAIHtWLr+lNqOiXUcRxMFEsRHUOh3KR75Aq5FA95mVnKFuQQOg/Gmapa3dtYzyRX4ChCcSJnHHtVuSlq0VF8qstyra3HnatZT9BPbt+hU/1NR+LUB0m5BxkrmqeiyK9xpahjuWB8g/RR/Or3iNgdNuO52ED8ql7FxVpIxbCZXXKHKnvWipyVYflWXbDECEYBKj+VWIZFPCkZ71mnZlS1JbmNjkwfLI3y7vT1z6ip5bWAwMDGCAmGDdMYxg+2OKSEEYapZQxtpQhwSuM1tG25jJngfjXwtJoV9p93ZLKIJYntpURvmWNgCVx/EueQvPAI+nlfijRpNJurW78qOazdPlmh/wBXOo4OO4ZSdrKckfKeQQT9Y+L7KLUreFnODAUKuOCD7fQH+deC654eF7fXMFnxFb7QqHogyV3fmQMd8H0rCdoOx0U3zK7MbQQ66Ze24uPMBtgbOV84aMjG0Dt1PfqOPSu6vrldSh1R4wxF0sVugbhfKI4P1AVSPw964XWBdaJcxaNqwhexgnJQ7QpToWUEdiQCR6g+tdj4fYWfh/yb8bryVY7pjJgEuowBzxgKRwPSo5uhbXU898a206aJpwjcFVkluvL4A+dtuT78KOfQ0S6cdMvmlicSxxNA2Il3LsyDtJzg4+YZB/Oug1rT4rmO0s2UsJCFcd/LVf5k7z+A9aoaTbTf2drlpdKzvawmJWydqseQSO3zHIPTGRS5x8vU19OZv7Ae00928trJhdBvvYUvsT13YwM+hNdZ4kuP7I8P+LHt2OZraCC3G3PmKzK7Y+hUj8azri1bTbXQ/IiOb8Qs6KA3LjYQT/usef8AZqL4nXKaLpemuFMu66csM7gRESwXB7Elc/Wri2iJWZ59omlC68V61IciHSrYiQj+8m1G7d23fnVDWPNv9R0/5G88xtcvux/E5Kj8Biuo8LRGz+HGp3s7+ZNqMmZGHG47uAScZwQT6VzWn77nV3uUztX90kh5wQgAbHrjJx61Emk/QcFdf16iWtv5ySShR5czELnqR7+9b7aez6b5zrlIcR/MP4vXHscfrV/+zlsLCI4O+IK4GMnA9R9f5Gtu2tNngu9aaTzH3lg/97kc/rWRo2eS6jZukk6ueB+8POA30/E1kCPEwyyrzuOfauu8WwtHdiMYABIQdCRgYrkrghYyhX947dT2A7fn/KumlK5jVS3HXEpmVnChN7cKOg+lUpeGC/nWnJbOBBgfIRkVnTgeY3rmtYNHNNaCKucMexwR/I10vh/d/bESpkt5WOO2a521AMqgnCt8p+ldz4SshHrroB86oAT/AIVNTexK0i2dxZW7GW0RgG2AsRXfaOv7sLnIwMkCuV0iHdL5h9CBzXa6agEagcYPXOK6KSsjkk7nQWa4RCBt+taaHKD+grNs84AYEexNaCnA+QAg9s11x2MmeXSgBST2/nWVekkNxkHrzWpNnOPzyKzrpSc5J4HasWWjmtSH3sdOeormlvHsNThuIzjY3OD2711WpL1x0PpXJapbli3HFc9XTU2ie56NqMd1awSq2dwya6azugQOwNeNfDLUw8Emn3B/ex8oSeo7V6Zp1zhgDnimpXXMbQfQ6qCbGT1B9Kuq47ViW0gOOeB1rQhf8jUyNEaMeRjpg1KCM+xqsknG3gnOKsZLdDj61CVhjwFUE54NLGdpOAME9DTAWIPfFOUO3DNweOlJ6gWI2DLkHj1zUd4BGyXAGcHH4GpIUCgDHHrmku1SSB1bhccmlFtMhmvoc8UsOwN93jn0qzq+l/aLCaNXwrrjB6Vxmiag1vMI5jhhwrdmFdTf6kTpzAEAkVq5O12g5WmmjkNFSaDV7szOCsYESY/Mn+X5VZ8QXiR6fK0hKqoyxHp6VVjuUiZmZgDySc4Hvk1g294nizV4I7BjNo9jJ5k1wPuXEo+6qH+JV6k9CcelZKWnmzfrdnQwxOYI1YYYgZH4ULbMrkY68/WtmOIAgkA5pXgUYA+92xVuKepHOUIwVA3c053wh4JPQc1I0JZ8NlRjPFQ3aBEQlzs3c4PQVLdkTuZPiCeGz0iYz5dvujB5Ge/1wDXBeG4fLe1adUafUJ/PZMcqqDcq89sMB+Brd8RK2pX43ti3gjySTgZJxj3OKi0KO3sZPt12TgEKARkqpyAfqeK53K80bxVonCfFzRifKIjXe0YjXvjOcZ/IZPtWZFOX0l9JZUkleZVlEqfPbtkfMpBzjaAARkHIBHWuq+IF7KdXtJLhMzyShVg9MDgH6Yrl9ZzZeZNF819IqogU43SMMsCPzPsOazlO0nY2grxSYtlv1LxOj24/cwfKqc7kO4E57HIXPHrVpdP/ALPvtSm2k22orLAGPKl85GPwbj3Wug8DaWbO0aeRma55EznpuP3vyGBVu6tvtlzY2so8pJLhplVj91QQSfqeB9OKV+om9bGO8j3cfhgeUqyhhMoL7tmCMAY/3T1rzb4qahJrviqHS7YM0VmrZOfvFjljj3wBXoialY6LDr+rmJpRGGitB2IPXB6AFyfwrivDGm6gbeW+v2ds3BnII3BGZQCwHcnAA+lUp21Dku7dCTxbE8OkWuhQufKsbZZZii4G9toVR7kmrvhzQkNtJvXazuuzbyff9Aea249Ea3Fml2jPeXFx9sdGJJYgHaCf94p+Arq20xdOmgkYAJCvltt6cCs27lN20OS1O2a6cxry6YZtvQY5xVS5u47bwy1tIxUAB3B53KTnFdJGohnvZ3C75ImdVHXHp+lcBd2r3s0FsCRHGPMl9h2qttQWuhxutXD6hNJPKhX5wEHou2sK4+ctwTtUsM8nj3rqNUUS3E8MUZLtINnsoB4rBv4ltR2a4UncM5C/X3rak7k1FodDpv2RtJe5uAp+z2+R2JY9K4eUZdgOSW61sWiidPLllZY1BYgdT6VlSgPJhO5wK3gzmnCxaS3KG1Kg7nbGT0P0r0HwfbSf2hfSuCWXainHbFczNcLOdLiEYUxEKD68f/Wr3b4SaFbalf36KqnawZzjOc9KqEPaSVjCtLlVitpKFevBPeup05QVUleev0P9K373wkibjGpVvUVmpYTWbASc7T19q6+Vx3OO6ZqQHAGM4q4gyMA475qhB6YwPWrsL59sVtHUhnmL/OMDBI71RuFJJyPfp61f8tmyOnf8aJLfIOT3zWFzSxzN1b7s5HFZF3ZZ3ZHOK7aWzLMeOP5VQnsupxxWcldFRdji7aCawvYrq3JV0OcA43CvUNL1CO7tY7iMndj5gBzXKyWQLDj+lXtDV7W52g/Ix5FYQ92XL0ZfNbVHeWV2u3BPHatm3nPr3rj4t0Ug2kFD0IrZt7nYy5P3vU1q49zeM0zpopjgYzj0zV5HG0HJxXPW84PUj8+taEE2RknioaLuaavubI71MpGOpGKoRS5I68mrAc9R/OkDLqMMcZx0pWxtwcEHgg+lUxJjAHWlEgAxnI+tQ0I5nU73+w7xlv0cafJys4QssZ/2sdPrSXXizSzZmO2vlvpCdixWj72c+gx0+prpm2SLiQKyHqCMjFU7bTdPtJTLbWcEUh5LKgBNHNK3KWppHFjwVea/OLnxFcNFak5j063O2NR6Oern1zXfabYW2mWqW9pAkUSDConAH5UefzyPwqYSe46dKUEkxSnKW5chHI4UH161Z2jvyfyqpDJgD19jVpWyuPxrW5BBKuXIA69KxNStSzN5kmABuGegPtXRBAG561Wu1BGAoLAHr0I71nJFR0OBlt4p90WNqtIG3Dg7R3GPw4qOW3QwzIGcGMkk5ztPY49farV9MkWp75MwwgbANp/Oq8t+WZ4LBJmRgfPmK7VHHHPWuS6OlXOKv5Gv/EtvKUBt7RGIyM8sOT9eKx9Csvt+tPeSqJLS2I2ADgDGOvrx+VdDqOmSRTyIJMq8edx6DjnArZ0HSvJ050aNUGQvl92JIrJ3ZtdJF7Srby45wZAQp87p7Z4/HNYeu3UgnTylCzSxOPlPRcgE/wBB+Naer30dgW2Pk52bU5L5qlaxx/bxc320SEKoTqEAGQMDvScugox6lW/8Nx3Fvp8MqHyof3oXqqkdMjue9bGg6EJdQtp3i8uzjOY4ycbiowGb1zzXT6fpkmtRCeeF7fT1OdhGHlx0+gq/qsEkNkkFlaskm0jceAq+1aqH2uhDm3ocfDENS8Ty3siqlpbSeWnfIAOT+dO1uM3qKCQkAl8x2PHArXtdOmttOjgYjfIcsMcgVn640SxSRzSFAkZyPX2+tCV9yb9jidbnDahAtv8A6sIVY9iO1cVG0kY1JlfLSOF3DHHtXYX8D/Zo3CEZbJY44H0/CqOl2CXQlMYJSNy2T0z7029NDWJxd9bfZ3EUeFkKbCe5J75rOg8ONfv9mXCyM+M16DpelC8vr2RkB8iQKhxkHjrWPrc5029dlOxj8wwO/anT0d5Dm7q0Tzi/tf7PlvYQwOxvKLfSqmh2gmu2Z1BjTrn1q/qpZmuTIf3jSFySfWtDwdYrcQSGTOdwGMda2UtHYylHVXE1HS3OlrOikOjbge9ex/s8619l1WWK+Ow3KqFJ4BIFY66Qs2n+Uw4YYrQ0bSVtowuMY5BHUfSnSm6ck0Y1YKcWmfTclusse9RlT1FYmoacjA/Lj2Nc74B8XsJE03VH+fGI5T0f2z616JcxJPFvQg98ivUp1VLXoeXOm4uzPOrmyaJiUHygdDUKbSDnn3rq7uFJXIHDjjFYl1YlX4wCa1cbaozTuebxwdCOp5qylqSMfiantwOeB/kmrsYB7CuQ2MtrTvt59PQ1WktBgZ61vSAYk4HANU5gMdO9AHOzWiqCQpIzjp+tRJGI5M7Rg1qy/wAR71ny9R+P9K5qis9BXLsEq7VyctyAetTLMSMDkj1qgDiM49asWn+tP41vCXOlccXYv294U6/TJrWtb5AB+tc3c8MSODkf0qzbk1lezsdMZXOqjuhtGG/OrAujxz1rnYGO/qeD61cUnnk9KlyNEbS3XGM8GgXIB46c1jozeZjccc9/anxk7TzUvuM1Rc4Jwc037UScZ/KszOBxSp94VmOxrLNuqxC5IHQD9azIfu/gKvQ/cH1/rTEaULNkZIx71eiJ4HXiqMHWr0X3R+FaEkynIwSQacIw2Ce3rQev41LbgbBxSLKd5ZQzoRNGjA8cjpWVJYxQqYlhUuRxxwa6OYAKeKoxDdIxbkjpntWbjqUnocJdaM0t2kkocIG2v6YHNZ9/ei0D7PMeYggDHftmu6veIePU/wA6zbeNHmJdFY7h1Ga5pq2xtCV9zitC8PX+obLibA3n53Yc5PXHoK7jQfCtpZ3KtjzZA27e/NaqgLaS7RjDDGK1LP8AgqoU0twlUbJZIiwEcY2r/ERVe9QLFjqxG3PtWinRarXXU1szFPWxzt7JHCzPJ97GP/rV5/rcMl5vuXwke/jJHIBrsdWJMzgnIArG1VV+xIMDGPSsJvdG0Ecffxt5CSgbt42Rx/1qKJ10uxNrsDTyjJA7ZrXmA86H23Y/OsjUeSWP3iBz36VCk7GvkSaHZS26tngTHLHPTNcl46sYZNQwjEkkLjr716dbIn2OMbVxgdvavPvEYH9oLx6/yrRb2Enrc43WdLis7GSRl3lgERTyWNbXhLRZbOxgMsfzNz0qTWUVtTiBUEAKQCOhyea7u1VTFECBjYO3vWtZWdkZxk2tQhs1ESkDjHNWBCBytW7YDYvA+8RT2A3dB1NSmJlOSNZEx34IPpXc+B/FjwMlhqkm4HhZW649642H+I9+lMl+457g5B9K0hUdN3RlUpqasz2++slk/fwHqMnFYV7yQJAQfUVr+DmZ9Cti5LHYOpzVfVAPtB4HWvaoSu+VnkyVtT//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread patchy hair loss is present in this patient with extensive alopecia areata involving the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36212=[""].join("\n");
var outline_f35_23_36212=null;
var title_f35_23_36213="Clinical manifestations, diagnosis, and evaluation of osteoporosis in men";
var content_f35_23_36213=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36213/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36213/contributors\">",
"     Joel S Finkelstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36213/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36213/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36213/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36213/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/23/36213/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a common disease that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture. The World Health Organization has defined diagnostic thresholds for low bone mass and osteoporosis based upon bone mineral density (BMD) measurements compared with a young adult reference population (T-score) (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"mobipreview.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial osteoporosis evaluation includes a history to assess for clinical risk factors for fracture and to evaluate for other conditions that contribute to bone loss, a physical examination, and basic laboratory tests. There are many coexisting medical conditions that contribute to bone loss (",
"    <a class=\"graphic graphic_table graphicRef60440 \" href=\"mobipreview.htm?7/50/7981\">",
"     table 2",
"    </a>",
"    ). Thus, evaluation for alternative causes of bone loss to detect potentially reversible causes should be considered in those with abnormal initial findings.",
"   </p>",
"   <p>",
"    Early diagnosis and quantification of bone loss and fracture risk have become more important because of the availability of therapies that can slow or even reverse the progression of osteoporosis.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis and evaluation of osteoporosis in men will be reviewed here. The treatment and the epidemiology and etiology of osteoporosis in men are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link\">",
"     \"Epidemiology and etiology of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis has no clinical manifestations until there is a fracture. Many vertebral fractures are asymptomatic. They may be diagnosed as an incidental finding on chest or abdominal radiographs. The clinical manifestations of symptomatic vertebral fractures include pain and height loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men may also have symptoms of disorders that are known to cause osteoporosis, such as hypogonadism, malabsorption, and hyperparathyroidism (",
"    <a class=\"graphic graphic_table graphicRef60440 \" href=\"mobipreview.htm?7/50/7981\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link\">",
"     \"Epidemiology and etiology of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture, particularly at the spine, hip, wrist, humerus, rib, and pelvis. The bone densitometry definition of osteoporosis in men is not as well-standardized as it is in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36213/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Bone mineral density definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone density measurements are obtained infrequently in men and therefore the diagnosis of osteoporosis is often made as a result of low-trauma fractures or radiographic osteopenia detected by chance or during evaluation for unrelated reasons. However, as in women, bone mineral density measurements are useful for predicting osteoporotic fractures in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36213/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. For every standard deviation reduction in BMD, men have a relative risk of fracture that is similar to, or even greater than, the relative risk in women. In contrast, the age-specific prevalence of osteoporosis and fracture is lower in men than in women and therefore men have a lower absolute risk for fracture than women at any bone density T-score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36213/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H7#H7\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Dual-energy x-ray absorptiometry (DXA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the similar relationship between BMD and fracture in men and women, the World Health Organization (WHO) recommends using the same classification of BMD to define osteoporosis in men (age 50 and older) as in women (",
"    <a class=\"graphic graphic_table graphicRef74190 \" href=\"mobipreview.htm?11/28/11723\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36213/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Bone mineral density definition'",
"    </a>",
"    .) In most centers in the United States, a male reference database is used for calculating T-scores in men. As an example, osteoporosis in men is defined by a value for BMD 2.5 or more standard deviations below the young healthy male reference mean (rather than female reference mean). This is because all of the randomized trials in men recruited subjects based on T-scores calculated using male normal controls. Thus, we use a male reference database for calculating T-scores in men.",
"   </p>",
"   <p>",
"    The International Society for Clinical Densitometry recommends that BMD measurements alone should not be used to define osteoporosis in men younger than 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36213/abstract/5\">",
"     5",
"    </a>",
"    ]. In men below age 50 years with low BMD (Z-score &le;-2.0), we diagnose osteoporosis if there is a history of a fragility fracture and, possibly, if other risk factors for osteoporosis (such as glucocorticoid therapy, hypogonadism, or hyperparathyroidism) are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR BONE DENSITY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of data supporting routine bone mineral density testing in men above a certain age, we suggest not performing routine testing in men. However, measurement of bone mineral density is recommended in men with clinical manifestations of low bone mass, such as radiographic osteopenia, history of low trauma fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36213/abstract/6\">",
"     6",
"    </a>",
"    ], and loss of more than 1.5 inches in height, as well as in those with risk factors for fracture, such as long-term glucocorticoid therapy, androgen deprivation therapy for prostate cancer, hypogonadism, primary hyperparathyroidism, and intestinal disorders (",
"    <a class=\"graphic graphic_table graphicRef60440 \" href=\"mobipreview.htm?7/50/7981\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and etiology of osteoporosis in men\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some groups, such as the National Osteoporosis Foundation (NOF), International Society for Clinical Densitometry (ISCD), and the Endocrine Society recommend BMD testing for all men older than 70 years, and in men 50 to 70 years when risk factors are present. Screening for osteoporosis, including recommendations by expert groups, is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link&amp;anchor=H13#H13\">",
"     \"Screening for osteoporosis\", section on 'Candidates for BMD testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Skeletal site to measure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture risk can be predicted by measurement or estimation of BMD at many skeletal sites. However, the preferred site for measurement of bone density and the number of sites to measure are debatable, and may vary according to the clinical situation. This topic is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening for osteoporosis\", section on 'Skeletal site to measure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H16#H16\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Skeletal site to measure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men who are candidates for BMD testing, we suggest DXA measurements of the spine and hip because fractures at these sites have the greatest impact on patients' health. Measurement of hip BMD also has the highest predictive value for hip fracture. In addition, if pharmacologic therapy is planned, measurement of spine BMD is useful as it shows less variability and can detect responses to therapy earlier than hip BMD. We make the diagnosis according to the lowest T-score measured.",
"   </p>",
"   <p>",
"    Osteophytes and vascular calcifications are common in aging men and often interfere with the assessment of BMD at this site. In this setting, measurement of hip BMD alone is sufficient. If degenerative changes limit interpretation of BMD measurements of both the spine and hip, forearm DXA should be assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men with clinical manifestations of osteoporosis (low trauma fracture) or with low bone mass by DXA (T-score less than -2.0), an initial evaluation for secondary causes of osteoporosis, such as renal or liver disease, hyperparathyroidism, Cushing's syndrome, celiac disease and other forms of malabsorption, or idiopathic hypercalciuria, should be performed.",
"   </p>",
"   <p>",
"    Sometimes, the initial history and physical examination will provide an explanation for low bone mass (eg, hypogonadism, glucocorticoid excess). The initial evaluation should also include routine biochemical tests to uncover renal or hepatic disease, a complete blood count, serum testosterone, calcium, alkaline phosphatase, 25-hydroxyvitamin D (calcidiol), and 24-hour urine calcium and creatinine (",
"    <a class=\"graphic graphic_table graphicRef51140 \" href=\"mobipreview.htm?7/36/7756\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Men who have abnormalities on the initial laboratory testing, have suspicious findings on history and physical examination, or who have unexplained low bone mass after the initial evaluation may also require additional laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef51140 \" href=\"mobipreview.htm?7/36/7756\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These studies may include measurement of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parathyroid hormone to screen for primary hyperparathyroidism &mdash; We typically measure this in men with hypercalcemia. Some clinicians prefer to measure PTH in all men with osteoporosis as part of the initial evaluation.",
"     </li>",
"     <li>",
"      Estradiol &mdash; In adult men with acquired hypogonadism, estrogen deficiency may contribute more to bone loss than does androgen deficiency, particularly if levels are below 10 to 15",
"      <span class=\"nowrap\">",
"       pg/mL.",
"      </span>",
"      Accurate measurement of such levels of estradiol is best performed using mass spectroscopy.",
"     </li>",
"     <li>",
"      Tissue transglutaminase antibodies to screen for celiac disease &mdash; We typically measure this in men who have a low 25-hydroxyvitamin D level",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low urinary calcium. Some experts recommend these tests in all men with idiopathic osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum and urine protein electrophoresis to uncover a hematological or myeloproliferative disorder &mdash; We typically recommend these measurements in men with anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertebral compression fractures.",
"     </li>",
"     <li>",
"      Markers of bone formation and resorption &mdash; We typically measure markers of bone remodeling to help determine if otherwise unexplained low bone density is related to inadequate peak bone mass acquisition, previous bone loss, or to continuing bone loss, although data validating this practice are sparse. Elevated markers imply continuing bone loss and increased fracture risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"       \"Use of biochemical markers of bone turnover in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary cortisol excretion &mdash; We typically measure 24-hour urinary free cortisol if clinical manifestations of Cushing's syndrome are present. Some experts recommend measurement of 24-hour urine free cortisol in men with unexplained low bone density or vertebral fractures, even in the absence of traditional clinical manifestations of Cushing&rsquo;s syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Subclinical hypercortisolism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link\">",
"       \"Establishing the diagnosis of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum tryptase to screen for systemic mastocytosis &mdash; We typically perform this measurement in men with fractures, unexplained osteoporosis, or bone pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"       \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In rare cases, iliac crest bone biopsy after double",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      labeling may be useful, particularly for distinguishing osteoporosis from osteomalacia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=see_link\">",
"       \"Patient information: Medicines for osteoporosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoporosis is a silent disease until fracture occurs. Complications of fractures include pain, deformity, disability, and loss of height. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men &ge;50 years of age, the WHO has established diagnostic thresholds for low bone mass and osteoporosis based upon BMD measurements of the hip (",
"      <a class=\"graphic graphic_table graphicRef74190 \" href=\"mobipreview.htm?11/28/11723\">",
"       table 1",
"      </a>",
"      ). A DXA T-score &le;-2.5 is consistent with osteoporosis, whereas a T-score between -1.0 and -2.5 is osteopenia. We use a male reference database for calculating T-scores in men. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men younger than 50 years, BMD measurements alone should not be used to define osteoporosis. In young men with low BMD (Z-score &le;-2.0), we diagnose osteoporosis if there is a history of a fragility fracture and, possibly, if other risk factors for osteoporosis (such as glucocorticoid therapy, hypogonadism, or hyperparathyroidism) are present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not performing routine bone mineral density testing in men (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some expert groups recommend screening men based on age alone (eg, 70 or above).",
"      <br/>",
"      <br/>",
"      Measurement of bone density is suggested for men with clinical manifestations of low bone mass, such as radiographic osteopenia, history of low trauma fractures, loss of more than 1.5 inches in height, as well as in those with risk factors for fracture, such as long-term glucocorticoid therapy, hypogonadism, primary hyperparathyroidism, and intestinal disorders (",
"      <a class=\"graphic graphic_table graphicRef60440 \" href=\"mobipreview.htm?7/50/7981\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Candidates for bone density testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of the evaluation of men with low bone mass (T-score below -2.0) or fragility fracture is to rule out secondary causes (",
"      <a class=\"graphic graphic_table graphicRef60440 \" href=\"mobipreview.htm?7/50/7981\">",
"       table 2",
"      </a>",
"      ). Many secondary etiologies of osteoporosis can be determined on history and physical examination. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, most men with low bone mass or fragility fracture should have basic laboratory testing. Initial laboratory studies should include a CBC, biochemistry profile, 25-hydroxyvitamin D, testosterone, and measurement of urinary calcium excretion (",
"      <a class=\"graphic graphic_table graphicRef51140 \" href=\"mobipreview.htm?7/36/7756\">",
"       table 3",
"      </a>",
"      ), particularly if there is no clear explanation for their low bone mineral density.",
"      <br/>",
"      <br/>",
"      Based on the results of the history, physical examination, and basic laboratory testing, more extensive testing may be indicated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36213/abstract/1\">",
"      Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am 2007; 36:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36213/abstract/2\">",
"      G&auml;rdsell P, Johnell O, Nilsson BE. The predictive value of forearm bone mineral content measurements in men. Bone 1990; 11:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36213/abstract/3\">",
"      Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006; 21:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36213/abstract/4\">",
"      Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone 2008; 42:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36213/abstract/5\">",
"      Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008; 43:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36213/abstract/6\">",
"      Haentjens P, Johnell O, Kanis JA, et al. Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res 2004; 19:1933.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2052 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-9B24B61484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36213=[""].join("\n");
var outline_f35_23_36213=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CANDIDATES FOR BONE DENSITY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Skeletal site to measure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2052\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2052|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/28/11723\" title=\"table 1\">",
"      Osteopenia and osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/50/7981\" title=\"table 2\">",
"      Causes of osteoporosis men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/36/7756\" title=\"table 3\">",
"      Lab eval men osteo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=related_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_23_36214="Paroxysmal hypertension (pseudopheochromocytoma)";
var content_f35_23_36214=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paroxysmal hypertension (pseudopheochromocytoma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36214/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36214/contributors\">",
"     Samuel J Mann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36214/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36214/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36214/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36214/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/23/36214/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of severe and symptomatic paroxysmal hypertension should always generate suspicion of a catecholamine-secreting pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the reality is that this tumor is rarely found among such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/2\">",
"     2",
"    </a>",
"    ]. In one report, the diagnosis was established in only 1 of 300 patients evaluated for pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/3\">",
"     3",
"    </a>",
"    ]. Up to 40 percent of patients in this series fulfilled the criteria for panic disorder.",
"   </p>",
"   <p>",
"    In most patients with paroxysmal hypertension and a negative evaluation for pheochromocytoma, the cause remains unknown, treatment is difficult, and many incur chronic disability. This clinical constellation is sometimes called \"pseudopheochromocytoma\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/4\">",
"     4",
"    </a>",
"    ]. A paucity of data concerning the clinical characteristics of this disorder exists.",
"   </p>",
"   <p>",
"    The proposed cause, clinical features (including link to emotions), differential diagnosis, and management of pseudopheochromocytoma will be reviewed here. The diagnosis and treatment of pheochromocytoma and panic disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudopheochromocytoma most likely involves activation of the sympathetic system; this has been inferred from the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paroxysmal nature",
"     </li>",
"     <li>",
"      Association with tachycardia in some patients",
"     </li>",
"     <li>",
"      Increase in plasma catecholamines documented during attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increase in baseline plasma epinephrine and metanephrines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Response to",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      blockade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism that underlies sympathetic activation is unclear but appears to involve emotional factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients in whom the diagnosis of a pheochromocytoma has been excluded, who are considered to have pseudopheochromocytoma, hypertensive episodes are generally characterized by the following three features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abrupt elevation of blood pressure (which can be greater than",
"      <span class=\"nowrap\">",
"       200/110",
"      </span>",
"      mmHg in some patients) that is documented by a clinician or home blood pressure monitor",
"     </li>",
"     <li>",
"      Equally abrupt onset of distressful physical symptoms, such as headache, chest pain, dizziness, nausea, palpitations, flushing, and diaphoresis",
"     </li>",
"     <li>",
"      Attacks are not triggered by fear or panic, although fear does occur as a consequence of the frightening physical symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of episodes can range from 10 minutes to many hours, with frequency ranging from several per day to once every few months. Between episodes, the blood pressure is normal or may be mildly elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Psychological characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pseudopheochromocytoma usually insist that episodes are unrelated to emotional distress. This feature has tended to discourage consideration of a causal role for emotional factors. However, details of patients' psychosocial history and the success of psychologically-based intervention in some cases (as described below) suggest that the disorder is related to emotions that have been kept from conscious awareness and therefore are not reported.",
"   </p>",
"   <p>",
"    In the largest study to date, 14 of 21 patients (67 percent) acknowledged a past history of severe emotional trauma (such as the Holocaust or severe childhood trauma) or prolonged physical or emotional abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8\">",
"     8",
"    </a>",
"    ]. They uniformly insisted that those events bore no lingering emotional impact. The remaining seven individuals did not report a history of overt emotional trauma or abuse, but careful interviewing indicated a pattern of minimizing awareness of distressful emotions and of not confiding in anyone.",
"   </p>",
"   <p>",
"    Individuals with this disorder may feel some degree of emotional distress but seem immune to the more severe emotional distress experienced at times by most other people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to pseudopheochromocytoma, the following diagnoses should be strongly considered among patients presenting with paroxysmal hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pheochromocytoma",
"     </li>",
"     <li>",
"      Labile hypertension",
"     </li>",
"     <li>",
"      Panic disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pheochromocytoma must be excluded in all patients with unprovoked paroxysmal hypertension. Assays of plasma or urine catecholamines are diagnostic in 95 percent of patients with symptoms, and the high sensitivity of the plasma metanephrine assay is also documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Although there is still uncertainty as to the \"best\" test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ], most patients with clinically evident pheochromocytoma have very abnormal, rather than mildly abnormal, values. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Labile hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clear relationship between blood pressure elevation and stress or emotional distress is usually evident among patients with labile hypertension. Patients know they are upset and blame the hypertensive episodes on emotional distress. In contrast, patients with pseudopheochromocytoma insist that the disorder is unrelated to psychologic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic disorder is characterized by episodes of fear or panic, and is commonly associated with physical symptoms such as chest pain, headache, palpitations, flushing, and dizziness, along with some degree of blood pressure elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Panic disorder and pseudopheochromocytoma share similar physical symptoms, and both respond to treatment with an antidepressant agent. As mentioned above, panic disorder is present in as many as 40 percent of patients evaluated for pseudopheochromocytoma, compared with 5 percent of control patients with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/3\">",
"     3",
"    </a>",
"    ], and, in one report, panic disorder presented as paroxysmal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the two disorders differ from each other in that the presentation of pseudopheochromocytoma is dominated by autonomic manifestations (ie, paroxysmal hypertension). In patients with pseudopheochromocytoma, fear occurs only in response to the physical symptoms. In contrast, panic disorder is dominated by emotional manifestations (ie, panic), and accompanying blood pressure changes are milder.",
"   </p>",
"   <p>",
"    The most critical clinical difference is that, in the absence of antecedent panic or emotional distress, pseudopheochromocytoma is viewed as an unexplained medical disorder. Therefore, physicians and patients rarely consider an emotion-based cause or treatment because, by definition, patients fail to report any triggering emotional distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other causes of paroxysmal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many additional disorders may present with paroxysmal hypertension, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      Hyperthyroidism (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cluster or migraine headaches (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link\">",
"       \"Headache syndromes other than migraine\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypertensive encephalopathy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coronary insufficiency",
"     </li>",
"     <li>",
"      Renovascular hypertension (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central nervous system lesions, such as stroke, tumor, hemorrhage, compression of lateral medulla, and trauma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"       \"Clinical diagnosis of stroke subtypes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seizure disorder",
"     </li>",
"     <li>",
"      Carcinoid (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drugs &mdash; cocaine, lysergic acid diethylamide, amphetamine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tyrosine ingestion combined with monoamine oxidase inhibitors",
"     </li>",
"     <li>",
"      Baroreflex failure, which is characterized by marked and frequent fluctuations in blood pressure, with both high and low readings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/23\">",
"       23",
"      </a>",
"      ]. It is caused by hypofunctioning of the baroreflexes that normally buffer blood pressure fluctuations. The disorder is usually a result of injury to carotid baroreceptors, with most patients reporting a history of neck irradiation or surgery.",
"     </li>",
"     <li>",
"      Factitious hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such disorders must be considered when suggested by the history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diagnostic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/1\">",
"     1",
"    </a>",
"    ]. However, such causes are uncommon among patients with recurrent paroxysmal hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of pseudopheochromocytoma is usually possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8,24\">",
"     8,24",
"    </a>",
"    ]; it involves the use of the following three modalities, either alone or in combination:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antihypertensive agents",
"     </li>",
"     <li>",
"      Psychopharmacologic agents",
"     </li>",
"     <li>",
"      Psychological intervention",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antihypertensive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe or very symptomatic paroxysms often require acute intervention, either with an oral or IV agent, as well as chronic preventative therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acute management of paroxysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    (beginning with a bolus of 20 mg initially, followed by 40 to 80 mg every 10 minutes to a maximum dose of 200 to 300 mg) is usually very effective. If the blood pressure elevation is not extreme, oral agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , can be employed acutely. An anxiolytic agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    , used alone or in combination with an antihypertensive agent, can also effect rapid improvement in both symptoms and blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=see_link\">",
"     \"Drug treatment of hypertensive emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chronic preventive management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since pseudopheochromocytoma involves activation of the sympathetic system, treatment with adrenergic blockade is more likely to be effective than management with agents such as angiotensin converting enzyme inhibitors and diuretics, which are directed at mechanisms other than the sympathetic nervous system. The combination of any beta blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    at a dose of 12.5 to 50 mg per day or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    2.5 to 10 mg daily) and an alpha blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    at a dose of 0.5 to 2 mg per day) is frequently effective as preventive therapy in reducing the magnitude of blood pressure elevation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    can also be effective but provide a less reliable degree of alpha and beta blockade. In addition, central alpha agonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ) may be effective, but fatigue and somnolence usually hamper chronic administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Psychopharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding an antidepressant is usually dramatically effective in eliminating paroxysms and restoring a normal quality of life in patients in whom severe or very symptomatic paroxysms recur despite alpha and beta blockade, particularly when the disorder is substantially affecting quality of life. Even when the patient rejects the possibility of an emotional basis, an antidepressant drug, such as a selective serotonin reuptake inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    at a starting dose of 10 to 20 mg per day), or a tricyclic antidepressant, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    (starting dose 10 to 25 mg per day), perhaps initially combined with an anxiolytic agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    (0.5 to 1 mg twice daily), can eliminate attacks. There are inadequate data to indicate whether one antidepressant agent or class is more effective than any other.",
"   </p>",
"   <p>",
"    These agents may have to be prescribed by the primary care physician if the patient is unwilling to consult a psychiatrist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Psychotherapeutic intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihypertensive and psychopharmacologic agents can control, but cannot cure, pseudopheochromocytoma. In some cases, psychological intervention has the potential to cure, providing an attractive alternative to endless pharmacologic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8\">",
"     8",
"    </a>",
"    ]. However, further studies are needed to determine the success rate of psychological interventions in treating this disorder.",
"   </p>",
"   <p>",
"    A cure is sometimes possible in patients who are willing to consider the possibility that the disorder is linked to emotional factors. However, many patients, particularly those whose psychological well-being depends upon continued repression of deep-seated, potentially overwhelming, emotions, cannot and will not consider such a possibility. Their refusal to pursue psychotherapy should be honored. It is never appropriate to coerce a patient into psychotherapy, which would be fruitless and potentially harmful.",
"   </p>",
"   <p>",
"    Clinical experience suggests that two other psychological interventions can be extremely helpful in managing this disorder. One is reassurance that hypertensive paroxysms are very unlikely to cause a sudden cardiovascular event, unless blood pressure elevation is extremely severe. This reassurance helps considerably in reducing patients' overwhelming fear of recurrent attacks. The other intervention is empathetic acknowledgment of prior severe trauma and of the patient's resilience in having survived psychologically. Even in patients who are averse to psychological discussion, affirmation of their psychological resilience can sometimes result in surprising clinical improvement. Studies to formally assess these simple interventions are needed.",
"   </p>",
"   <p>",
"    The effectiveness of different treatment modalities was evaluated in the previously mentioned study of 21 patients with pseudopheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8\">",
"     8",
"    </a>",
"    ]. At a mean follow-up of nine months, a successful outcome was achieved in 13 of 15 evaluable patients, and there was spontaneous resolution in one patient. Treatment failed in two patients. The response to treatment could not be evaluated in the remaining seven patients, among whom two died before treatment could be assessed (neither had pheochromocytoma); one was lost to follow-up; one refused treatment; and one was intolerant of medications.",
"   </p>",
"   <p>",
"    Among those successfully treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three responded to psychological intervention alone without requiring pharmacologic agents.",
"     </li>",
"     <li>",
"      Ten responded to pharmacologic therapy, seven of whom received an antidepressant, and all of whom received alpha- and beta-blocker therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Obstacles to successful treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emotional basis of pseudopheochromocytoma is rarely suspected since its manifestations are physical, and emotional distress is viewed as a consequence rather than as a cause of paroxysms. As a result, physicians are unlikely to consider an emotional basis, even when a diagnosis or effective treatment has been elusive.",
"   </p>",
"   <p>",
"    Psychological awareness, whether achieved with or without psychotherapy, offers the possibility of cure, but in many patients is not an option, since the pertinent repressed emotions may be too overwhelming for patients to confront. In addition, a repressive coping style often is not amenable to psychotherapy. Therefore, in many cases, a psychopharmacologic rather than psychotherapeutic approach is more likely to be effective.",
"   </p>",
"   <p>",
"    Some patients will initially refuse either psychotherapeutic or psychopharmacologic intervention. However, the severity of the symptoms and the disruption caused by the disorder will ultimately motivate many patients to accept a therapeutic trial of a psychopharmacologic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13076675\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudopheochromocytoma refers to the clinical constellation of symptomatic paroxysmal hypertension in the setting of a negative evaluation for a catecholamine-secreting pheochromocytoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism most likely involves activation of the sympathetic nervous system, as is suggested by the paroxysmal nature of the hypertension, association, in some cases, with tachycardia, increase in plasma catecholamines during attacks and in baseline plasma epinephrine and metanephrines, and the response to",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      blockade. The underlying cause of sympathetic activation may involve emotional factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical characteristics include abrupt elevation of blood pressure (which can exceed",
"      <span class=\"nowrap\">",
"       200/110",
"      </span>",
"      mmHg in some patients); abrupt onset of distressful physical symptoms, such as headache, chest pain, dizziness, nausea, palpitations, flushing, and diaphoresis; and the absence of emotional precipitants such as fear or panic, although fear does occur as a consequence of the frightening physical symptoms. Duration of episodes can range from ten minutes to several hours; frequency ranges from several per day to once every few months. Between episodes, the blood pressure is normal or may be mildly elevated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main differential diagnosis of paroxysmal hypertension includes pheochromocytoma, labile hypertension, and panic disorder. Other causes include anxiety, hyperthyroidism, cluster or migraine headaches, hypertensive encephalopathy, coronary insufficiency, renovascular hypertension, central nervous system lesions, seizure disorder, carcinoid, drugs including cocaine, lysergic acid diethylamide, amphetamine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      , tyrosine ingestion combined with monoamine oxidase inhibitors, baroreflex failure, and factitious hypertension. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute management of pseudopheochromocytoma often includes an oral or IV antihypertensive agent. Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      is usually effective. If the blood pressure elevation is not extreme, oral agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , can be employed. An anxiolytic agent such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      , used alone or in combination with an antihypertensive agent, can effect rapid improvement in both symptoms and blood pressure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute management of paroxysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic preventive management includes treatment with adrenergic blockade. The combination of a beta blocker with an alpha blocker may reduce the severity of blood pressure elevation during paroxysms.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       Labetalol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      provide less reliable degrees of alpha and beta blockade than do separate alpha- and beta-blocking agents. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Chronic preventive management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The addition of an antidepressant, sometimes combined with an anxiolytic agent, is usually effective in eliminating paroxysms, and merits consideration in patients in whom frequent, severe, or very symptomatic paroxysms continue to recur. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Psychopharmacologic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some cases, psychological intervention may cure pseudopheochromocytoma, although further studies are needed to determine its success rate. Unwilling patients should",
"      <strong>",
"       not",
"      </strong>",
"      be coerced to pursue psychotherapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Psychotherapeutic intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Manger WM, Gifford RW. Pheochromocytoma: A clinical overview. In: Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed, Laragh JH, Brenner BM (Eds), Raven Press, Ltd, New York City 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/2\">",
"      Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/3\">",
"      Fogarty J, Engel C, Russo J, et al. Hypertension and pheochromocytoma testing: The association with anxiety disorders. Arch Fam Med 1994; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/4\">",
"      Kuchel O. Pseudopheochromocytoma. Hypertension 1985; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/5\">",
"      Mann SJ. Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions. Psychosomatics 1996; 37:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/6\">",
"      Kuchel O, Buu NT, Hamet P, et al. Dopamine surges in hyperadrenergic essential hypertension. Hypertension 1982; 4:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/7\">",
"      Hamada M, Shigematsu Y, Mukai M, et al. Blood pressure response to the Valsalva maneuver in pheochromocytoma and pseudopheochromocytoma. Hypertension 1995; 25:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/8\">",
"      Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. Arch Intern Med 1999; 159:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/9\">",
"      Sharabi Y, Goldstein DS, Bentho O, et al. Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens 2007; 25:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/10\">",
"      Mackenzie IS, Brown MJ. Pseudopheochromocytoma. J Hypertens 2007; 25:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/11\">",
"      Hunt J, Lin J. Paroxysmal hypertension in a 48-year-old woman. Kidney Int 2008; 74:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/12\">",
"      Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 2000; 160:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/13\">",
"      Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/14\">",
"      Hickman PE, Leong M, Chang J, et al. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology 2009; 41:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/15\">",
"      Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994; 15:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/16\">",
"      Balon R, Ortiz A, Pohl R, Yeragani VK. Heart rate and blood pressure during placebo-associated panic attacks. Psychosom Med 1988; 50:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/17\">",
"      Liebowitz MR, Gorman JM, Fyer AJ, et al. Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 1985; 42:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/18\">",
"      Cameron OG, Lee MA, Curtis GC, McCann DS. Endocrine and physiological changes during \"spontaneous\" panic attacks. Psychoneuroendocrinology 1987; 12:321.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders IV, 8th ed, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/20\">",
"      Katon W, Roy-Byrne PP. Panic disorder in the medically ill. J Clin Psychiatry 1989; 50:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/21\">",
"      White WB, Baker LH. Episodic hypertension secondary to panic disorder. Arch Intern Med 1986; 146:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/22\">",
"      Krentz AJ, Mikhail S, Cantrell P, Hill GM. Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine. BMJ 2001; 322:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/23\">",
"      Zar T, Peixoto AJ. Paroxysmal hypertension due to baroreflex failure. Kidney Int 2008; 74:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36214/abstract/24\">",
"      Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma). Curr Hypertens Rep 2008; 10:12.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3856 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36214=[""].join("\n");
var outline_f35_23_36214=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13076675\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Psychological characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Labile hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other causes of paroxysmal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antihypertensive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acute management of paroxysms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chronic preventive management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Psychopharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Psychotherapeutic intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Obstacles to successful treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13076675\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_23_36215="Rapid transporters on maintenance peritoneal dialysis";
var content_f35_23_36215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid transporters on maintenance peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36215/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36215/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36215/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36215/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36215/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/23/36215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is now well appreciated that peritoneal dialysis (PD) patients have different peritoneal membrane transport characteristics. These differences are best classified and determined by use of the peritoneal equilibration test (PET) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) If the standard PET is done, and all recommended measurements obtained, this test has helped characterize the relationship between dwell time, solute transport, glucose absorption, drain volume, and net solute removal. Those patients who have the highest rates of diffusive transport are classified as rapid transporters (Figure 1). According to PET testing in different populations, about 15 percent of patients will be rapid transporters at the start of PD.",
"   </p>",
"   <p>",
"    As a result of the high rates of diffusive transport, rapid transporters transport small solutes (such as urea, creatinine and glucose) quickly, leading to equilibration between the dialysate small solute concentration and that of the blood relatively early in a dwell (",
"    <a class=\"graphic graphic_figure graphicRef62604 \" href=\"mobipreview.htm?6/26/6574\">",
"     figure 1",
"    </a>",
"    ). These patients also rapidly absorb dialysate glucose, leading to early dissolution of the crystalloid osmotic gradient between dialysate and blood that is required to sustain ultrafiltration. Once the osmotic gradient is dissipated, the stimulus for ultrafiltration is gone and ultrafiltration ceases. However there is slow but continuous absorption of fluid via the peritoneal lymphatics, potentially leading to poor net ultrafiltration, low drain volume and potential systemic volume expansion. Lower drain volumes lead to lower solute clearance.",
"   </p>",
"   <p>",
"    If one was to design a peritoneal dialysis prescription based upon transport characteristics alone, ignoring patient convenience or life style constraints, attempting to optimize ultrafiltration, drain volumes, and creatinine clearance, rapid transporters would do best with short dwell times (1.5 to 3",
"    <span class=\"nowrap\">",
"     hours/dwell).",
"    </span>",
"    In theory when using only glucose-containing solutions, such patients would do best with automated therapies (APD), such as nightly intermittent peritoneal dialysis (NIPD) or nightly cycler therapy with a last bag fill (first AM fill) and a midday exchange when only using glucose-containing solutions. By contrast, low average, or low transporters would do best with prolonged dwells, such as those associated with continuous ambulatory peritoneal dialysis (CAPD) or continuous cycling peritoneal dialysis with less overnight exchanges (",
"    <a class=\"graphic graphic_figure graphicRef62604 \" href=\"mobipreview.htm?6/26/6574\">",
"     figure 1",
"    </a>",
"    ). Low average or low transporters may need large instilled volumes, which enhance clearance by maximizing contact surface area. In such patients, solute clearance and ultrafiltration tend to be maintained throughout the dwell because of the slow rates of transport for both small solutes and glucose. Patients who are high average transporters would typically do well with either therapy.",
"   </p>",
"   <p>",
"    Despite these theoretical concepts, most patients could do either CAPD or APD if one is knowledgeable in PD kinetics, PD fluids and willing to individualize the patient's prescription. This is especially true in incident patients who have some residual renal function (making it easier to maintain euvolemia and solute removal). At our center, approximately 85 percent of all PD patients are on APD. In addition, the removal of larger solutes such as B2-microglobulin are dwell time-dependant even among rapid transporters. Therefore although these patients could often reach their minimal",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    urea targets with NIPD and a dry day, most are on 24 hours a day of PD dwell. If they were not, they would not be optimizing middle molecule removal due to the dry day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RAPID TRANSPORT AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the potential for suboptimal ultrafiltration volumes and inadequate solute clearance, rapid transport status may be an independent predictor of enhanced mortality among patients undergoing continuous peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. This was shown in a 2006 meta-analysis of 20 observational studies, with 19 studies pooled to generate a summary mortality risk based upon transport status as defined by the ratio of creatinine in the dialysate to plasma after a standardized four-hour dwell",
"    <span class=\"nowrap\">",
"     (D/P)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/5\">",
"     5",
"    </a>",
"    ]. For every 0.1 increase in the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    value, there was an increase in the relative risk of death of 1.15 (95% CI 1.07-1.23). Thus, as compared to patients with low transport status, an increased mortality risk of 22, 46, and 77 percent was noted for low-average, high-average, and high transporters, respectively. In addition, there was a trend for an increased relative risk for death-censored technique failure with every 0.1 increase in the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    value (1.18, 95% CI 0.96-1.46). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for decreased survival among these patients is unclear, although most of the deaths were cardiovascular in nature. Postulated mechanisms include fluid overload, malnutrition, increased protein losses, and chronic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This meta-analysis reviewed data from patients who were mainly on CAPD, and if rapid transporters, exactly the patients predicted to do poorly with ultrafiltration with consequently low drain volume and solute clearances. In a small cohort of patients who were all on the same CAPD prescription, compared with low transporters, rapid transporters were more likely to be hypertensive (0 versus 100 percent) and have LVH (33 versus 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/8\">",
"     8",
"    </a>",
"    ]. In follow-up of these hypertensive patients, blood pressure improved when their prescription was altered to increase ultrafiltration. When these and other observations were noted, more attention was paid to individualizing the PD prescription for patients with high peritoneal membrane transport. Subsequent data suggest that if there is an increased baseline risk associated with transport status that it may be more related to physician practice and management rather than an increased risk due to transport status alone.",
"   </p>",
"   <p>",
"    The following studies also support the theory that the risk may be due to how patients are managed rather than transport status alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center observational cohort study, peritoneal transport status predicted the risk of death in patients who started PD between 1990 and 1997 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/9\">",
"       9",
"      </a>",
"      ]; in patients who started PD between 1998 and 2005, transport status was not predictive of relative risk of death (",
"      <a class=\"graphic graphic_figure graphicRef59677 \" href=\"mobipreview.htm?3/41/3743\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/9\">",
"       9",
"      </a>",
"      ]. During the later vintage, patients were more likely to be treated with automated peritoneal dialysis or alternative osmotic agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      . With such maneuvers, patients with high membrane transport can be managed on PD without the increased mortality risk demonstrated in historical studies.",
"     </li>",
"     <li>",
"      The European APD outcomes study showed that risk of death at one year was not related to transport type in patients treated with APD and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"       Icodextrin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large registry report from Australia and New Zealand confirmed that peritoneal transport type was only a significant predictor of outcome in patients on CAPD, not in those on APD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single center study, among 193 incident patients who started PD between 2000 and 2004 (78 percent of whom were on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      or treated with APD), survival was not related to transport type (71, 69, and 67 percent for rapid, high average and low average transporters respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 628 rapid transporters from Australia and New Zealand (ANZDATA) who started PD between 1999 and 2004, better survival was associated with APD compared with CAPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, this survival disadvantage is not observed if rapid transporters transfer to hemodialysis (HD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/15\">",
"     15",
"    </a>",
"    ]. This suggests that early transfer to hemodialysis may be indicated among such patients. However, the reasons for and timing of transfer were not noted. At our unit, we do not routinely transfer rapid transporters to HD unless there is a clinical indication such as uncontrolled volume overload, hypertension, or malnutrition.",
"   </p>",
"   <p>",
"    Clinically, the rate of diffusion or dialysate to plasma ratio after a timed dwell is related to the vascular peritoneal surface area (capillary density). Larger surface areas can be the result of increased perfusion of current capillaries (increased effective surface area) or an increase in the number of capillaries per unit area (an anatomic increase in surface area). These conditions can be inherent or acquired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STABILITY OF PERITONEAL MEMBRANE TRANSPORT OVER TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term success of PD is dependent upon the ability of the peritoneal membrane to maintain acceptable solute transfer rates and ultrafiltration. Clinical experience suggests that this is the case in most patients; in most studies, creatinine and glucose equilibration rates remained stable in approximately 70 percent of patients at 12 to 18 months and over 50 percent at 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/16\">",
"     16",
"    </a>",
"    ]. These clinical observations have been confirmed by histologic examination showing only minimal pathologic changes over time in most patients on maintenance PD unless there have been repeated bouts of peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients are inherently rapid transporters. This is either due to an associated co-morbidity (where there are high levels of dialysate VEGF or IL-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/18\">",
"     18",
"    </a>",
"    ]) or, in the absence of co-morbidity, an increase in the peritoneal mesothelial cell mass (characterized by high peritoneal effluent CA-125 appearance rates, a surrogate for estimating mesothelial cell mass and health) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, peritoneal transport changes over time. The most frequent acquired change occurs during an episode of peritonitis when there is an increased perfusion per capillary because of inflammation. However, an increase in peritoneal transport is associated with peritoneal angioneogenesis in a subgroup of long-term patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another common change that occurs is a gradual increase in solute transport (",
"    <a class=\"graphic graphic_figure graphicRef64191 \" href=\"mobipreview.htm?25/53/26461\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/16\">",
"     16",
"    </a>",
"    ]. As noted above, this is usually associated with a decrease in net ultrafiltration rate, a change that historically has been called type 1 membrane failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/21\">",
"     21",
"    </a>",
"    ]. The development of rapid transport characteristics is responsible for approximately 70 to 80 percent of cases with permanent loss of ultrafiltration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who become rapid transporters after a long time on PD are likely to have a different pathophysiologic process than those who are rapid transporters at the initiation of dialysis. The rise in solute transport rate has been associated with increasing duration of dialysis and the use of hypertonic exchanges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. It is thought that the glucose or the glucose degradation products in these solutions are responsible for the observed changes in the peritoneal membrane over time.",
"   </p>",
"   <p>",
"    To assess the relationship among changes in solute transport and ultrafiltration over time and patient characteristics, a single center study was performed of 574 incident peritoneal dialysis patients in which a standard peritoneal equilibration test (PET) was performed at least annually from 1990 to 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/23\">",
"     23",
"    </a>",
"    ]. During the first six months, there was an increase in solute transport (eg, an increase in",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine) but no decrease in ultrafiltration ability. Subsequently, an increase in solute transport and a decrease in ultrafiltration capacity were observed. The eventual ultrafiltration failure in a subset of 48 patients correlated in part with early exposure to higher intraperitoneal glucose concentrations, suggesting that the use of more hypertonic glucose solutions was associated with subsequent increases in transport. Denudation of the mesothelial surface has been noted histologically, similar to what is seen with peritonitis.",
"   </p>",
"   <p>",
"    An accumulation of advanced glycosylation end-products in the peritoneal vessel wall may also alter peritoneal permeability. Increased immunohistochemical staining of glycosylated products appears to correlate with increased solute transport rates among long-standing PD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The large amount of advanced glycosylation end-products found in conventional peritoneal dialysis fluids may be the direct result of the heat sterilization process and other processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients with acquired increase in transport, a temporary transfer to hemodialysis with \"resting\" of the peritoneum has been associated with an improvement in ultrafiltration and a return to baseline peritoneal transport characteristics. Shortening the dwell time improves net ultrafiltration and thus also maximizes clearances. As a result, transfer to NIPD or Daytime Automated Peritoneal Dialysis (DAPD), which is the use of cycler during the day in non-ambulatory patients, may help optimize net ultrafiltration per gram of glucose absorbed and increase appetite. However it is not known whether this approach will protect the membrane from further damage.",
"   </p>",
"   <p>",
"    Peritoneal mesothelial cells have a functional local renin angiotensin system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/30\">",
"     30",
"    </a>",
"    ]. When unregulated, this can lead to angiogenesis and fibrosis. The production of intermediary cytokines such as VEGF and TGF beta can be reduced with use of ACE or ARB therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/31\">",
"     31",
"    </a>",
"    ]. The only published retrospective observational study correlating changes in transport over time with ACE or ARB use suggests that these agents may be protective, in that patients being administered these agents were less likely to have a change in transport over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/32\">",
"     32",
"    </a>",
"    ]. Further data are needed, but certainly there are other current indications for ACE or ARB use (preservation of residual renal function, cardiovascular protection, hypertension control) so it may be reasonable to use these agents as first line for one of these conditions because it may also prevent peritoneal membrane changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHANGES IN TRANSPORT ASSOCIATED WITH PERITONITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration decreases during peritonitis due to a transient increase in small solute clearances that is associated with an enhanced rate of glucose absorption, as seen in rapid transporters. In addition, peritonitis is often associated with a marked increase in dialysate protein losses. Preliminary results suggest that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    dialysate, may help preserve ultrafiltration capabilities in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes are usually transient but, in some patients, they persist as a result of progression to peritoneal fibrosis and perhaps sclerosing peritonitis. Permanent injury to the peritoneal membrane is most common in long-term PD patients after severe episodes of peritonitis that fail to respond rapidly to treatment. Patient death and catheter loss during an episode of peritonitis have been associated with a large drop in the plasma albumin concentration that is probably due to increased protein loss in the dialysate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/34\">",
"     34",
"    </a>",
"    ]. One possible way to minimize the development of peritonitis-induced hypoalbuminemia is the administration of intraperitoneal amino acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data highlight the need for us to monitor transport characteristics over time and during episodes of peritonitis, not only to be able to match dwell time with transport type to maximize small solute clearances and net ultrafiltration, but also to monitor for pathologic changes in the peritoneal membrane. Some clinicians simply anticipate ultrafiltration problems during peritonitis and empirically reduce oral fluid intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increase the use of hypertonic exchanges. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RELATIONSHIP BETWEEN TRANSPORT TYPE AND PLASMA ALBUMIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross sectional data from CAPD patients have shown an inverse correlation between peritoneal transport characteristics (as estimated from the four-hour",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine ratio) and the plasma albumin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/36\">",
"     36",
"    </a>",
"    ]. This relationship tends to be independent of dialysis dose, and hypoalbuminemia is typically accompanied by other signs of malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/37\">",
"     37",
"    </a>",
"    ]. The association of higher creatinine transfer rates with hypoalbuminemia and malnutrition is probably related to enhanced dialysate protein losses, which can be as high as 15",
"    <span class=\"nowrap\">",
"     g/day;",
"    </span>",
"    in comparison, the mean for all patients on CAPD is about 6",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    Another explanation is that the high transport status is caused by chronic inflammation which itself is associated with low serum albumin concentration.",
"   </p>",
"   <p>",
"    There are probably other factors that contribute to tendency toward malnutrition in rapid transporters. As an example, patients on long dwells often require hypertonic fluids to achieve net ultrafiltration and maintain euvolemia. It is possible that the increased glucose load may suppress appetite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/38\">",
"     38",
"    </a>",
"    ]. Another possibility is that these patients tend to be slightly volume expanded and are hypoalbuminemic in part due to dilution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/39\">",
"     39",
"    </a>",
"    ]. The role of comorbid diseases and chronic inflammation also must be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term success of PD is dependent upon the ability of the peritoneal membrane to provide adequate solute clearances and ultrafiltration over time. Peritoneal transport characteristics can be monitored most easily by a PET. We generally obtain a PET after four weeks on chronic therapy to use as a baseline value and then repeat the test when clinically indicated, such as when there is unexplained volume overload, hypertension, suboptimal",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    or change in drain volumes.",
"   </p>",
"   <p>",
"    If a patient is found to be a rapid transporter on baseline PET, close attention must be paid to the adequacy of ultrafiltration and nutrition. With CAPD, for example, the loss of residual renal function (specifically the volume of urine) may lead to fluid retention and volume-dependent hypertension, resulting in the need for a greater use of hypertonic exchanges.",
"   </p>",
"   <p>",
"    Most such patients will have a tendency for hypoalbuminemia and some will actually be malnourished. The clinician should consider transferring malnourished patients to short-dwell therapy, such as NIPD or DAPD. Both NIPD and CCPD have multiple short dwells at night. The major advantage of NIPD in rapid transporters is that the abdomen is dry during the day, thereby possibly minimizing some of the protein losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/40\">",
"     40",
"    </a>",
"    ], although not all studies have confirmed this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. If possible, one should consider using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    for the long daytime dwell. This will minimize glucose absorption, possible appetite suppression, and excessive fluid absorption. Supplemental parenteral nutrition or, when available, intraperitoneal amino acid solutions should be considered if the patient continues on CAPD.",
"   </p>",
"   <p>",
"    Issues concerning the use and effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    in this setting are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adequacy of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study in the early 1990s showed that rapid transporters treated with NIPD have a lower rate of dialysate protein loss and a lesser need for hypertonic dialysate solutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/40\">",
"     40",
"    </a>",
"    ], whereas other studies showed protein losses to be similar in all types of PD therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. If the dialysis dose is adequate, then the reductions in protein loss and glucose absorption should permit an increase in energy intake and at least partial correction of the malnourished state. Among the benefits noted in a study of patients initially switched from CAPD to NIPD were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36215/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increase in weekly",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      from 1.60 to 1.77",
"     </li>",
"     <li>",
"      An increase in weekly creatinine clearance from 50.7 to 54.7",
"      <span class=\"nowrap\">",
"       L/1.73",
"      </span>",
"      m2 body surface area",
"     </li>",
"     <li>",
"      A rise in the plasma albumin concentration from 3.40 to 3.49",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      An elevation in protein catabolic rate, an estimate of protein intake, from 0.54 to 0.57",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      A reduction in dialysate protein losses from 6.76 to 5.39",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lack of normalization of the plasma albumin concentration in this setting may be related to persistent inadequate dialysis, since the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    did not reach suggested target levels recommended in the late 1990s.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Changes in the peritoneal membrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, the clinician must address whether a change over time from an average to rapid transport is associated with underlying peritoneal membrane pathology. As noted above, only minimal histologic changes are present in most patients, although peritoneal fibrosis or early sclerosing peritonitis can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link&amp;anchor=H9#H9\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\", section on 'Inadequate solute clearance and ultrafiltration failure'",
"    </a>",
"    .) These patients may have additional symptoms of abdominal pain, diarrhea, nausea, and vomiting. The diagnosis is usually based upon clinical parameters and indirectly via radiologic procedures. It can be confirmed by pathologic findings at exploratory laparotomy, if indicated. Affected patients may benefit from \"resting\" the peritoneal membrane by a temporary transfer to hemodialysis. Healing and return of baseline peritoneal membrane transport characteristics can usually be achieved by resting the membrane for six months or more.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/1\">",
"      Twardowski ZJ. Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 1989; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/2\">",
"      Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/3\">",
"      Churchill DN, Thorpe KE, Nolph KD, et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/4\">",
"      Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal transport rate an independent risk factor for CAPD mortality? Kidney Int 2000; 57:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/5\">",
"      Brimble KS, Walker M, Margetts PJ, et al. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/6\">",
"      Blake PG. What is the problem with high transporters? Perit Dial Int 1997; 17:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/7\">",
"      Wang T, Heimb&uuml;rger O, Cheng HH, et al. Does a high peritoneal transport rate reflect a state of chronic inflammation? Perit Dial Int 1999; 19:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/8\">",
"      Tonbul Z, Altintepe L, S&ouml;zl&uuml; C, et al. The association of peritoneal transport properties with 24-hour blood pressure levels in CAPD patients. Perit Dial Int 2003; 23:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/9\">",
"      Davies SJ. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Kidney Int Suppl 2006; :S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/10\">",
"      Brown EA, Davies SJ, Rutherford P, et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/11\">",
"      Chung SH, Heimb&uuml;rger O, Stenvinkel P, et al. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003; 23:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/12\">",
"      Yang X, Fang W, Bargman JM, Oreopoulos DG. High peritoneal permeability is not associated with higher mortality or technique failure in patients on automated peritoneal dialysis. Perit Dial Int 2008; 28:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/13\">",
"      Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/14\">",
"      Johnson DW, Hawley CM, McDonald SP, et al. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2010; 25:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/15\">",
"      Wiggins KJ, McDonald SP, Brown FG, et al. High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis. Nephrol Dial Transplant 2007; 22:3005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/16\">",
"      Blake PG, Abraham G, Sombolos K, et al. Changes in peritoneal membrane transport rates in patients on long term CAPD. Adv Perit Dial 1989; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/17\">",
"      Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/18\">",
"      Chung SH, Chu WS, Lee HA, et al. Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 2000; 20:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/19\">",
"      Rodrigues A, Martins M, Santos MJ, et al. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport. Adv Perit Dial 2004; 20:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/20\">",
"      Honda K, Nitta K, Horita S, et al. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/21\">",
"      Heimb&uuml;rger O, Waniewski J, Werynski A, et al. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/22\">",
"      Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/23\">",
"      Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/24\">",
"      Nakayama M, Kawaguchi Y, Yamada K, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/25\">",
"      De Vriese AS, Flyvbjerg A, Mortier S, et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/26\">",
"      Linden T, Forsb&auml;ck G, Deppisch R, et al. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998; 18:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/27\">",
"      Zimmeck T, Tauer A, Fuenfrocken M, Pischetsrieder M. How to reduce 3-deoxyglucosone and acetaldehyde in peritoneal dialysis fluids. Perit Dial Int 2002; 22:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/28\">",
"      Ishikawa N, Miyata T, Ueda Y, et al. Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. Kidney Int 2003; 63:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/29\">",
"      Zeier M, Schwenger V, Deppisch R, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/30\">",
"      Witowski J, J&ouml;rres A. Preventing peritoneal fibrosis--an ace up our sleeve? Perit Dial Int 2005; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/31\">",
"      Noh H, Ha H, Yu MR, et al. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/32\">",
"      Kolesnyk I, Noordzij M, Dekker FW, et al. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009; 24:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/33\">",
"      Posthuma, N, ter Wee, PM, Donker, AJ, et al. Icodextrin (I) used in CCPD patients during peritonitis: Serum disaccharide (maltose) levels and ultrafiltration (abstract). J Am Soc Nephrol 1997; 8:270A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/34\">",
"      Tzamaloukas AH, Murata GH, Fox L. Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters. Perit Dial Int 1993; 13 Suppl 2:S338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/35\">",
"      Dwatwa, M, Vladutiu, D, Keller, J. Nutritional support with Nutrineal for CAPD peritonitis (abstract). Perit Dial Int 1995; 15:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/36\">",
"      Burkart, JM, Jordan, J, Rocco, MV. Cross sectional analysis of D/P creatinine ratios versus serum albumin levels in NIPD. Perit Dial Int 1994; 14:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/37\">",
"      Nolph KD, Moore HL, Prowant B, et al. Continuous ambulatory peritoneal dialysis with a high flux membrane. A preliminary report. ASAIO J 1993; 39:M566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/38\">",
"      Mamoun, H, Anderstam, B, Lindholm, B, et al. Peritoneal dialysis solutions with glucose and amino acids suppress appetite in rats (abstract). J Am Soc Nephrol 1994; 5:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/39\">",
"      Jones CH, Wells L, Stoves J, et al. Can a reduction in extracellular fluid volume result in increased serum albumin in peritoneal dialysis patients? Am J Kidney Dis 2002; 39:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/40\">",
"      Burkart JM. Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Perit Dial Int 1995; 15:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/41\">",
"      Kathuria P, Moore HL, Khanna R, et al. Effect of dialysis modality and membrane transport characteristics on dialysate protein losses of patients on peritoneal dialysis. Perit Dial Int 1997; 17:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36215/abstract/42\">",
"      Twardowski ZJ, Nolph KD, Khanna R, et al. Daily clearances with continuous ambulatory peritoneal dialysis and nightly peritoneal dialysis. ASAIO Trans 1986; 32:575.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1862 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36215=[""].join("\n");
var outline_f35_23_36215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RAPID TRANSPORT AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STABILITY OF PERITONEAL MEMBRANE TRANSPORT OVER TIME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHANGES IN TRANSPORT ASSOCIATED WITH PERITONITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RELATIONSHIP BETWEEN TRANSPORT TYPE AND PLASMA ALBUMIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adequacy of dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Changes in the peritoneal membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1862\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1862|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/26/6574\" title=\"figure 1\">",
"      PET rapid vs slow transporters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/41/3743\" title=\"figure 2\">",
"      Comparison of survival of PD pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/53/26461\" title=\"figure 3\">",
"      Changes in PD transport over time",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_23_36216="Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults";
var content_f35_23_36216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36216/contributors\">",
"     Michael Ronthal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36216/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36216/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/23/36216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sir Charles Bell first described the anatomy and function of the facial nerve in the 1800s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bell's initial description of facial palsy related to facial paralysis caused by trauma to the peripheral branches of the facial nerve.",
"   </p>",
"   <p>",
"    Bell's palsy is the appellation commonly used to describe an acute peripheral facial palsy of unknown cause. However, the terms \"Bell's palsy\" and \"idiopathic facial paralysis\" may no longer be considered synonymous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. A peripheral facial palsy is a clinical syndrome of many causes, and evaluation requires more than a superficial examination.",
"   </p>",
"   <p>",
"    This review will discuss the pathogenesis, clinical features, and diagnosis of Bell's palsy. Other causes of facial palsy are mentioned only as part of the differential diagnosis.",
"   </p>",
"   <p>",
"    The prognosis and treatment of Bell's palsy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link\">",
"     \"Bell's palsy: Prognosis and treatment in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE FACIAL NERVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The facial nerve is a mixed nerve, containing the following (",
"    <a class=\"graphic graphic_figure graphicRef55677 \" href=\"mobipreview.htm?23/41/24218\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fibers for motor output to the facial muscles",
"     </li>",
"     <li>",
"      Parasympathetic fibers to the lacrimal, submandibular, and sublingual salivary glands",
"     </li>",
"     <li>",
"      Afferent fibers for taste from the anterior two thirds of the tongue",
"     </li>",
"     <li>",
"      Somatic afferents from the external auditory canal and pinna",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nerve arises by two roots from the pontomedullary junction (one motor and one visceral mixed - the nervus intermedius) and courses laterally through the cerebellopontine angle together with the vestibulocochlear nerve to the internal auditory meatus, which is about 1 cm in length, becoming encased in periosteum and perineurium. The facial (fallopian) canal is about 33 mm in length, and consists of three consecutive segments: labyrinthine; tympanic; and mastoid. Because the canal is narrowest in the labyrinthine segment (average 0.68 mm in diameter), any swelling of the nerve is more likely to cause compression here. The nerve runs laterally toward the medial wall of the epitympanic recess where it bends sharply backward; at the bend or genu is a swelling, the geniculate ganglion, lying in the labyrinthine segment of the canal. The nerve then passes backward and downward to reach the stylomastoid foramen. The precise anatomy and relationship to the vestibular and auditory apparatus is of particular importance to surgeons operating in the area.",
"   </p>",
"   <p>",
"    The greater petrosal nerve leaves the geniculate ganglion, enters the middle cranial fossa extradurally, and enters foramen lacerum on its way to the pterygopalatine ganglion (",
"    <a class=\"graphic graphic_figure graphicRef55677 \" href=\"mobipreview.htm?23/41/24218\">",
"     figure 1",
"    </a>",
"    ). It supplies the lacrimal and palatine glands.",
"   </p>",
"   <p>",
"    The next branch as the nerve passes downward is the nerve to the stapedius. More distally, the chorda tympani arises from the main trunk of the facial nerve about 6 mm above the stylomastoid foramen (",
"    <a class=\"graphic graphic_figure graphicRef55677 \" href=\"mobipreview.htm?23/41/24218\">",
"     figure 1",
"    </a>",
"    ). The chorda, the largest branch of the facial nerve, passes across the tympanic membrane, separated from the middle ear cavity only by a mucous membrane. It continues anteriorly to join the lingual nerve and is distributed to the anterior two-thirds of the tongue. The chorda tympani contains secretomotor fibers to sublingual and submandibular glands, and visceral afferent fibers for taste. The cell bodies of the unipolar gustatory neurons lie in the geniculate ganglion and travel via the nervus intermedius to tractus solitarius.",
"   </p>",
"   <p>",
"    The facial nerve emerges at the stylomastoid foramen, turns anterolaterally and passes through the parotid gland. Five groups of nerves emerge from the gland (pes anserinus) and are distributed to the facial muscles in a variable pattern (",
"    <a class=\"graphic graphic_figure graphicRef55677 \" href=\"mobipreview.htm?23/41/24218\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of all cases of facial palsy qualify for the label \"Bell's palsy,\" defined as an acute peripheral facial nerve palsy of unknown cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/7\">",
"     7",
"    </a>",
"    ]. The annual incidence rate is between 13 and 34 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/8\">",
"     8",
"    </a>",
"    ]. There is no race, geographic, or gender predilection, but the risk is three times greater during pregnancy, especially in the third trimester or in the first postpartum week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/9\">",
"     9",
"    </a>",
"    ]. Diabetes is present in about 5 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recurrence rate of Bell's palsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link&amp;anchor=H3#H3\">",
"     \"Bell's palsy: Prognosis and treatment in adults\", section on 'Recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A herpes simplex-mediated viral",
"    <span class=\"nowrap\">",
"     inflammatory/immune",
"    </span>",
"    mechanism was the subject of controversy for years but was suspected based upon serological evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/12\">",
"     12",
"    </a>",
"    ]. Polymerase chain reaction DNA testing supports the notion of axonal spread and multiplication of a reactivated neurotropic virus leading to inflammation, demyelination, and palsy. Herpes simplex virus activation has become widely accepted as the likely cause of Bell's palsy in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In one study, HSV-1 genomes were identified in facial nerve endoneurial fluid and auricular muscle in 11 of 14 patients undergoing decompression surgery for Bell's palsy but in no controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpes zoster is probably the second most common viral infection associated with facial palsy. In a large series of 1701 cases of Bell's palsy, 116 had herpes zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/15\">",
"     15",
"    </a>",
"    ]. Other infectious causes of Bell's palsy include cytomegalovirus, Epstein Barr virus, adenovirus, rubella virus, mumps, influenza B, and coxsackievirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/17\">",
"     17",
"    </a>",
"    ]. Two cases due to Rickettsial infection have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/18\">",
"     18",
"    </a>",
"    ], and ehrlichiosis can present as facial diplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An inactivated intranasal influenza vaccine that was introduced and since withdrawn from the market in Switzerland was significantly associated with Bell's palsy in a case-control study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/20\">",
"     20",
"    </a>",
"    ]. The peak occurrence of Bell's palsy was between 31 and 60 days after intranasal vaccination, suggesting that the palsy was not due to a direct toxic response but rather an induced immune response, such as reactivation of latent herpes simplex or varicella-zoster virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histopathology of the facial nerve in patients with Bell's palsy is consistent with an inflammatory and possibly infectious cause, and the appearance is similar to that found with herpes zoster infection, further supporting an infectious hypothesis. Specifically, the facial nerve has a thickened, edematous perineurium with a diffuse infiltrate of small, round, inflammatory cells between nerve bundles and around intraneural blood vessels. Myelin sheaths undergo degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/22\">",
"     22",
"    </a>",
"    ]. These changes are seen throughout the bony course of the facial nerve, although nerve damage is maximal in the labyrinthine part of the facial canal where edema causes compression and the tenuous blood supply adds to the damage.",
"   </p>",
"   <p>",
"    Alternate postulated mechanisms of Bell's palsy include a genetic predisposition in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/23-25\">",
"     23-25",
"    </a>",
"    ] and ischemia of the facial nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. A retrospective study found that 190 (74 percent) of 257 patients with Bell's palsy first noticed facial weakness in the morning, suggesting that actual development of facial palsy occurred during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/27\">",
"     27",
"    </a>",
"    ]; the authors speculated that nocturnal onset suggested an ischemic mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Bell's palsy typically present with the sudden onset (usually over hours) of unilateral facial paralysis. Common findings include the eyebrow sagging, inability to close the eye, disappearance of the nasolabial fold, and the mouth drawn to the non affected side (",
"    <a class=\"graphic graphic_picture graphicRef59141 \" href=\"mobipreview.htm?11/54/12133\">",
"     picture 1",
"    </a>",
"    ). Decreased tearing, hyperacusis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of taste sensation on the anterior two-thirds of the tongue may help to site the lesion in the fallopian canal, but is of little practical use and is used more as an indicator of severity than anatomical diagnosis.",
"   </p>",
"   <p>",
"    An acute facial palsy is often devastating for patients. Of 22,594 patients surveyed at the Edinburgh facial palsy clinic, one-half exhibited a considerable degree of psychological distress and restriction in social activities as a consequence of their facial palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Facial movement is assessed by observing the response to command for closing the eyes, elevating the brow and frowning, showing the teeth, puckering the lips, and tensing the soft tissues of the neck to observe for platysma activation. The examination also includes a general physical examination, neurologic examination, and particular attention directed at the external ear for vesicles or scabbing (which indicates zoster), and for mass lesions within the parotid gland. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peripheral versus central lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sparing of the forehead muscles is suggestive of a central (upper motor neuron) lesion because of bilateral innervation to this area. However, this finding does not exclude a peripheral site of pathology in all cases. As an example, a partial lesion in the pes anserinus that spares the temporal branch to the frontalis results in facial paralysis, but the patient is still able to wrinkle the forehead.",
"   </p>",
"   <p>",
"    Central activation of the facial nerve is both volitional and automatic or emotional in origin, and the facial nerve is the final common pathway. Thus, dissociation of movement of the face to command from spontaneous movement, as in smiling, indicates an upper motor neuron lesion. Lack of dissociation (absence of both voluntary and spontaneous movement) indicates a lower motor neuron (peripheral) lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Additional cranial neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Bell's palsy typically have only isolated peripheral seventh cranial nerve neuropathy. However, clinical findings suggestive of additional cranial neuropathies may infrequently occur. A prospective case series of 51 patients diagnosed with Bell's palsy found four with additional cranial neuropathies; these included contralateral trigeminal (one), glossopharyngeal (two), and hypoglossal (one) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the same study, an additional 13 patients had ipsilateral facial sensory impairment suggestive of ipsilateral trigeminal neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/29\">",
"     29",
"    </a>",
"    ]. Such ipsilateral sensory loss in the setting of Bell's palsy has usually been attributed not to neuropathy, but to abnormal perception based on droopy facial muscles, skin, and associated tissue. Three additional patients had bilateral facial palsy, possibly from the same pathogenesis as typical unilateral Bell's palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Bell's palsy is based upon the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a diffuse facial nerve involvement manifested by paralysis of the facial muscles, with or without loss of taste on the anterior two-thirds of the tongue or altered secretion of the lacrimal and salivary glands. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Peripheral versus central lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onset is acute, over a day or two; the course is progressive, reaching maximal clinical",
"      <span class=\"nowrap\">",
"       weakness/paralysis",
"      </span>",
"      within three weeks or less from the first day of visible weakness; and recovery or some degree of function is present within six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An associated prodrome, ear pain, or dysacusis is variable.",
"   </p>",
"   <p>",
"    A diagnosis of Bell's palsy is doubtful if some facial function - however small - has not returned within four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/8,30,31\">",
"     8,30,31",
"    </a>",
"    ]. Additional evaluation to determine the etiology is warranted in this instance.",
"   </p>",
"   <p>",
"    A prolonged, slowly progressive, or relapsing course suggests a tumor, especially if paralysis persists with no recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/32\">",
"     32",
"    </a>",
"    ]. Discrete involvement of only one or two distal branches of the facial nerve also suggests tumor, and active middle ear disease or a parotid mass suggests that the palsy is associated with that finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpes zoster is diagnosed if vesicles are found in the external meatus. Ramsay Hunt syndrome refers to either herpes zoster oticus (geniculate herpes) or any cephalic zoster complicated by facial paralysis or by auditory or vestibular symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Ramsay Hunt syndrome (Herpes zoster oticus)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seroconversion is occasionally seen in the absence of vesicles, known as zoster sine herpete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Dermatomal pain and dysesthesia that occurs before the presence of vesicles is known as preherpetic neuralgia, and it may be the only sign that herpes zoster is the etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/36\">",
"     36",
"    </a>",
"    ]. Up to one-third of Bell's palsy cases previously considered idiopathic may be caused by zoster sine herpete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies help determine the prognosis, and imaging studies can define potential surgical causes of facial palsy. However, these tests are not necessary in all patients. Patients with a typical lesion that is incomplete and recovers do not need further study.",
"   </p>",
"   <p>",
"    In contrast, electrodiagnostic studies may be warranted in patients with clinically complete lesions for prognostic purposes. Imaging is warranted if the physical signs are atypical, there is slow progression beyond three weeks, or if there is no improvement at four months. Screening blood studies for underlying systemic disease or infection should also be considered in these cases. However, no test provides prognostic information sufficiently early as to be used for determining who should or should not be treated.",
"   </p>",
"   <p>",
"    Attempting to localize the site of the lesion with tests such as the Schirmer test for lacrimation, stapedial reflex, and evaluation of taste and salivation have only moderate accuracy and are of little practical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/38\">",
"     38",
"    </a>",
"    ]. Furthermore, in patients studied at surgery, only 6 percent had lesions distal to the geniculate ganglion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/39\">",
"     39",
"    </a>",
"    ], the site that these tests target.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simplest electrodiagnostic test is the electromyograph (EMG). In patients who have a clinically complete lesion, the EMG may show some potentials on active volition, which allows one to conclude that the nerve is still in continuity with a potential for regrowth.",
"   </p>",
"   <p>",
"    In the first days after symptoms onset, the blink reflex (stimulation of the supraorbital nerve) can confirm the peripheral origin of weakness and assess the degree of axonal conduction block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor nerve conduction studies (motor NCS, also called electroneurography or evoked electromyography) of the facial nerve is a technique whereby the facial nerve is supramaximally stimulated near the parotid, and the evoked potential is measured by surface recording electrodes over the orbicularis oculi, nasalis, or lower facial muscles, yielding a compound muscle action potential (CMAP) reflecting activity in the muscles beneath the electrodes. At approximately 10 days after the onset of symptoms, the amplitude of the CMAP on the paralyzed side compared with that on the normal side yields an estimate of the degree of axonal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CMAP value obtained by facial nerve stimulation correlates histologically with the number of degenerating motor neurons; a CMAP value of 10 percent of normal corresponds with a degeneration or loss of 90 percent of the motor axons on that side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/42\">",
"     42",
"    </a>",
"    ]. In one study, 90 percent degeneration was considered to be a critical value below which recovery was poor; degeneration of greater than 98 percent predicted a very poor result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/43\">",
"     43",
"    </a>",
"    ]. Recovery was variable with degeneration between 90 and 98 percent, and often weakness and synkinesis resulted. In another study, 75 percent was regarded as the critical cutoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Facial nerve stimulation is most useful when performed within two weeks after progression to complete facial paresis in cases in which surgical decompression might be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/45\">",
"     45",
"    </a>",
"    ]. Severe degeneration of the facial nerve is probably irreversible after two to three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=see_link&amp;anchor=H10#H10\">",
"     \"Bell's palsy: Prognosis and treatment in adults\", section on 'Surgical decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At approximately 20 to 30 days after onset, needle EMG may provide confirmation of muscle denervation and the degree of axonal damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/41\">",
"     41",
"    </a>",
"    ]. In patients with axonal loss, needle EMG at about three months after onset may be used to assess for evidence of subclinical reinnervation from the facial nerve. The patient is interested mainly in prognosis &mdash; the EMG in this instance serves to indicate an incomplete lesion with potential for recovery.",
"   </p>",
"   <p>",
"    Additional electrodiagnostic studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The maximal stimulation test (MST) uses suprathreshold stimulation to achieve maximal stimulation, and the response is subjectively observed by the tester. It is of doubtful value.",
"     </li>",
"     <li>",
"      Nerve excitability threshold testing is similar, but the tester attempts to quantify the current required to produce a threshold response. A critical value of 3.5 mA is said to correlate with 90 percent degeneration on motor NCS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/47\">",
"       47",
"      </a>",
"      ], and implies a poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, imaging is warranted if the physical signs are atypical, there is slow progression beyond three weeks, or if there is no improvement at four months. History of a facial twitch or spasm that precedes facial weakness suggests nerve irritation from tumor and should also prompt imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/45\">",
"     45",
"    </a>",
"    ]. For patients with acute onset of facial paralysis and negative imaging studies at four months who have continued complete flaccid paralysis at seven months, repeat imaging is warranted, and biopsy is suggested if repeat imaging is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging in these cases should be performed with high resolution contrast-enhanced CT or gadolinium-enhanced MRI and should include the brain, temporal bone, and parotid gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/49\">",
"     49",
"    </a>",
"    ]. High resolution CT scanning is excellent for bony detail and will demonstrate erosion. MRI delineates the soft tissue structures, and is the best study to evaluate the intraparotid facial nerve for inflammation, edema, or neoplasm. In normal people there is mild to moderate enhancement of the geniculate ganglion and the tympanic-mastoid segment within the facial canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Pathological enhancement in Bell's palsy is reported in between 57 and 100 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/52\">",
"     52",
"    </a>",
"    ], and absence of enhancement may be a good prognostic sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Enhancement of the inner ear structures occurs only in herpes zoster facial palsy and can be taken to suggest this diagnosis even without a vesicular eruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176722136\">",
"    <span class=\"h3\">",
"     Other investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing for Lyme disease is recommended for adults with acute-onset facial palsy when there is the possibility of exposure in Lyme-endemic areas during the spring through autumn seasons, particularly for those with bilateral facial palsy or other clinical manifestations of Lyme disease. Serologic testing should follow the two-tier strategy, which uses a sensitive enzyme-linked immunosorbent assay (ELISA) or an immunofluorescent assay (IFA) in place of ELISA, followed by a Western blot if the ELISA or IFA is positive or equivocal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=see_link&amp;anchor=H4821958#H4821958\">",
"     \"Nervous system Lyme disease\", section on 'Serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of the first four to six weeks of infection, serologic testing is highly sensitive and specific for the diagnosis of Lyme disease. Occasionally the cranial neuropathy occurs before the patient has become seropositive; in such patients, follow-up serology in several weeks is typically diagnostic. Cerebrospinal fluid analysis is of limited utility if Lyme disease is limited to the peripheral nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=see_link&amp;anchor=H10939504#H10939504\">",
"     \"Nervous system Lyme disease\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parotid gland biopsy is suggested for patients with acute onset facial paralysis when there is no recovery and imaging studies (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Imaging studies'",
"    </a>",
"    above) are negative at seven months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Imaging studies'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial nerve palsy may be caused by a variety of disorders that can be confused with Bell's palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial nerve palsy is the most common cranial neuropathy associated with Lyme disease. It occurred in 63 percent of patients with Lyme meningitis in a European series and in 50 percent of patients in an American series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Involvement of the facial nerve can be unilateral or bilateral, and usually lasts less than two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=see_link&amp;anchor=H10939461#H10939461\">",
"     \"Nervous system Lyme disease\", section on 'Cranial neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to facial nerve palsy in children who live in areas endemic for Lyme disease is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25257?source=see_link&amp;anchor=H7#H7\">",
"     \"Facial nerve palsy in children\", section on 'Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings suggestive of possible Lyme disease (",
"    <a class=\"graphic graphic_table graphicRef72018 \" href=\"mobipreview.htm?39/7/40060\">",
"     table 1",
"    </a>",
"    ) include the development of facial palsy in a young patient (with or without a known history of tick bite or antecedent skin rash), heart block, arthritis, vertigo, and hearing loss. Painless, non-tender swelling and erythema of the face preceding the facial palsy are distinctive features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/58\">",
"     58",
"    </a>",
"    ]. The likelihood that Lyme disease is the cause of a seventh nerve palsy diminishes in either nonendemic areas or at a time of year when Lyme disease is not prevalent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=see_link\">",
"     \"Nervous system Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of Lyme disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection rarely causes facial palsy. If it does, onset is at the time of seroconversion when a CSF lymphocytosis is usually present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/59\">",
"     59",
"    </a>",
"    ]. In the later stages when cellular immunity wanes, the facial palsy is typically due to another infection such as zoster, chronic demyelinating polyradiculopathy, or meningeal lymphomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Melkersson-Rosenthal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Melkersson-Rosenthal syndrome is characterized by facial paralysis, episodic facial swelling, and a fissured tongue, typically beginning in adolescence, but with recurrent episodes of facial palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/60\">",
"     60",
"    </a>",
"    ]. Incomplete forms of this syndrome outnumber those with the classic triad. Perivascular tuberculoid granulomas are seen in the edematous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/61\">",
"     61",
"    </a>",
"    ], but the cause is unknown, and treatment unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other disorders may cause facial palsy and should be considered in the differential diagnosis of Bell's palsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial infection of the middle ear (otitis media) is usually easily diagnosed by simple inspection of the external meatus and tympanic membrane",
"     </li>",
"     <li>",
"      Cholesteatoma should be suspected if the onset of facial palsy is gradual [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sarcoidosis should be considered, especially in patients with bilateral facial palsy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=see_link\">",
"       \"Neurologic sarcoidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sj&ouml;gren syndrome is an unusual cause [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36216/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Malignant parotid gland tumor (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=see_link&amp;anchor=H6966761#H6966761\">",
"       \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/13/32977?source=see_link\">",
"       \"Patient information: Bell's palsy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/13/41168?source=see_link\">",
"       \"Patient information: Bell's palsy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About one-half of all cases of facial palsy qualify for the label \"Bell's palsy,\" defined as an acute peripheral facial nerve palsy of unknown cause. The annual incidence rate is between 13 and 34 cases per 100,000 population. There is no race, geographic, or gender predilection, but the risk is three times greater during pregnancy, especially in the third trimester or in the first postpartum week. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Herpes simplex virus activation has become widely accepted as the likely cause of Bell's palsy in most cases. Herpes zoster is probably the second most common viral infection associated with facial palsy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bell's palsy typically presents with the sudden onset (usually over hours) of unilateral facial paralysis. Common findings include the eyebrow sagging, inability to close the eye, disappearance of the nasolabial fold, and the mouth drawn to the non affected side (",
"      <a class=\"graphic graphic_picture graphicRef59141 \" href=\"mobipreview.htm?11/54/12133\">",
"       picture 1",
"      </a>",
"      ). Associated manifestations may include decreased tearing, hyperacusis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of taste sensation on the anterior two-thirds of the tongue. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Bell's palsy is based upon the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is a diffuse facial nerve involvement (",
"      <a class=\"graphic graphic_figure graphicRef55677 \" href=\"mobipreview.htm?23/41/24218\">",
"       figure 1",
"      </a>",
"      ) manifested by paralysis of the facial muscles, with or without loss of taste on the anterior two-thirds of the tongue or altered secretion of the lacrimal and salivary glands. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Peripheral versus central lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onset is acute, over a day or two; the course is progressive, reaching maximal clinical",
"      <span class=\"nowrap\">",
"       weakness/paralysis",
"      </span>",
"      within three weeks or less from the first day of visible weakness; and recovery or some degree of function is present within six months. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a typical Bell's palsy that is incomplete and recovers do not need further study. However, imaging of the brain, temporal bone, and parotid gland with high resolution contrast-enhanced CT or gadolinium-enhanced MRI is warranted if the physical signs are atypical, there is slow progression beyond three weeks, or if there is no improvement at four months. In patients with clinically complete lesions, electrodiagnostic studies may be useful for prognostic purposes. Serologic testing for Lyme disease is recommended for adults with acute-onset facial palsy when there is the possibility of exposure in Lyme-endemic areas during the spring through autumn seasons, particularly for those with bilateral facial palsy or other clinical manifestations of Lyme disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Facial nerve palsy may be caused by a variety of disorders that can be confused with Bell's palsy. The differential diagnosis includes (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lyme disease",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Melkersson-Rosenthal syndrome",
"     </li>",
"     <li>",
"      Otitis media",
"     </li>",
"     <li>",
"      Cholesteatoma",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Sj&ouml;gren syndrome",
"     </li>",
"     <li>",
"      Parotid gland tumor",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bell C. An exposition of the natural system of nerves of the human body, Spottiswoode, London 1824.",
"    </li>",
"    <li>",
"     Bell C. The nervous system of the human body, Longman, London 1830.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/3\">",
"      Cawthorne T. Idiopathic facial palsy. Arch Otolaryngol 1965; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/4\">",
"      James DG. All that palsies is not Bell's. J R Soc Med 1996; 89:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/5\">",
"      Jackson CG, von Doersten PG. The facial nerve. Current trends in diagnosis, treatment, and rehabilitation. Med Clin North Am 1999; 83:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/6\">",
"      Monkhouse WS. The anatomy of the facial nerve. Ear Nose Throat J 1990; 69:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/7\">",
"      May M, Klein SR. Differential diagnosis of facial nerve palsy. Otolaryngol Clin North Am 1991; 24:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/8\">",
"      Peitersen E. The natural history of Bell's palsy. Am J Otol 1982; 4:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/9\">",
"      Hilsinger RL Jr, Adour KK, Doty HE. Idiopathic facial paralysis, pregnancy, and the menstrual cycle. Ann Otol Rhinol Laryngol 1975; 84:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/10\">",
"      Mountain RE, Murray JA, Quaba A, Maynard C. The Edinburgh facial palsy clinic: a review of three years' activity. J R Coll Surg Edinb 1994; 39:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/11\">",
"      Adour KK, Byl FM, Hilsinger RL Jr, et al. The true nature of Bell's palsy: analysis of 1,000 consecutive patients. Laryngoscope 1978; 88:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/12\">",
"      Adour KK, Bell DN, Hilsinger RL Jr. Herpes simplex virus in idiopathic facial paralysis (Bell palsy). JAMA 1975; 233:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/13\">",
"      Baringer JR. Herpes simplex virus and Bell palsy. Ann Intern Med 1996; 124:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/14\">",
"      Schirm J, Mulkens PS. Bell's palsy and herpes simplex virus. APMIS 1997; 105:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/15\">",
"      Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002; :4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/16\">",
"      Murakami S, Mizobuchi M, Nakashiro Y, et al. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996; 124:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/17\">",
"      Morgan M, Nathwani D. Facial palsy and infection: the unfolding story. Clin Infect Dis 1992; 14:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/18\">",
"      Bitsori M, Galanakis E, Papadakis CE, Sbyrakis S. Facial nerve palsy associated with Rickettsia conorii infection. Arch Dis Child 2001; 85:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/19\">",
"      Lee FS, Chu FK, Tackley M, et al. Human granulocytic ehrlichiosis presenting as facial diplegia in a 42-year-old woman. Clin Infect Dis 2000; 31:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/20\">",
"      Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/21\">",
"      Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 2004; 350:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/22\">",
"      Liston SL, Kleid MS. Histopathology of Bell's palsy. Laryngoscope 1989; 99:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/23\">",
"      DeSanto LW, Schubert HA. Bell's palsy: ten cases in a family. Arch Otolaryngol 1969; 89:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/24\">",
"      Hageman G, Ippel PF, Jansen EN, Rozeboom AR. Familial, alternating Bell's palsy with dominant inheritance. Eur Neurol 1990; 30:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/25\">",
"      Clement WA, White A. Idiopathic familial facial nerve paralysis. J Laryngol Otol 2000; 114:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/26\">",
"      Devriese PP. Compression and ischaemia of the facial nerve. Acta Otolaryngol 1974; 77:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/27\">",
"      Kanoh N, Nomura J, Satomi F. Nocturnal onset and development of Bell's palsy. Laryngoscope 2005; 115:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/28\">",
"      Weir AM, Pentland B, Murray J. Bell's palsy: The effect on self image, mood state and social activity. Clin Rehabil 1993; 7:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/29\">",
"      Benatar M, Edlow J. The spectrum of cranial neuropathy in patients with Bell's palsy. Arch Intern Med 2004; 164:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/30\">",
"      Hashisaki GT. Medical management of Bell's palsy. Compr Ther 1997; 23:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/31\">",
"      Selesnick SH, Patwardhan A. Acute facial paralysis: evaluation and early management. Am J Otolaryngol 1994; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/32\">",
"      Boahene DO, Olsen KD, Driscoll C, et al. Facial nerve paralysis secondary to occult malignant neoplasms. Otolaryngol Head Neck Surg 2004; 130:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/33\">",
"      May M, Hughes GB. Facial nerve disorders: update 1987. Am J Otol 1987; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/34\">",
"      LEWIS GW. Zoster sine herpete. Br Med J 1958; 2:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/35\">",
"      Mayo DR, Booss J. Varicella zoster-associated neurologic disease without skin lesions. Arch Neurol 1989; 46:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/36\">",
"      Holland NJ, Weiner GM. Recent developments in Bell's palsy. BMJ 2004; 329:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/37\">",
"      Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001; 71:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/38\">",
"      Hughes GB. Practical management of Bell's palsy. Otolaryngol Head Neck Surg 1990; 102:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/39\">",
"      Fisch U. Surgery for Bell's palsy. Arch Otolaryngol 1981; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/40\">",
"      Somia NN, Rash GS, Epstein EE, et al. A computer analysis of reflex eyelid motion in normal subjects and in facial neuropathy. Clin Biomech (Bristol, Avon) 2000; 15:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/41\">",
"      Valls-Sol&eacute; J. Electrodiagnostic studies of the facial nerve in peripheral facial palsy and hemifacial spasm. Muscle Nerve 2007; 36:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/42\">",
"      Halvorson DJ, Coker NJ, Wang-Bennett LT. Histologic correlation of the degenerating facial nerve with electroneurography. Laryngoscope 1993; 103:178.",
"     </a>",
"    </li>",
"    <li>",
"     Esslen E. Investigations on the localization and pathogenesis of meato-labyrinthine facial palsies. In: The Acute Facial Palsies, Esslen E (Ed), Springer-Verlag, Berlin 1977. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/44\">",
"      May M, Klein SR, Taylor FH. Indications for surgery for Bell's palsy. Am J Otol 1984; 5:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/45\">",
"      Gilden DH. Clinical practice. Bell's Palsy. N Engl J Med 2004; 351:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/46\">",
"      Fisch U. Prognostic value of electrical tests in acute facial paralysis. Am J Otol 1984; 5:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/47\">",
"      Coker NJ, Fordice JO, Moore S. Correlation of the nerve excitability test and electroneurography in acute facial paralysis. Am J Otol 1992; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/48\">",
"      Ikeda M, Abiko Y, Kukimoto N, et al. Clinical factors that influence the prognosis of facial nerve paralysis and the magnitudes of influence. Laryngoscope 2005; 115:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/49\">",
"      Quesnel AM, Lindsay RW, Hadlock TA. When the bell tolls on Bell's palsy: finding occult malignancy in acute-onset facial paralysis. Am J Otolaryngol 2010; 31:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/50\">",
"      Sartoretti-Schefer S, Wichmann W, Valavanis A. Idiopathic, herpetic, and HIV-associated facial nerve palsies: abnormal MR enhancement patterns. AJNR Am J Neuroradiol 1994; 15:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/51\">",
"      Martin-Duverneuil N, Sola-Mart&iacute;nez MT, Miaux Y, et al. Contrast enhancement of the facial nerve on MRI: normal or pathological? Neuroradiology 1997; 39:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/52\">",
"      Kuo MJ, Drago PC, Proops DW, Chavda SV. Early diagnosis and treatment of Ramsay Hunt syndrome: the role of magnetic resonance imaging. J Laryngol Otol 1995; 109:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/53\">",
"      Girard N, Poncet M, Chays A, et al. MRI exploration of the intrapetrous facial nerve. J Neuroradiol 1993; 20:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/54\">",
"      Kress BP, Griesbeck F, Efinger K, et al. Bell's palsy: what is the prognostic value of measurements of signal intensity increases with contrast enhancement on MRI? Neuroradiology 2002; 44:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/55\">",
"      Ackermann R, H&ouml;rstrup P, Schmidt R. Tick-borne meningopolyneuritis (Garin-Bujadoux, Bannwarth). Yale J Biol Med 1984; 57:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/56\">",
"      Pachner AR, Steere AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology 1985; 35:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/57\">",
"      Clark JR, Carlson RD, Sasaki CT, et al. Facial paralysis in Lyme disease. Laryngoscope 1985; 95:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/58\">",
"      Markby DP. Lyme disease facial palsy: differentiation from Bell's palsy. BMJ 1989; 299:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/59\">",
"      Murr AH, Benecke JE Jr. Association of facial paralysis with HIV positivity. Am J Otol 1991; 12:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/60\">",
"      Levenson MJ, Ingerman M, Grimes C, Anand KV. Melkersson-Rosenthal syndrome. Arch Otolaryngol 1984; 110:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/61\">",
"      Hornstein OP, Stosiek N, Sch&ouml;nberger A, Meisel-Stosiek M. [Classification and scope of clinical variations of Melkersson-Rosenthal syndrome]. Z Hautkr 1987; 62:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36216/abstract/62\">",
"      Hadithi M, Stam F, Donker AJ, Dijkmans BA. Sj&ouml;gren's syndrome: an unusual cause of Bell's palsy. Ann Rheum Dis 2001; 60:724.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5281 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36216=[""].join("\n");
var outline_f35_23_36216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY OF THE FACIAL NERVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peripheral versus central lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Additional cranial neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H176722136\">",
"      - Other investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Melkersson-Rosenthal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5281|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/41/24218\" title=\"figure 1\">",
"      Facial nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5281|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/54/12133\" title=\"picture 1\">",
"      Bell palsy photos",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5281|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/7/40060\" title=\"table 1\">",
"      Signs of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9655?source=related_link\">",
"      Bell's palsy: Prognosis and treatment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=related_link\">",
"      Nervous system Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/13/41168?source=related_link\">",
"      Patient information: Bell's palsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/13/32977?source=related_link\">",
"      Patient information: Bell's palsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_23_36217="Treatment of Burkitt leukemia/lymphoma in adults";
var content_f35_23_36217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Burkitt leukemia/lymphoma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/23/36217/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/23/36217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burkitt lymphoma (BL) is a highly aggressive B-cell neoplasm characterized by the translocation and deregulation of the c-Myc gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic, sporadic, and immunodeficiency-associated. Although these differ in their epidemiology, clinical presentation, and genetic features, they are histologically identical and have similar clinical behavior. All three clinical forms are generally treated in a similar fashion.",
"   </p>",
"   <p>",
"    BL and Burkitt leukemia are classified as different manifestations of the same disease. Diagnostic criteria have evolved to incorporate immunohistochemical, cytogenetic, and molecular diagnostic techniques. As such, many older studies included a heterogeneous patient population that contained many patients that would not be diagnosed with BL by current criteria.",
"   </p>",
"   <p>",
"    The treatment of BL is presented here. The epidemiology, clinical presentation, and genetic features are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oncologic emergencies and treatment-related hematologic toxicities are common in the highly aggressive NHLs. Physicians must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. In particular, patients with BL are at high risk for the development of tumor lysis syndrome (TLS). Prophylactic therapy for and management of TLS is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the bulk of disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with BL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), hepatitis B, HIV, and uric acid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is recommended for all patients.",
"     </li>",
"     <li>",
"      Lumbar puncture is recommended for all patients but may be performed at the start of therapy if intrathecal chemotherapy is a component of the treatment regimen. Cerebrospinal fluid should be sent for both cytology and flow cytometry. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'CNS involvement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen and pelvis should be performed. This study provides critical information on the measurement of disease prior to treatment and aids in staging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/1\">",
"       1",
"      </a>",
"      ]. Although most cases of BL are likely FDG-avid, results of positron emission tomography (PET) scans are unlikely to change management and their potential impact on treatment has not been studied prospectively. As such, PET scanning is reserved for use in clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed if anthracyclines are used. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women of child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Given the urgent need for treatment with BL, options for women are limited, but men can often participate in sperm banking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care for BL has yet to be defined and our preferred treatment approach is to enroll patients in well-controlled cooperative research trials. However, for patients who are not candidates for such trials or for those who choose not to participate, we use aggressive combination chemotherapy with central nervous system (CNS) prophylaxis. Dose reduction should be avoided if at all possible and therapy should be initiated quickly. At our institutions, we aim to start therapy within 48 hours of encountering a patient with suspected BL.",
"   </p>",
"   <p>",
"    As response to chemotherapy is rapid and disease is inevitably diffuse, there is no role for radiation therapy in BL, even in patients with localized disease. In addition, surgery is no longer employed in BL. Most patients with BL can be treated according to the method outlined below. Patients with AIDS-related lymphoma, cardiac disease, central nervous system involvement at presentation, and older adults require special consideration. Treatment of these patient populations is presented below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Special scenarios'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BL require intensive, frequent multi-agent therapy with adequate CNS prophylaxis. Less intensive regimens (eg, CHOP) used in other NHL are not adequate therapy as they result in frequent relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, approximately 30 to 50 percent of patients will develop CNS relapse if CNS prophylaxis is not given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/5\">",
"     5",
"    </a>",
"    ]. With the incorporation of CNS prophylaxis, CNS relapse rates have dropped to approximately 6 to 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy regimens used for adults with BL have been adapted from those used in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. There have been no randomized trials and it is virtually impossible to compare regimens because single-arm trials have differed in their diagnostic criteria, staging, and age of subjects included.",
"   </p>",
"   <p>",
"    There are three main treatment approaches that have been used in patients with BL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive, short-duration combination chemotherapy (eg,",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC,",
"      </span>",
"      CALGB 9251) (",
"      <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef76650 \" href=\"mobipreview.htm?11/43/11965\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/3,10-25\">",
"       3,10-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ALL-like therapy with a stepwise induction, consolidation, and maintenance therapy lasting at least two years from diagnosis (eg, CALGB 8811 regimen, HyperCVAD) (",
"      <a class=\"graphic graphic_table graphicRef67471 \" href=\"mobipreview.htm?12/56/13198\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination chemotherapy followed by high-dose therapy and autologous hematopoietic cell transplantation (HCT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/27-30\">",
"       27-30",
"      </a>",
"      ]. While HCT is an option, this is the least commonly used approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a paucity of data on these approaches in adult populations. A post hoc analysis of 470 adult patients (40 percent &gt;40 years) treated on prospective non-randomized clinical trials internationally examined the outcome of patients treated with each of these strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/31\">",
"     31",
"    </a>",
"    ]. Direct comparisons between treatment approaches cannot be drawn from this analysis; however, patients over age 40 had worse survival than younger patients with each treatment strategy. As examples, patients over age 40 treated with short-duration, intensive chemotherapy regimens had lower two-year overall survival rates when compared with survival rates for all ages combined (39 versus 71 percent, respectively). Patients over age 40 treated with ALL-like therapy also had lower two-year overall survival rates (40 versus 51 percent, respectively). Older patients treated with HCT had higher survival rates in this analysis, but are expected to have represented a highly selected population.",
"   </p>",
"   <p>",
"    Among these treatment approaches, we suggest intensive, short-duration combination chemotherapy rather than ALL-like therapy or combination therapy followed by high-dose therapy with autologous HCT. This is principally because the intensive, short-duration therapy is quicker and less complicated than ALL-like therapy or HCT. In addition, the reported literature includes more patients that have been treated with intensive, short-duration therapy and we have more clinical experience with this treatment approach.",
"   </p>",
"   <p>",
"    Intensive, short-duration combination chemotherapy regimens that have been studied in patients with BL or BLL include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CODOX-M (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) with IVAC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and intrathecal methotrexate), also called the Magrath regimen (",
"      <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/15,16,23\">",
"       15,16,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CALGB 9251 protocol (",
"      <a class=\"graphic graphic_table graphicRef76650 \" href=\"mobipreview.htm?11/43/11965\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/18,22\">",
"       18,22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, hyperfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (HyperCVAD) is an ALL-type treatment regimen which has been evaluated in BL with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    alternating with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/11,24,25\">",
"     11,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of these, the combination chemotherapy regimen most frequently used for the treatment of BL outside of a clinical trial is",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC.",
"    </span>",
"    These three regimens are described in more detail in the following sections. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to these regimens may improve outcomes and is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     CODOX-M plus IVAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;One case series and three prospective trials have been reported on the use of",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    (the Magrath regimen) in patients with newly diagnosed BL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/15,16,23,32\">",
"     15,16,23,32",
"    </a>",
"    ]. Dosing of",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    has varied slightly between studies. All of these trials used a risk-adapted approach. In general, patients were considered low risk if they had non-bulky, early stage disease with a good performance status and a normal LDH. Low risk patients were treated with three cycles of CODOX-M. All other patients were considered high risk and were treated with alternating",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    twice (ie,",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC/CODOX-M/IVAC)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All patients received prophylaxis for tumor lysis syndrome. In addition, CNS prophylaxis was administered with intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Patients with documented CNS involvement received additional intrathecal therapy. Patients could have received one cycle of a CHOP-like regimen prior to enrollment. Toxicity with",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    is severe and virtually all patients require a prolonged inpatient hospital stay and blood product support. With this approach, reported two-year overall survival ranges from 67 to 92 percent, although among adults the rate is approximately 75 percent.",
"   </p>",
"   <p>",
"    The following are the three largest reports of the use of",
"    <span class=\"nowrap\">",
"     CODOX/IVAC",
"    </span>",
"    in newly diagnosed BL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial report of",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      from the National Cancer Institute (NCI) was a series of 41 patients (20 adults, 21 children) with newly diagnosed BL including 34 high risk and 7 low risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/15\">",
"       15",
"      </a>",
"      ]. Low risk patients were those with a single extraabdominal mass or completely resected abdominal disease and a normal LDH. All others were considered high risk. Ninety-three percent completed protocol. There were no toxic deaths but severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity included neutropenia (100 percent), thrombocytopenia (96 percent), and mucositis (61 percent) (",
"      <a class=\"graphic graphic_table graphicRef64984 \" href=\"mobipreview.htm?25/21/25948\">",
"       table 5",
"      </a>",
"      ). Sepsis occurred in 22 percent of patients. The two-year event-free survival rate was 92 percent.",
"     </li>",
"     <li>",
"      A prospective multicenter study reported on the use of a risk-adapted",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      protocol in 52 patients with newly diagnosed BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/16\">",
"       16",
"      </a>",
"      ]. This protocol differed from the NCI protocol by the omission of an injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      on day 15. The trial included 12 low risk patients and 40 high risk patients. Low risk patients had a normal LDH level, WHO performance status of 0 or 1, Ann Arbor stage I-II, and no tumor mass &ge;10cm. All other patients were high risk. Approximately 80 percent of the patients completed protocol. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were common including neutropenia (100 percent), thrombocytopenia (66 percent), mucositis (42 percent), and diarrhea (8 percent). Two-year overall survival rates for the low- and high-risk patients were 82 and 70 percent, respectively. Several female patients were able to have successful pregnancies following completion of therapy.",
"     </li>",
"     <li>",
"      A prospective, non-randomized trial included 53 patients (median age 37 years) with newly diagnosed BL treated with a risk-adjusted, dose-modified (dm)",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      protocol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/23\">",
"       23",
"      </a>",
"      ]. This trial differed from the previous trial in that the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      dose was decreased to 3",
"      <span class=\"nowrap\">",
"       g/m2.",
"      </span>",
"      This trial included 11 low risk and 42 high risk patients. Low risk patients were those with a normal LDH, WHO performance status 0 to 1, Ann Arbor stage I to II and &le;1 extra-nodal sites. All other patients were high risk. Seventy-six percent of the patients were able to complete the planned therapy. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (99 percent), neutropenic fever (80 percent), thrombocytopenia (86 percent), mucositis (47 percent), and neuropathy (8 percent). There was an 8 percent treatment-related death rate. Two-year progression-free and overall survival rates were 64 and 67 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     CALBG 9251",
"    </span>",
"    &nbsp;&mdash;&nbsp;A six cycle high-intensity treatment regimen, based upon a protocol for the treatment of adult B-cell ALL, was developed by the Cancer and Leukemia Group B (study 9251) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/22\">",
"     22",
"    </a>",
"    ]. Treatment included one seven-day cycle of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CYT) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    followed by alternating 21-day cycles including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    or CYT, high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"      cytarabine",
"     </a>",
"     ,",
"    </span>",
"    and triple intrathecal therapy (MTX, cytarabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) with or without CNS irradiation (",
"    <a class=\"graphic graphic_table graphicRef76650 \" href=\"mobipreview.htm?11/43/11965\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A prospective, non-randomized study of this regimen in 92 patients with Burkitt lymphoma had the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete remission (CR) was attained in 80 percent, with 52 percent alive and in continuous CR at a median follow-up of 5.1 years.",
"     </li>",
"     <li>",
"      All patients not achieving CR died of their disease, and all recurrences occurred within 16 months of the end of treatment.",
"     </li>",
"     <li>",
"      Hematologic toxicity was profound and significant neurologic toxicity was present in the initial patients. Neurologic toxicity was significantly reduced in frequency and severity in a second cohort of patients by limiting the use of CNS irradiation to patients with bone marrow involvement at the time of diagnosis, and by reducing the number of intrathecal treatments given from 12 to 6. This reduction in CNS prophylaxis did not significantly affect the rates of CNS recurrence, disease-free survival, or overall survival between the two cohorts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     HyperCVAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single-arm prospective trials have evaluated the use of regimens containing hyperfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (HyperCVAD) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    alternating with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in patients with newly diagnosed BL. Such protocols are similar to the intensive treatment regimens used for ALL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-six adults with newly diagnosed BL were prospectively treated with HyperCVAD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/25\">",
"       25",
"      </a>",
"      ]. CNS prophylaxis included alternating cycles of intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      . There were five induction deaths. All patients had severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic toxicity despite prophylactic growth factor support (",
"      <a class=\"graphic graphic_table graphicRef64984 \" href=\"mobipreview.htm?25/21/25948\">",
"       table 5",
"      </a>",
"      ). Febrile neutropenia occurred in 86 percent. Complete remissions were obtained in 81 percent. The three-year overall survival rate was 49 percent.",
"     </li>",
"     <li>",
"      Another prospective, single-arm study evaluated HyperCVAD plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      in 31 patients with newly diagnosed BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/11\">",
"       11",
"      </a>",
"      ]. Planned treatment was completed in 73 percent. Severe, prolonged myelosuppression was universal and febrile neutropenia was common, occurring in 45 percent of patients during the first cycle. Complete responses were seen in 86 percent of patients and the three-year overall survival rate was 89 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data evaluating the role of the recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the treatment of BL. This is an attractive addition to conventional chemotherapy given the great successes with rituximab in other NHL subtypes and the expression of the CD-20 antigen in most cases of BL. There have been few studies published that incorporate rituximab into the treatment regimen for BL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/11,33,34\">",
"     11,33,34",
"    </a>",
"    ]. Two-year overall survival rates were 77 to 100 percent.",
"   </p>",
"   <p>",
"    The following is a summary of the studies that have incorporated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    into the treatment of BL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective trial evaluated the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus an intensive, short-duration combination chemotherapy in 19 HIV positive (HIV+) and 17 HIV negative patients with newly diagnosed BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/33\">",
"       33",
"      </a>",
"      ]. HAART was mandatory for all HIV+ patients. The two-year overall survival rate was 77 percent and did not differ by HIV status. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'AIDS-related lymphoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      As already described above, a prospective, single-arm study evaluated HyperCVAD plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      in 31 patients with newly diagnosed BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/11\">",
"       11",
"      </a>",
"      ]. The two and three-year overall survival rates were both approximately 89 percent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HyperCVAD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a prospective trial, 30 patients with BL or unclassifiable lymphoma with features intermediate between BL and diffuse large B cell lymphoma were treated with a combination of modified",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/34\">",
"       34",
"      </a>",
"      ]. A complete response was seen in 93 percent of patients and the four-year progression-free and overall survival rates were 78 and 82 percent, respectively. All patients had severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      myelosuppression despite growth factor support. Febrile neutropenia was seen in 45 percent. Other common side effects included gastrointestinal toxicities, neurologic toxicity, and arrhythmias. In addition, a retrospective analysis of 80 adults with BL suggested a trend towards improved progression-free and overall survival when rituximab was added to this regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to combination chemotherapy. Although practice varies, we generally wait until the second cycle of chemotherapy to add rituximab in order to minimize tumor lysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Our approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All available regimens for BL are highly toxic, primarily to the hematopoietic system and mucosal toxicity, and most patients will have a prolonged hospital stay requiring antibiotic therapy and blood product support. Since the different regimens have not been directly compared, the physician's experience with administration becomes very important when choosing among these regimens.",
"   </p>",
"   <p>",
"    At our institutions, we treat patients according to the",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    protocol (",
"    <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/15-17,23\">",
"     15-17,23",
"    </a>",
"    ]. As discussed above, there have been several variations on this protocol used and the authors of this topic differ on the specific",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    regimen they use but feel that any of the published variants are reasonable options. All of these regimens include intrathecal therapy given for CNS prophylaxis.",
"   </p>",
"   <p>",
"    Patients are treated according to the risk-adapted approach modified from that developed at the NCI. All patients are classified as having low or high risk disease as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with non-bulky, early stage disease, a good performance status, and a normal LDH have low-risk disease. These patients are treated with three cycles of CODOX-M plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      All other patients have high-risk disease and are treated with four cycles of chemotherapy consisting of alternating CODOX-M and IVAC, both with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a significant risk of",
"    <strong>",
"     tumor lysis syndrome",
"    </strong>",
"    in patients treated for BL. This syndrome is best prevented via appropriate treatment with aggressive intravenous hydration,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    , and correction of any prior electrolyte disturbances and elements of reversible renal failure (",
"    <a class=\"graphic graphic_table graphicRef57607 \" href=\"mobipreview.htm?22/10/22701\">",
"     table 6",
"    </a>",
"    ). In addition, we wait until the second cycle of chemotherapy before incorporating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    into the treatment program. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for BL apply to most disease presentations and patient populations. However, patients with HIV infection, those with cardiac disease, and older adults require special consideration. In addition, central nervous system involvement at the time of diagnosis requires additional therapy directed at this site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     AIDS-related lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HIV, the diagnosis of NHL is an AIDS-defining malignancy. A significant number of the lymphomas encountered in HIV-infected (HIV+) patients are clinically aggressive (eg, diffuse large B-cell lymphoma) or highly aggressive (eg, BL or immunoblastic lymphoma). Treatment of such patients is complicated by their immunocompromised state and also requires specific treatment for their HIV. As such, specific management issues concerning patients with AIDS-related lymphoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial studies investigating intensive chemotherapy excluded patients who were HIV+ for fear of worsening an already compromised immune system. However, as therapy directed at HIV has improved, studies have begun to investigate the use of combination chemotherapy in patients with BL and HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/36\">",
"     36",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis included 14 HIV+ and 24 HIV- patients with newly diagnosed BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/17\">",
"       17",
"      </a>",
"      ]. Eight HIV+ patients were treated with",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      while others received other regimens, such as CHOP. The use of highly active anti-retroviral therapy (HAART) varied and results were not reported stratified by HAART use. Results suggested that both HIV- and HIV+ patients with appeared to tolerate",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      equally well.",
"     </li>",
"     <li>",
"      A prospective, single-institution study reported on the use of HyperCVAD alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      for the treatment of 13 patients with AIDS-associated BL or leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/24\">",
"       24",
"      </a>",
"      ]. Nine patients received HAART. Median survival was 12 months. The two-year overall survival rate was 48 percent. The four patients who did not receive HAART died. Six of the seven patients who received HAART plus chemotherapy were alive and in complete remission after a median of 29 months. Side effects were severe and similar to that seen in HIV- populations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HyperCVAD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another prospective trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus intensive, short-duration combination chemotherapy included 19 HIV+ and 17 HIV- patients with newly diagnosed BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/33\">",
"       33",
"      </a>",
"      ]. HAART was mandatory for all HIV+ patients. Two HIV- and three HIV+ patients died due to treatment related toxicity. The two-year overall survival rate was 77 percent and did not differ by HIV status. HIV+ patients had higher rates of severe mucositis and infectious complications.",
"     </li>",
"     <li>",
"      The LMB86 regimen consisting of escalated CHOP-based therapy with consolidation",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      was prospectively evaluated in 63 HIV+ patients with newly diagnosed advanced stage BL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/37\">",
"       37",
"      </a>",
"      ]. All patients received HAART therapy in addition to chemotherapy. Median CD4 count at diagnosis was 239. There were seven treatment-related deaths. Most patients experienced severe neutropenia and thrombocytopenia. Ten patients developed one or more AIDS-associated opportunistic infections. The estimated two-year overall survival rate was 47 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many uncertainties still exist regarding the treatment of HIV+ patients with BL. Among these, the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in these patients remains controversial. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients with cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although anthracycline-based therapy, such as",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC,",
"    </span>",
"    is recommended for patients with BL, patients with underlying cardiac disease may not be able to tolerate the use of an anthracycline since this agent is toxic to cardiac cells.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    or other anthracyclines should not be administered to patients with a baseline ejection fraction below 30 percent. Patients with an ejection fraction greater than 30 percent may require monitoring and guidelines for this are available (",
"    <a class=\"graphic graphic_table graphicRef58738 \" href=\"mobipreview.htm?42/21/43355\">",
"     table 7",
"    </a>",
"    ). The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    may permit substantially higher cumulative doses with efficacy equivalent to the free anthracyclines but a lower incidence of heart failure. The use of anthracyclines in patients with cardiac disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H15#H15\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Approaches for reducing the risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an anthracycline is not an option, non-anthracycline-containing combination chemotherapy programs must be used. When choosing among such regimens, one must keep in mind not only the potential cardiac toxicity but also the intravenous fluid requirements of a regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns over the ability of older adults (ie, over age 60 years) to tolerate intensive chemotherapy and radiation therapy. The management of lymphoma in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/38\">",
"     38",
"    </a>",
"    ]. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older adults have not been included in most trials investigating the therapy of BL. A prospective trial of HyperCVAD with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    included 25 patients over the age of 60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/11\">",
"     11",
"    </a>",
"    ]. Those who are able to tolerate this regimen may have a similar survival benefit from intensive chemotherapy as younger adults. However, trials of HyperCVAD in other histologies have shown that most older adults are unable to tolerate this regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies are needed to evaluate other treatment strategies for older adults who are not fit enough for these intensive regimens. Until such trials are available, treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPOCH (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/40\">",
"       40",
"      </a>",
"      ]. This has not been directly studied in this patient population but is less toxic that conventional therapy and offers promising preliminary results in younger individuals. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard CHOP chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      with palliative intent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/4\">",
"       4",
"      </a>",
"      ]. Two-year progression-free survival is likely less than 30 percent with this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     CNS involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BL are at high risk for developing CNS involvement and so CNS prophylaxis is a standard component of first line therapy. If prophylaxis is not given, approximately 30 to 50 percent of patients will develop CNS relapse, usually with a median interval from diagnosis to relapse of 5 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/5\">",
"     5",
"    </a>",
"    ]. With the incorporation of CNS prophylaxis, rates drop to approximately 6 to 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a percentage of patients will have CNS involvement on presentation or later on in their disease course, despite prophylaxis. Most treatment protocols administer additional intrathecal chemotherapy for those who have CNS involvement at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/15,16,23,32\">",
"     15,16,23,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, patients treated with the",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    regimen who have CNS involvement at presentation are treated with more intensified intrathecal therapy for cycles 1 and 2. Intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    70 mg (or 15 mg if given via an Ommaya reservoir) is given days 1,3, and 5 of CODOX-M (cycle 1) and on days 7 and 9 of IVAC (cycle 2) supplemented by intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    12.5 mg (2 mg if given via an Ommaya reservoir) on days 15 and 17 of CODOX-M (cycle 1) and day 5 of IVAC (cycle 2). For cycles 3 and 4 the intrathecal drug dosing reverts back to the prophylactic doses with intrathecal cytarabine 70 mg given days 1 and 3 of CODOX-M (cycle 3) and intrathecal methotrexate 12 mg given on day 15 of CODOX-M (cycle 3) and day 5 of IVAC (cycle 4).",
"   </p>",
"   <p>",
"    A more detailed discussion on the diagnosis and treatment of secondary involvement of the central nervous system by non-Hodgkin lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice is the CT scan.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and CT scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"mobipreview.htm?29/27/30140\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/41\">",
"     41",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All lymph nodes are normal in size by CT criteria.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who fail to obtain a complete response are treated as refractory disease. This is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment of recurrent or refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. Our approach is based upon the following general understandings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of relapses occur during the first year after completion of treatment.",
"     </li>",
"     <li>",
"      Relapses are usually symptomatic and are rarely identified solely on the basis of routine imaging.",
"     </li>",
"     <li>",
"      When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"       \"Radiation-related risks of imaging studies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every two months during the first year, every three months during the second year, and every six months starting two years after complete response. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH. We obtain a CT scan of the chest, abdomen, and pelvis every six months for the first two years.",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data to guide the treatment of patients with recurrent or refractory BL. Whenever possible, patients should be encouraged to participate in clinical trials. Outside of a clinical trial, patients who relapse after an initial response to appropriate initial therapy have an extremely poor prognosis. They may benefit from another trial of chemotherapy followed by autologous hematopoietic cell transplantation (HCT) in those with chemotherapy sensitive disease. Those with chemotherapy resistant disease do not appear to benefit from autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/45\">",
"     45",
"    </a>",
"    ]. If eligible, such patients may benefit from an allogeneic HCT, although this is controversial.",
"   </p>",
"   <p>",
"    A retrospective analysis of 117 adult patients who underwent autologous HCT for BL included 47 patients with relapsed or resistant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/23/36217/abstract/29\">",
"     29",
"    </a>",
"    ]. Survival was dependent upon remission status and chemotherapy sensitivity at the time of transplant. Three-year overall survival rates were 72, 37, and 7 percent for those who underwent HCT in first complete remission, in chemosensitive relapse, or in chemoresistant relapse, respectively.",
"   </p>",
"   <p>",
"    It is our experience that autologous HCT for relapsed BL is generally associated with unfavorable results. Although the retrospective analysis described above is likely the best evidence for this option, it likely over-estimates the efficacy of HCT by including a highly selected patient population. Patients more likely to benefit from HCT include those who did not receive intensive, short-duration combination chemotherapy as part of their initial treatment. Despite this, there are no other treatment options for relapsed disease.",
"   </p>",
"   <p>",
"    For patients with relapsed disease that is sensitive to chemotherapy, we recommend high dose therapy followed by autologous HCT. For patients with chemotherapy resistant disease at the time of relapse, we recommend best supportive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Burkitt lymphoma (BL) is a highly aggressive B-cell neoplasm characterized by the translocation and deregulation of the c-Myc gene on chromosome 8. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretreatment evaluation both determines the bulk of disease and provides information about the individual's comorbidities that are likely to have impact on treatment options. In addition to a history and physical examination, it is our practice to perform laboratory studies, unilateral bone marrow biopsy, lumbar puncture, cardiac function evaluation, and imaging in all patients. Fertility counseling should be offered to patients in child-bearing years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard of care has yet to be defined and our preferred treatment is enrollment in a clinical trial. However, for patients who are not candidates for such trials or for those who choose not to participate, we suggest intensive, short-duration combination chemotherapy with central nervous system (CNS) prophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dose reduction should be avoided if at all possible and therapy should be initiated quickly. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various intensive, short-duration combination chemotherapy regimens have been studied in patients with BL. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CODOX-M (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) with IVAC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and intrathecal methotrexate) (",
"      <a class=\"graphic graphic_table graphicRef72511 \" href=\"mobipreview.htm?35/40/36493\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      CALGB 9251 protocol",
"      <br/>",
"      <br/>",
"      These regimens are highly toxic, primarily to the hematopoietic system and most patients will have a prolonged hospital stay. At our institutions, we treat patients according to the",
"      <span class=\"nowrap\">",
"       CODOX-M/IVAC",
"      </span>",
"      protocol. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Our approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of the recombinant anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to conventional chemotherapy is controversial. We suggest the addition of rituximab to combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although practice varies, we generally wait until the second cycle of chemotherapy to add rituximab in order to minimize tumor lysis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a significant risk of",
"      <strong>",
"       tumor lysis syndrome",
"      </strong>",
"      in patients treated for BL. This syndrome is best prevented via appropriate treatment with aggressive intravenous hydration,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/54/34661?source=see_link\">",
"       rasburicase",
"      </a>",
"      , and correction of any prior electrolyte disturbances and elements of reversible renal failure (",
"      <a class=\"graphic graphic_table graphicRef57607 \" href=\"mobipreview.htm?22/10/22701\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with HIV, cardiac disease, older adults, and those with CNS involvement at diagnosis require special attention. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Special scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After completion of the initially planned treatment, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for relapsed or refractory BL are limited but include clinical trials or autologous transplantation. For patients with relapsed disease that is sensitive to chemotherapy, we recommend high dose therapy followed by autologous HCT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with chemotherapy resistant disease at the time of relapse, treatment options are best supportive care or enrollment in a clinical trial. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of recurrent or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/1\">",
"      Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/2\">",
"      Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/3\">",
"      Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 2000; 18:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/4\">",
"      Smeland S, Blystad AK, Kval&oslash;y SO, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/5\">",
"      Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/6\">",
"      Sariban E, Edwards B, Janus C, Magrath I. Central nervous system involvement in American Burkitt's lymphoma. J Clin Oncol 1983; 1:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/7\">",
"      Bernstein JI, Coleman CN, Strickler JG, et al. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 1986; 4:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/8\">",
"      Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/9\">",
"      Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/10\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/11\">",
"      Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/12\">",
"      Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/13\">",
"      Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 2003; 120:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/14\">",
"      Spina M, Tirelli U, Zagonel V, et al. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer 1998; 82:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/15\">",
"      Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/16\">",
"      Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/17\">",
"      Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/18\">",
"      Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001; 19:4014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/19\">",
"      Di Nicola M, Carlo-Stella C, Mariotti J, et al. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol 2004; 126:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/20\">",
"      Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004; 104:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/21\">",
"      Kujawski LA, Longo WL, Williams EC, et al. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest 2007; 25:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/22\">",
"      Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/23\">",
"      Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/24\">",
"      Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/25\">",
"      Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/26\">",
"      Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/27\">",
"      Nademanee A, Molina A, O'Donnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997; 90:3844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/28\">",
"      Song KW, Barnett MJ, Gascoyne RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 2006; 133:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/29\">",
"      Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996; 14:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/30\">",
"      van Imhoff GW, van der Holt B, MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005; 19:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/31\">",
"      Friedberg JW, Ciminello L, Kelly J, et al. Outcome of patients &gt; age 40 with Burkitt lymphoma treated with aggressive chemotherapeutic regimens: results from the international burkitt lymphoma collaborative group (abstract). Blood 2005; 106:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/32\">",
"      Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/33\">",
"      Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008; 113:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/34\">",
"      Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol 2012; 156:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/35\">",
"      Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 2011; 22:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/36\">",
"      Blinder VS, Chadburn A, Furman RR, et al. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS 2008; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/37\">",
"      Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007; 110:2846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/38\">",
"      Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/39\">",
"      Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/40\">",
"      Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome (abstract). Blood 2006;108:774A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/41\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/42\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/43\">",
"      Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009; 251:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/44\">",
"      Berrington de Gonz&aacute;lez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/23/36217/abstract/45\">",
"      Ladenstein R, Pearce R, Hartmann O, et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90:2921.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4734 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36217=[""].join("\n");
var outline_f35_23_36217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Choice of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - CODOX-M plus IVAC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - CALBG 9251",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - HyperCVAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Our approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AIDS-related lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CNS involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/40/36493\" title=\"table 2\">",
"      R-CODOX-M IVAC regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/43/11965\" title=\"table 3\">",
"      Burkitt therapy CALGB 9251",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/56/13198\" title=\"table 4\">",
"      CALGB regimen ALL adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/21/25948\" title=\"table 5\">",
"      Hematologic toxicity grades NCI CTCAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/10/22701\" title=\"table 6\">",
"      TLS risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/21/43355\" title=\"table 7\">",
"      Doxorubicin cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/27/30140\" title=\"table 8\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_23_36218="Pseudoxanthoma elasticum neck 1";
var content_f35_23_36218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80952%7EDERM%2F59135%7EDERM%2F70421%7EDERM%2F76225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80952%7EDERM%2F59135%7EDERM%2F70421%7EDERM%2F76225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This woman with pseudoxanthoma elasticum has numerous yellow asymptomatic papules on her neck and upper chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Yahia Albaili, DO, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symmetric, confluent, yellow papules and redundant skin folds are present in this 38-year-old woman. The characteristic plucked chicken skin changes on the neck of patients with pseudoxanthoma elasticum are seen. An eye examination showed the characteristic angioid streaks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Rakhesh SV, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow papules are present on the inner aspect of the lower lip. Infiltration of the buccal mucosa of the lip is the most common mucous membrane involvement in pseudoxanthoma elasticum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Franziska Ringpfeil, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous, confluent yellow papules are present on the neck of this patient with pseudoxanthoma elasticum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36218=[""].join("\n");
var outline_f35_23_36218=null;
var title_f35_23_36219="Rx nonmeningeal crypto";
var content_f35_23_36219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antifungal treatment recommendations for nonmeningeal cryptococcosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial antifungal regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressed patients and immunocompetent patients with mild-to-moderate pulmonary cryptococcosis",
"       </td>",
"       <td>",
"        Fluconazole (400 mg per day)",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressed patients* and immunocompetent patients with severe pulmonary cryptococcosis",
"       </td>",
"       <td>",
"        Same as CNS disease",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Patients with nonmeningeal, nonpulmonary cryptococcosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patients with cryptococcemia",
"       </td>",
"       <td class=\"sublist_other\">",
"        Same as CNS disease",
"       </td>",
"       <td class=\"sublist_other\">",
"        12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patients for whom CNS disease has been ruled out with no fungemia, with a single site of infection, and with no immunosuppressive risk factors",
"       </td>",
"       <td class=\"sublist_other\">",
"        Fluconazole 400 mg per day",
"       </td>",
"       <td class=\"sublist_other\">",
"        6-12 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"     <br>",
"      * Should directly rule out CNS disease with lumbar puncture.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perfect, JR, Disnukes, WE, Dromer, F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291. Copyright &copy; 2010 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36219=[""].join("\n");
var outline_f35_23_36219=null;
var title_f35_23_36220="GIST progn site size mit";
var content_f35_23_36220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rates of progression-free survival for gastrointestinal stromal tumors (GISTs) of stomach, small intestine, and rectum grouped by mitotic rate and tumor size*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Tumor size",
"        <br/>",
"        (cm)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Mitotic rate",
"        <br/>",
"        (HPFs)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        <p>",
"         Percent of patients progression-free during long-term follow-up",
"        </p>",
"        <p>",
"         Primary site",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Gastric",
"       </td>",
"       <td class=\"subtitle2\">",
"        Jejunum/ileum",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duodenum",
"       </td>",
"       <td class=\"subtitle2\">",
"        Rectum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        &le;5/50",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 5",
"       </td>",
"       <td>",
"        &le;5/50",
"       </td>",
"       <td>",
"        98.1",
"       </td>",
"       <td>",
"        95.7",
"       </td>",
"       <td>",
"        91.7",
"       </td>",
"       <td>",
"        91.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        &le;5/50",
"       </td>",
"       <td>",
"        96.4",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td rowspan=\"2\">",
"        66*",
"       </td>",
"       <td rowspan=\"2\">",
"        43*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        &le;5/50",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" colspan=\"6\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        &gt;5/50",
"       </td>",
"       <td>",
"        100",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        50",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 5",
"       </td>",
"       <td>",
"        &gt;5/50",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        &gt;5/50",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td rowspan=\"2\">",
"        14*",
"       </td>",
"       <td rowspan=\"2\">",
"        29*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &gt;5/50",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Based on long-term follow-up studies on 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal cancers.",
"    <div class=\"footnotes\">",
"     HPFs: high power fields; GISTs: gastrointestinal stromal tumors.",
"     <br/>",
"     * Data are combined for tumors &gt;5 cm.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Small number of cases.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Miettinen M, et al. Semin Diagn Pathol 2006; 23:70.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36220=[""].join("\n");
var outline_f35_23_36220=null;
var title_f35_23_36221="Urea mass transfer coefficient";
var content_f35_23_36221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure showing the reduction in blood urea nitrogen during and immediately after hemodialysis among patients with a high versus low mass transfer coefficient for urea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the changes in BUN occurring during four hours of hemodialysis and the hour after dialysis is discontinued. Patients with a low mass transfer coefficient for urea (MTCurea) have, when compared to those with a high MTCurea, a more rapid reduction in BUN due to delayed urea equilibration with intracellular stores. This defect is associated with a greater urea rebound when dialysis is stopped and less total urea removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36221=[""].join("\n");
var outline_f35_23_36221=null;
var title_f35_23_36222="Subtype eval primary aldo";
var content_f35_23_36222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Subtype evaluation of primary aldosteronism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    See text for details.",
"    <div class=\"footnotes\">",
"     APA: aldosterone-producing adenoma; AVS: adrenal venous sampling; CT: computed tomography; GRA: glucocorticoid-remediable aldosteronism; IHA: idiopathic hyperaldosteronism; PAH: primary adrenal hyperplasia.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Young WF Jr, Hogan MJ. Renin-independent hypermineralocorticoidism. Trends Endocrinol Metab 1994; 5:97.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36222=[""].join("\n");
var outline_f35_23_36222=null;
var title_f35_23_36223="Construction of a loop ileostomy - defunctionalized distal limb";
var content_f35_23_36223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Construction of a loop ileostomy - defunctionalized distal limb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a loop ileostomy with a defunctionalized distal limb. The ileotomy is made circumferentially and 20 percent of the back wall of the ileum is intact, maintaining a bridge between the functional proximal limb&nbsp;and the defunctionalized distal limb. Only the proximal limb is everted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_23_36223=[""].join("\n");
var outline_f35_23_36223=null;
